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The normal ageing process is underpinned by progressive autonomic 
nervous system dysfunction, which can lead to the development of conditions 
such as heart failure.  In recent years there has been substantial interest in 
the therapeutic potential of electrical neuromodulatory therapies such as 
vagus nerve stimulation.  However, vagus nerve stimulation is an invasive 
technique requiring the use of a surgical procedure and non-invasive 
methods could have greater clinical utility.  This thesis investigated the 
cardiovascular autonomic effects of two non-invasive cranial nerve 
neuromodulatory techniques in humans: transcutaneous vagus nerve 
stimulation (tVNS) and non-invasive trigeminal nerve stimulation (TNS). 
tVNS applied to the tragus of the ear to stimulate the auricular branch of the 
vagus nerve (ABVN) was found to increase heart rate variability and 
baroreflex sensitivity in healthy older participants (n = 18) and patients with 
heart failure (n = 8).  Microneurography in aged volunteers (n = 5) showed 
this change in autonomic function may have been partly due to a reduction in 
muscle sympathetic nerve activity (MSNA).  However a validation study of 
stimulation at different ear sites detected a similar change in HRV elicited by 
helix stimulation in a subset of healthy volunteers (n = 12), suggesting a role 
for the auriculotemporal (trigeminal) nerve, which also innervates the tragus, 
in the observed autonomic effects. 
TNS applied to supraorbital region in healthy participants (n = 26) found no 
evidence however of changes in HRV or BRS, suggesting that this technique 
has a limited effect on cardiovascular autonomic function.  Further clinical 
studies are needed to determine if tVNS applied to the tragus could be an 
effective adjunctive therapy for disorders where autonomic dysregulation is 
present.  In addition, the precise mechanisms behind the autonomic effects 
of tVNS should be further investigated in animal studies in order to optimise 








Murray AR., Atkinson L., Mahadi, MK., Deuchars, SA., Deuchars J. (2016) 
The strange case of the ear and the heart: the auricular vagus nerve and its 
influence on cardiac control.  Autonomic Neuroscience: Basic and Clinical. 
199 48 – 53. 
 
Abstracts 
Murray AR., Clancy, JA., Deuchars, SA., Deuchars, J. (2017) The acute 
effects of non-invasive trigeminal nerve stimulation on cardiovascular 
autonomic function.  British Neuroscience Association main meeting 2017. 
 
Murray AR., Clancy, JA., Deuchars, SA., Deuchars, J. (2016) 
Transcutaneous Vagus Nerve Stimulation (tVNS) Decreases Sympathetic 
Nerve Activity in Older Healthy Human Subjects. The FASEB Journal 30 (1) 













Table of Contents 
 
Acknowledgements .................................................................................... iii 
Abstract ....................................................................................................... iv 
Publications.................................................................................................. v 
List of Tables ............................................................................................. xiii 
List of Figures ............................................................................................ xv 
List of Abbreviations ............................................................................... xvii 
Chapter 1 ...................................................................................................... 1 
General Introduction .................................................................................... 1 
1.1 The autonomic nervous system ........................................................... 2 
1.1.1 The sympathetic nervous system ..................................................... 3 
1.1.2 The parasympathetic nervous system .............................................. 4 
1.1.3 The enteric nervous system ............................................................... 6 
1.1.4 Regulation of cardiovascular autonomic function ........................... 8 
1.2 Assessment of cardiovascular autonomic activity ........................... 10 
1.2.1 Heart rate variability.......................................................................... 10 
1.2.2 Baroreflex sensitivity ........................................................................ 12 
1.2.3 Direct measures of cardiovascular autonomic function ............... 13 
1.3 Heart failure and autonomic dysregulation ....................................... 15 
1.4 The vagus nerve ................................................................................... 18 
1.4.1 Vagus nerve stimulation ................................................................... 20 
1.4.2 VNS for the treatment of epilepsy ................................................... 22 
1.4.3 VNS for the treatment of major depressive disorder (MDD) .......... 24 
1.4.4 VNS for the treatment of chronic heart failure (CHF) ..................... 24 
1.4.5 Complications associated with VNS ............................................... 29 
1.4.6 Non-invasive methods of vagus nerve stimulation ....................... 30 
vii 
 
1.4.6.1 Non-invasive cervical vagus nerve stimulation (gammaCore™) 30 
1.4.6.2 The auricular branch of the vagus nerve ..................................... 32 
1.4.6.3 Central projections of the ABVN .................................................. 35 
1.4.6.4 Auricular reflexes ........................................................................... 36 
1.4.6.5 Transcutaneous vagus nerve stimulation (tVNS) of the ABVN .. 37 
1.4.6.6 The cardiac effects of tVNS ........................................................... 40 
1.4.6.7 The effects of tVNS on cardiovascular autonomic function ...... 42 
1.5 Non-invasive trigeminal nerve stimulation (TNS) ............................. 44 
1.5.1 Neuroanatomy of the trigeminal nerve............................................ 44 
1.5.2 Non-invasive TNS for the treatment of intractable epilepsy ......... 46 
1.5.3 Non-invasive TNS for treatment-resistant major depressive 
disorder ...................................................................................................... 48 
1.5.4 Non-invasive TNS for the treatment of migraine ............................ 48 
1.5.5 Cardiovascular effects of trigeminal nerve stimulation................. 50 
1.6 General hypothesis .............................................................................. 51 
1.7 Aims and Objectives ............................................................................ 51 
Chapter 2 .................................................................................................... 52 
General Methods ........................................................................................ 52 
2.1 Human research participants .............................................................. 53 
2.2 Experimental protocol ......................................................................... 54 
2.2.1 General protocol ............................................................................... 54 
2.2.3 Transcutaneous vagus nerve stimulation ...................................... 54 
2.2.3.1 Sham tVNS ...................................................................................... 55 
2.2.3.2 Stimulation tolerability questionnaire .......................................... 55 
2.2.4 Trigeminal nerve stimulation ........................................................... 55 
2.2.4.1 Stimulation parameters for TNS ................................................... 56 
2.2.4.1 Sham TNS ....................................................................................... 56 
viii 
 
2.4 Heart rate variability ............................................................................ 59 
2.5 Respiration ........................................................................................... 61 
2.6 Finger arterial blood pressure ............................................................ 61 
2.7 Baroreflex sensitivity ........................................................................... 62 
2.8 Microneurography ............................................................................... 62 
2.8.1 Cold pressor test .............................................................................. 66 
2.8.2 Isometric handgrip test .................................................................... 66 
2.9 Data acquisition ................................................................................... 67 
2.10 Statistical analysis ............................................................................. 67 
Chapter 3 .................................................................................................... 69 
An investigation of the autonomic effects of transcutaneous electrical 
nerve stimulation applied to different sites on the external ear in healthy 
human research participants .................................................................... 69 
3.1 Introduction .......................................................................................... 70 
3.1.1 Overview of the great auricular nerve and its central projections 70 
3.1.2 Overview of the auriculotemporal nerve and its central projections
 ..................................................................................................................... 72 
3.1.3 Knowledge gap ................................................................................. 73 
3.2 Hypothesis ............................................................................................ 74 
3.3 Aims and objectives ............................................................................ 74 
3.4 Materials and Methods ........................................................................ 75 
3.4.1 General protocol ............................................................................... 75 
3.4.2 Cardiovascular autonomic measurements and data acquisition . 78 
3.4.3 Statistical Analysis ........................................................................... 78 
3.5 Results .................................................................................................. 79 
3.5.1 Baseline characteristics ................................................................... 79 
3.5.3 Baroreflex sensitivity ........................................................................ 93 
3.5.4 Heart rate and blood pressure ......................................................... 96 
ix 
 
3.5.5 Reported sensations during electrical stimulation ...................... 102 
3.6 Discussion .......................................................................................... 103 
3.6.1 Central mechanisms ....................................................................... 105 
3.6.2 Response to tragus stimulation .................................................... 107 
3.6.3 Distribution of the cutaneous nerves of the external ear ............ 107 
3.6.4 Conclusion ...................................................................................... 109 
Chapter 4 .................................................................................................. 110 
The autonomic effects of transcutaneous vagus nerve stimulation 
(tVNS) applied to the tragus of the external ear in older healthy human 
research participants ............................................................................... 110 
4.1 Introduction ........................................................................................ 111 
4.1.1 Knowledge gap ............................................................................... 112 
4.2 Hypothesis .......................................................................................... 113 
4.3 Aims and objectives .......................................................................... 113 
4.4 Materials and methods ...................................................................... 114 
4.4.1 General protocol ............................................................................. 114 
4.4.2 Cardiovascular autonomic measurements and data acquisition 115 
4.4.3 Statistical Analysis ......................................................................... 115 
4.5 Results ................................................................................................ 116 
4.5.1 Baseline characteristics of participants ....................................... 116 
4.5.2 tVNS significantly improved heart rate variability in healthy older 
adults ........................................................................................................ 120 
4.5.3 The LF/HF ratio at baseline is correlated with the change in LF/HF 
ratio during active tVNS .......................................................................... 124 
4.5.4 The tVNS-induced changes in LF/HF ratio were reproducible in 
tVNS responders ...................................................................................... 125 
4.5.5 tVNS increased baroreflex sensitivity in healthy older adults .... 126 
x 
 
4.5.6 tVNS reduced muscle sympathetic nerve activity in healthy older 
adults ........................................................................................................ 130 
4.5.7 Effects of active and sham tVNS on heart rate and blood pressure
 ................................................................................................................... 132 
4.6 Discussion .......................................................................................... 134 
4.6.1 tVNS effects on cardiovascular function ...................................... 135 
4.6.2 tVNS as a therapeutic adjunct for age-associated autonomic 
dysfunction............................................................................................... 137 
4.7 Conclusion ......................................................................................... 138 
Chapter 5 .................................................................................................. 139 
The autonomic effects of transcutaneous vagus nerve stimulation 
applied to the tragus in chronic heart failure patients ......................... 139 
5.1 Introduction ........................................................................................ 140 
5.2 Hypothesis .......................................................................................... 141 
5.3 Aims and Objectives .......................................................................... 142 
5.4. Methods ............................................................................................. 142 
5.4.1 Research subjects .......................................................................... 142 
5.4.2 Experimental protocol .................................................................... 143 
5.4.3 Measurements ................................................................................. 144 
5.4.4 Data analysis ................................................................................... 144 
5.5.7 Statistical Analysis ......................................................................... 144 
5.6. Results ............................................................................................... 145 
5.6.1 Baseline characteristics ................................................................. 145 
5.6.2 tVNS reduced LF/HF ratio and increased BRS in heart failure 
patients ..................................................................................................... 147 
5.6.3 Effects of tVNS on HR and BP ....................................................... 152 
5.6.4 Tolerability questionnaire results .................................................. 152 
5.7 Discussion .......................................................................................... 154 
xi 
 
5.7.1 tVNS as a potential anti-arrhythmic agent .................................... 156 
5.8 Conclusion ......................................................................................... 158 
Chapter 6 .................................................................................................. 159 
The autonomic effects of supraorbital trigeminal nerve stimulation in 
healthy human research participants .................................................... 159 
6.1 Introduction ........................................................................................ 160 
6.1.1 Knowledge gap ............................................................................... 161 
6.2 Hypothesis .......................................................................................... 162 
6.3 Aims and objectives .......................................................................... 162 
6.4 Materials and methods ...................................................................... 163 
6.4.1 General protocol ............................................................................. 163 
6.4.2 Cardiovascular autonomic measurements and data acquisition 163 
6.4.3 Statistical Analysis ......................................................................... 164 
6.5 Results ................................................................................................ 164 
6.5.1 Baseline characteristics ................................................................. 164 
6.5.2 Cardiovascular autonomic measurements ................................... 165 
6.5.3 Reported sensations due to trigeminal nerve stimulation .......... 172 
6.6 Discussion .......................................................................................... 173 
6.7 Conclusion ......................................................................................... 176 
Chapter 7 .................................................................................................. 177 
General Discussion ................................................................................. 177 
7.1 Summary of findings ......................................................................... 178 
7.1.1 TENS applied to different sites on the external ear can elicit 
variable cardiovascular autonomic responses in healthy adults ........ 178 
7.1.2 tVNS applied to the tragus of the external ear can alter 
cardiovascular autonomic function towards parasympathetic 
predominance in healthy aged adults and heart failure patients ........ 178 
xii 
 
7.1.3 Supraorbital TNS has a minimal effect on cardiovascular 
autonomic function in healthy humans ................................................. 179 
7.2 Potential mechanisms behind the cardiovascular autonomic effects 
of tVNS applied to the tragus .................................................................. 179 
7.3 Potential clinical applications of tVNS applied to the tragus ......... 183 
7.3.1 tVNS for treatment-resistant hypertension ................................... 183 
7.3.3 Obstructive sleep apnoea .............................................................. 185 
7.3.3 Rheumatoid Arthritis ...................................................................... 186 
7.4 Limitations .......................................................................................... 187 
7.5 Future directions ................................................................................ 189 
7.5.1 Effects of chronic tVNS in healthy aged volunteers .................... 189 
7.5.2. Effects of long-term application of tVNS in chronic heart failure
 ................................................................................................................... 190 
7.5.3 Distribution of the ABVN ................................................................ 191 
7.5.4 Determining the central mechanisms of tVNS ............................. 192 
7.6 Conclusion ......................................................................................... 192 
List of References .................................................................................... 193 
Appendix .................................................................................................. 218 











List of Tables 
 
Table 1.1  The New York Heart Association classification 
system 16 
Table 1.2 Cutaneous distribution of auricular nerves 
reported by Peuker and Filler (2002) 33 
Table 2.1 Overview of the stimulation parameters included 
in this thesis 57 
Table 3.1 Baseline characteristics of participants enrolled 
in the study 80 
Table 3.2 HRV data for all participants (n = 22) for the 
different stimulation sites 84 
Table 3.3 HRV data for the tragus responder subgroup (n = 
12) at different stimulation sites 85 
Table 3.4 HRV data for the tragus non-responder subgroup 
(n = 10) at different stimulation sites 86 
Table 3.5 HRV data for the female participants (n = 11) at 
the different auricular stimulation sites. 87 
Table 3.6 HRV data for the male participants (n = 11) at the 
different auricular stimulation sites. 88 
Table 3.7 BRS data for all participants (n = 14) during 
stimulation at different sites on the ear 94 
Table 3.8 BRS data for participants in the tragus responder 
subgroup (n = 11)  95 
Table 3.9 Male and female participant HR responses as a 
result of stimulation at different sites on the ear 98 
Table 3.10 BP responses during stimulation at different 
sites on the ear in participants with successful finger 
arterial pressure recordings (n = 21) 99 
Table 3.11 BP responses measured using a brachial BP 
cuff immediately after the baseline period and immediately 




Table 4.1: Baseline characteristics of the older healthy 
participants    118 
Table 4.2: Baseline characteristics of the older healthy 
participants compared with younger healthy participants 119 
Table 4.3: HRV responses to active tVNS and sham tVNS in 
older healthy participants    121 
Table 4.4: BRS responses in healthy older participants 128 
Table 4.5: Effect of active tVNS on MSNA in healthy older 
participants 129 
Table 4.6: BP responses to active and sham tVNS in 
healthy older participants 130 
Table 4.7: BP responses to active and sham tVNS in 
healthy older participants 133 
Table 5.1: Baseline characteristics of heart failure patients 
and healthy controls 146 
Table 5.2: Mean HR and HRV data for heart failure patients 
and healthy controls 148 
Table 5.3: Blood pressure and BRS data for heart failure 
patients and healthy controls 149 
Table 5.4: Results of the tVNS tolerability questionnaire 153 
Table 6.1: Baseline characteristics of participants enrolled 
in the TNS study 165 
Table 6.2: HRV data for all participants in the TNS study (n 
= 26) 168 
Table 6.3: HRV data for male participants (n = 11) 169 
Table 6.4: HRV data for female participants (n = 15) 170 
Table 6.5: Blood pressure data for all participants included 
in the TNS study (n = 24) 160 
Table 6.6: Baroreflex sensitivity data for all participants 






List of Figures 
 
Figure 1.1 An overview of the sympathetic and 
parasympathetic divisions of the autonomic nervous system 7 
Figure 1.2 An example of an implanted vagus nerve 
stimulation (VNS) system 21 
Figure 1.3 The gammaCore™ system for non-invasive cervical 
vagus nerve stimulation 31 
Figure 1.4 Anatomical landmarks and cutaneous innervation 
of the external ear 34 
Figure 2.1 Transcutaneous vagus nerve stimulation (tVNS) 
applied to the tragus of the ear 58 
Figure 2.2 Non-invasive trigeminal nerve stimulation applied 
to the supraorbital nerves of the forehead 58 
Figure 2.3: An example of heart rate variability analysis 60 
Figure 2.4 An example of the needle-insertion for 
microneurography 63 
Figure 2.5 An example of a raw neurogram from one volunteer 65 
Figure 3.1 Overview of the stimulation sites used in the 
present study 77 
Figure 3.2: LF/HF ratio response trends for tragus stimulation 89 
Figure 3.3: LF/HF ratio response trends in the tragus 
responder and tragus non-responder subgroups during helix 
stimulation 90 
Figure 3.4: LF/HF ratio response trends in the tragus 
responder and tragus non-responder subgroups during 
earlobe stimulation 91 
Figure 3.5: LF/HF ratio response trends in the tragus 
responder and tragus non-responder subgroups during 
cymba concha stimulation 92 
Figure 3.6 Mean HR responses during stimulation at different 
sites on the ear  97 
xvi 
 
Figure 4.1 HRV responses to active tVNS and sham tVNS in 
older healthy participants    122 
Figure 4.2 Individual HRV responses to active tVNS and sham 
tVNS in older healthy participants. 123 
Figure 4.3 Relationship between baseline LF/HF ratio and 
change in LF/HF ratio from baseline 124 
Figure 4.4 LF/HF ratio response to active tVNS in participants 
who returned for microneurography 125 
Figure 4.5 BRS response to active tVNS and sham tVNS in the 
older participants 127 
Figure 4.6 Effect of active tVNS on MSNA frequency and 
incidence in healthy older participants (normalised data) 131 
Figure 5.1: The effects of tVNS on LF/HF ratio in individual 
heart failure patients and healthy controls 150 
Figure 5.2: The effects of tVNS on spontaneous BRS in 
individual heart failure patients and healthy controls 151 
Figure 6.1 Mean HR data for TNS participants (n = 26) 167 
Figure 7.1: Outline of potential neural pathways through which 
stimulation of the auricular branch of the vagus nerve (ABVN) 













List of Abbreviations 
 
ABVN  Auricular branch of the vagus nerve 
ACE Angiotensin converting enzyme 
ACh Acetylcholine 
AF Atrial fibrillation 
ANS Autonomic nervous system 
ANOVA Analysis of variance 
ATN  Auriculotemporal nerve 
BMI Body mass index 
BOLD Blood oxygenation level dependent 
BP Blood pressure 
BPM Beats per minute 
BRS Baroreflex sensitivity 
ChAT Cholinergic acetyl transferase 
CHF Chronic heart failure 
CN Cranial nerve 
CNS  Central nervous system 
CRP C-reactive protein 
CTB  Cholera toxin B 
CVLM  Caudal ventrolateral medulla 
DVN  Dorsal vagal nuclei 
ECG Electrocardiogram 
EEG  Electroencephalographic 
FDA  Federal Drug Administration 
FFT Fast Fourier transform 
xviii 
 
fMRI Functional magnetic resonance imaging  
GABA Gamma-aminobutyric acid 
GAN  Great auricular nerve 
GI Gastrointestinal 
GVA  General visceral afferent 
GVE  General visceral efferent 
HF  High frequency 
HR Heart rate 
HRP  Horseradish peroxidase 
HRT Hormone replacement therapy 
HRV Heart rate variability 
HSP Heat shock protein 
HTN Hypertension 
H-TNS High frequency trigeminal nerve stimulation 
IL-6 Interleukin-6 
IML  Intermediolateral nucleus 
LF  Low frequency 
LLTS  Low level tragus stimulation 
L-TNS Low frequency trigeminal nerve stimulation 
LV Left ventricular 
LVEDP Left ventricular end-diastolic pressure 
LVEF  Left ventricular ejection fraction 
LVESVI Left-ventricular end-systolic volume index 
MDD Major depressive disorder 
MI Myocardial infarction 
MSNA  Muscle sympathetic nerve activity 
xix 
 
MVC Maximum voluntary contraction 
NA  Nucleus ambiguus 
N-N Normal to normal heartbeat interval 
NO  Nitric oxide 
NTS  Nucleus tractus solitarius 
nVNS Non-invasive vagus nerve stimulation 
NYHA  New York Heart Association 
OSA Obstructive sleep apnoea 
Pa5  Paratrigeminal nucleus 
PBS Phosphate buffer saline 
pNN50 
Number of pairs of adjacent NN-intervals 
differing by > 50 ms 
QoL Quality of Life 
RA Rheumatoid arthritis 
RHR Resting heart rate 
RMSSD 
Square root of the sum of squares of differences 
between adjacent normal to normal heart beat 
intervals 
RSA Respiratory sinus arrhythmia 
RVLM  Rostral ventrolateral medulla 
SDANN 
Standard deviation of the averages of normal to 
normal intervals in a 5 minute data recording 
SDNN Standard deviation of normal to normal intervals 
SSNA Skin sympathetic nerve activity 
TENS Transcutaneous electrical nerve stimulation 
TNF-alpha Tumour necrosis factor alpha 
TNS Trigeminal nerve stimulation 
xx 
 
tVNS Transcutaneous vagus nerve stimulation 
V1 Ophthalmic division of trigeminal nerve 
V2 Maxillary division of trigeminal nerve 
V3 Mandibular division of trigeminal nerve 
VF Ventricular fibrillation 
VNS  Vagus nerve stimulation 
VSEP Vagus somatosensory evoked potential 













































1.1 The autonomic nervous system 
The autonomic nervous system (ANS; from the Greek “auto” meaning “self” 
and “nomos” meaning “law” or “governance”) regulates physiological 
processes without conscious input.  The term “autonomic nervous system” 
was invented by the physiologist John Newport Langley, who divided the 
ANS into three principal components: the sympathetic nervous system 
(derived from the Greek “sympathes” or “affected by like feelings”), the 
parasympathetic nervous system (from the Greek adjective “para” meaning 
“beside”) and the enteric nervous system which is found in the 
gastrointestinal (GI) tract (Langley, 1921).  The parasympathetic and 
sympathetic subdivisions form a complex network of central structures within 
the brain and spinal cord associated with ascending and descending spinal 
pathways as well as peripheral nerves.  These peripheral nerves allow the 
central nervous system (CNS) to exert an effect on a target or end-organ via 
efferent neurons, with afferent neurons providing sensory input from the end-
organ to the CNS.  This allows the autonomic nervous system to maintain 
homeostasis and modulate visceral function. 
The sympathetic and parasympathetic nervous systems provide dual input to 
a number of different visceral organs throughout the body including the heart, 
lungs and GI tract.  Both divisions are tonically active under normal 
circumstances: activity in one will influence activity in the other, allowing for 
subtle modulation of visceral function via integrated responses.  External 
stimuli can also exert a profound influence on ANS activity, leading to a shift 
in autonomic predominance whereby one division becomes more active over 
the other.  Increased activation of the sympathetic nervous system is referred 
to as the “flight, fight or fright” response, whereby the presence of a physical 
or emotional stressor leads to rapid physiological changes such as increased 
heart rate and blood pressure (Karemaker, 2017).  Meanwhile, a “rest and 
recovery” state is associated with increased parasympathetic predominance, 
an example of which would be the reduction in heart rate at rest via tonic 
inhibition at the sinoatrial node (Jose and Collison, 1970, Karemaker, 2017).  
However, the increase in heart rate observed during physical activity is in fact 




increased sympathetic activation (Fagraeus and Linnarsson, 1976).  This 
complexity in the interaction between the actions of the parasympathetic and 
sympathetic subdivisions of the ANS, coupled with the ability to rapidly 
respond to physiological stress without conscious input, is vital for 
homeostasis and normal visceral function.  Nevertheless, a chronic 
imbalance in sympathetic and parasympathetic activation can have a 
progressive damaging effect on the structure and function of organs such as 
the heart, leading to pathological conditions such as ischaemic heart disease 
and heart failure.  
 
1.1.1 The sympathetic nervous system 
The sympathetic nervous system has a complex neuroanatomy with 
extensive distribution throughout the body to sites as wide-ranging as the 
heart, GI tract, smooth muscle of blood vessels, erector pili muscle and 
sweat glands.  In mammals, the cell bodies of sympathetic preganglionic 
neurones are located in the lateral horns of the spinal cord from the thoracic 
to the upper lumber spinal segments, with the majority in the 
intermediolateral (IML) cell column (Gilbey and Spyer, 1993).  Myelinated 
sympathetic preganglionic axons exit the spinal cord at their segment of 
origin along with somatic motor fibres in the ventral nerve roots (Deuchars 
and K. Lall, 2015).  The sympathetic preganglionic neurones then divert into 
the paravertebral ganglia of the sympathetic chain via white rami 
communicantes or connecting branches.  At this point the sympathetic 
preganglionic neurone axons may synapse upon entering the chain with a 
sympathetic postganglionic neurone, or travel in a rostral or caudal direction 
in the sympathetic chain before synapsing with a postganglionic neurone 
(Gilbey and Spyer, 1993).  The non-myelinated sympathetic postganglionic 
neurones exit the sympathetic chain via grey rami communicantes and 
project to target end-organs by travelling in the spinal nerves or along major 
blood vessels such as the common carotid arteries.  Some sympathetic 
preganglionic neurones do not synapse within the sympathetic chain and 




prevertebral ganglia in the abdomen including the coeliac, superior 
mesenteric and inferior mesenteric ganglia (Figure 1.1).  These preganglionic 
neurones then synapse at the prevertebral ganglia with postganglionic 
neurones.  In addition, there are substantial preganglionic projections to the 
chromaffin cells in the medulla of the adrenal gland which are involved in the 
secretion of norepinephrine and epinephrine into the bloodstream. 
Norepinephrine and acetylcholine are the integral neurotransmitters in the 
sympathetic nervous system.  Acetylcholine (ACh) is released from 
preganglionic neurones into the synaptic cleft where it binds with nicotinic 
receptors on sympathetic postganglionic neurones, facilitating the activation 
of these postganglionic neurones.  These in turn release norepinephrine, 
which binds to alpha and beta adrenergic receptors on the target end-organs.  
For this reason, postganglionic neurones are described as being adrenergic, 
while preganglionic neurones are cholinergic.  Postganglionic neurones also 
provide cholinergic innervation to the sweat glands of the skin, where 
activation is elicited by the binding of acetylcholine to muscarinic receptors. 
 
1.1.2 The parasympathetic nervous system 
Activation of the parasympathetic nervous system is integral to a wide range 
of processes including digestion, salivation, urination and lacrimation.  The 
parasympathetic nervous system is traditionally considered to be organised 
into a craniosacral outflow as the parasympathetic preganglionic neurones 
arise from various cranial nerve (CN) nuclei in the brainstem as well as S2 – 
S4 segments in the sacral spinal cord (Langley, 1921, McCorry, 2007).  
Cranial nerves which contain parasympathetic efferent fibres are the 
oculomotor nerve (CN III), the facial nerve (CN VII), the glossopharyngeal 
nerve (CN IX) and the vagus nerve (CN X).  The nucleus ambiguus (NA) and 
the dorsal vagal nucleus (DVN) of the medulla contain the cell bodies of 
vagal preganglionic neurones.   
There has been recent controversy over whether the sacral component of the 
parasympathetic nervous system should be reclassified as part of the 




markers and transcription factors in developing cranial and spinal 
preganglionic neurones at different mouse embryonic stages, specifically 
days E11.5, E13.5 and E16.5 of embryological development (Espinosa-
Medina et al., 2016).  The expression of several transcription factors was 
shared by both thoracolumbar preganglionic neurones and sacral 
preganglionic neurones but not cranial preganglionic neurones.  Langley’s 
traditional model of the craniosacral parasympathetic outflow was based on 
observations of the functional effects of neurostimulation, whereas the 
proposed new model by Espinosa-Medina et al. is based on developmental 
observations.  As the latter offers no explanation for the distinct functional 
characteristics of the sacral autonomic outflow and the thoracolumbar 
sympathetic outflow, Langley’s model should continue to be supported.  
Moreover, Espinosa-Medina et al. offer no explanation as to why sacral 
preganglionic neurones do not enter the sympathetic chain. 
Like sympathetic preganglionic neurones, parasympathetic preganglionic 
neurones are cholinergic.  However, parasympathetic preganglionic axons 
are generally much longer than those of sympathetic preganglionic neurones, 
as parasympathetic ganglia are situated near to the end-organ.  
Parasympathetic preganglionic neurones then synapse with parasympathetic 
post-ganglionic neurones, which have much shorter axons and also use ACh 
as a neurotransmitter.  While ACh from parasympathetic preganglionic 
neurones binds to nicotinic receptors, ACh from the postganglionic neurones 
binds to muscarinic receptors at the target end-organ, similar to the 











1.1.3 The enteric nervous system 
The enteric nervous system (ENS) receives limited modulatory input from the 
parasympathetic and sympathetic nervous systems but can otherwise be 
considered to be functionally independent from these divisions.  This 
complex self-regulatory capacity is facilitated by approximately 200 – 600 
million neurons which are organised into two neuronal plexi spanning the 
course of the GI tract (Furness et al., 2014).  The myenteric or Auerbach’s 
plexus is located in between the circular and longitudinal muscle layers and 
coordinates their activity to generate peristaltic contractions.  It extends from 
the smooth muscle in the lower pharynx to the internal anal sphincter 
(Furness et al. 2014).  The submucosal or Meissner’s plexus regulates 
secretion and is found between the circular muscle and the inner mucosa of 
the small and large intestine.  While the ENS can function without input from 
the central nervous system, under normal circumstances there is 
considerable signalling from the gut to the brain via vagal afferents.  This 
signalling can include information about sensations of satiety and nausea 
from the stomach, although much of the transmitted information is not 























Figure 1.1 An overview of the sympathetic and parasympathetic divisions of 
the autonomic nervous system 





1.1.4 Regulation of cardiovascular autonomic function 
The brainstem medulla is of vital importance to the regulation of 
cardiovascular autonomic function as it is the site of major sympathetic and 
parasympathetic nuclei containing preganglionic cell bodies.  These 
autonomic nuclei provide dynamic control of activity in the cardiovascular 
system in order to respond to changes in physiological demand.  Visceral 
afferent information transmitted via the vagus and glossopharyngeal nerves 
is critical to the modulation of cardiovascular autonomic efferent outflow.  In 
the first instance, cardiovascular afferent signals converge on the nucleus 
tractus solitarius (NTS) of the dorsomedial medulla.   
The NTS is a major integration site for cardiovascular reflexes such as the 
arterial baroreceptor reflex, which is important for the regulation of arterial 
blood pressure (Dampney and Horiuchi, 2003).  The arterial baroreflex is 
initiated by mechanosensitive afferent nerve endings in the aortic arch and 
carotid sinus which fire in response to the arterial wall distension caused by 
an increase in blood pressure (Andresen and Kunze, 1994).  Afferent fibres 
in the aortic depressor (vagus) and carotid sinus (glossopharyngeal) nerves 
have been shown in cats to project to the NTS from baroreceptors in the 
aortic arch and carotid sinus respectively, as confirmed using retrograde 
transganglionic transport of horseradish peroxidase (HRP) (Ciriello et al., 
1981).  Some barosensitive NTS neurones project to the dorsal vagal motor 
nucleus (DVN) and nucleus ambiguus, key nuclei associated with thoracic 
and subdiaphragmatic vagal activity (Deuchars et al., 2000).  The nucleus 
ambiguus contains cardioinhibitory vagal efferent preganglionic neurones 
and excitatory projections from the NTS can induce a rapid reduction in heart 
rate via these parasympathetic efferents (Izzo et al., 1993).  These 
preganglionic neurones project to the cardiac plexi located in the epicardium 
(Singh et al., 1999) where they synapse with vagal postganglionic neurones 
which release acetylcholine at the sinoatrial node.  Acetylcholine binds to 
muscarinic (M2) receptors on cardiomyocytes in the sinoatrial node, with the 
subsequent hyperpolarisation leading to a reduction in heart rate (Neff et al., 
1998, Hasan, 2013). This reduction in heart rate is accompanied by reduced 




In addition, the reduction in blood pressure observed during activation of the 
arterial baroreflex is further enhanced by inhibition of the rostral ventrolateral 
medulla, the primary regulatory centre for central sympathetic outflow to the 
heart and vasculature (Kumada et al., 1990).   The RVLM has a critical role in 
the maintenance of blood pressure and lesions at this site produce marked 
decreases in blood pressure at rest (Dampney and Moon, 1980).  The RVLM 
has been shown to have direct excitatory projections to the intermediolateral 
(IML) cell column of the lateral horn of the spinal cord, where sympathetic 
preganglionic neurones arise (Ross et al., 1984a, Zagon and Smith, 1993).  
This was confirmed through work by Ross et al. in anaesthetised rats where 
electrical stimulation applied to the rostral ventrolateral medulla induced 
tachycardia, increased arterial pressure, inhibited the arterial baroreflex and 
greatly increased the plasma concentration of norepinephrine (five-fold 
increase) and epinephrine (seventeen-fold increase) (Ross et al., 1984b).  
Transection of the cervical spinal cord at C1 spinal level abolished this 
response (Ross et al., 1984b).  Microinjection of the inhibitory amino-acid 
GABA into the RVLM in six rats elicited a dose-dependent depressor 
response which manifested in decreased arterial pressure in all animals and 
bradycardia in four out of six rats (Ross et al., 1984b).   
GABAergic projections from the caudal ventrolateral medulla (CVLM) have 
been found to exert a strong inhibitory effect on the RVLM (Li et al., 1992).  
The CVLM receives glutamatergic projections from the NTS which fire in 
response to increased baroreceptor activation, which in turn causes a 
reciprocal inhibition of the RVLM via GABAergic projections from the CVLM 
and a decrease in sympathetic tone (Guyenet, 2006).  Blessing et al. showed 
that this depressor response could be artificially induced using microinjection 
of glutamate into the CVLM and abolished through injection of a GABA 








1.2 Assessment of cardiovascular autonomic activity 
There are a variety of techniques that are used in research and clinical 
contexts to measure cardiovascular autonomic function in humans.  Many of 
these techniques are by necessity indirect, as direct recordings of autonomic 
nervous system activity are invasive and difficult to perform in human 
research participants.  As the heart is under the influence of both the 
parasympathetic and sympathetic nervous systems, the simplest and least 
specific marker of cardiovascular autonomic activity is resting heart rate.  The 
normal range for resting heart rate is from 60 beats per minute (bpm) to 100 
bpm depending on physical activity levels, although individuals with athletic 
training may have much lower resting heart rates.  Resting heart rate is 
known to be a prognostic factor in the outcome of cardiovascular disease and 
individuals with high RHR (> 75 bpm) have a greatly increased risk of sudden 
death due to myocardial infarction (Jouven et al., 2005). 
 
1.2.1 Heart rate variability 
Heart rate variability analysis is one of the most common non-invasive 
methods of assessing cardiovascular autonomic function.  Heart rate which is 
in normal sinus rhythm naturally fluctuates on a beat-to-beat basis due to the 
modulation of sinoatrial node activity by sympathetic and parasympathetic 
inputs.  This modulation in heart rate can occur in response to a wide range 
of factors including changes associated with respiratory control, exercise 
intensity and baroreceptor activation.  Heart rate variability is typically 
measured in clinical and research contexts using electrocardiography (ECG) 
recordings but can also be derived from photoplethysmographic recordings.  
However, the ECG method is considered to be more accurate as it allows for 
improved detection and identification of ectopic beats, which may disrupt 
HRV analysis algorithms (Shaffer et al., 2014).  HRV can be assessed using 
a variety of different methods but the most commonly used measures are 
time-domain HRV and frequency-domain HRV (Malik, 1996). 
Time-domain measures of HRV are simple statistical analyses of a sample of 




minutes for short-term recordings (Malik, 1996).  Moreover, these analyses 
are based on the normal-to-normal or NN-intervals, the interbeat intervals 
between R-peaks which are in sinus rhythm and free from disruptions caused 
by signal artefacts or ectopic beats (Tarvainen et al., 2014). A common time-
domain measure is SDNN (standard deviation of normal-to-normal intervals), 
which is associated with overall variation in the RR-interval data in either a 
long-term (24 hours) or short-term (5 minutes) context.  In short-term 
recordings, SDNN is primarily derived from respiratory sinus arrhythmia 
(Shaffer et al., 2014).  RMSSD (root mean square of successive differences 
in RR-intervals) and pNN50 (percentage of pairs of consecutive NN-intervals 
which differ by > 50 ms) are measures of short-term RR-interval variability 
which correlate with vagal activation (Malik, 1996).  
Frequency-domain measures of HRV use power spectral density (PSD) 
analysis to separate the RR-interval signal into oscillating rhythms which are 
associated with discrete frequency bandwidths.  This can be achieved 
through the use of PSD algorithms such as the Lomb-Scargle periodogram or 
fast Fourier transform (FFT).  The separate frequency components can be 
used to describe how variance (power) distributes as a function of frequency.  
These frequency bands are: very low frequency power (< 0.04 Hz; VLF); low 
frequency power (0.04 – 0.15 Hz; LF) and high frequency power (0.15 – 0.4 
Hz, HF).  All variance within the entire frequency bandwidth is known as the 
total power.  To date the VLF component has been poorly characterised but 
is thought to be influenced by changes in circadian rhythms, hormonal 
fluctuations and thermoregulation i.e. physiological processes which may 
occur over long time periods (Kleiger et al., 2005; Shaffer et al., 2014).  The 
HF component has been associated with parasympathetic modulation of 
heart rate, whereas LF power reflects both parasympathetic and sympathetic 
modulation of heart rate (Akselrod et al., 1981; Shaffer et al., 2014).  
Akselrod and colleagues (1981) showed that parasympathetic blockade 
using glycopyrrolate (a muscarinic receptor antagonist) eliminated the HF 
power component of HRV in conscious dogs, while propranolol did not, 
indicating that HF power is generated by vagal activity (Akselrod et al., 1981).  




LF power appears to originate from both parasympathetic and sympathetic 
activity, as evidenced by a propranolol-induced decrease in LF power in rats 
which was not completely abolished (Aubert et al., 1999).  Atropine blockade 
which abolished the HF power component also failed to completely abolish 
the LF power component, suggesting that the LF power component may 
reflect both sympathetic and parasympathetic activity (Aubert et al., 1999).  
LF power and HF power are typically measured in absolute values of power 
(ms2) but can also be converted to normalised units (n.u.) to reduce the 
impact of changes in total power on these components (Malik, 1996).  The 
balance between these normalised units can then be represented using the 
LF/HF ratio, a combined reflection of sympathetic and parasympathetic 
modulation on sinoatrial node activity with a reduced LF/HF ratio signifying 
parasympathetic predominance (Malik, 1996). 
 
1.2.2 Baroreflex sensitivity 
Baroreflex sensitivity (BRS) is defined as the beat-to-beat change in the RR 
interval (in milliseconds) in response to a change in blood pressure (Swenne, 
2013).  Initial investigations into the assessment of BRS in man were 
conducted by Smyth et al. in a study which used the infusion of angiotensin 
or phenylephrine via an intra-arterial catheter to generate a brief rise in BP 
(Smyth et al., 1969).  This technique caused a reflexive increase in RR 
interval to occur, corresponding to the decrease in heart rate.  Angiotensin 
was replaced in later studies with phenylephrine, a vasoactive 
pharmacological agent which is an agonist for α1-adrenergic receptors and 
thus has no effect on sinoatrial node activity (Ebert and Cowley, 1992, Rudas 
et al., 1999, La Rovere et al., 2008).  However, the invasive cannulation 
required to monitor continuous beat-to-beat changes in BP and infuse the 
pharmacological agent limits the scope for applying this method of 
quantifying BRS.  Non-invasive beat-to-beat measurement of blood pressure 
can be achieved using a non-invasive blood pressure (NIBP) system such as 
a Finapres or Finometer (Finapres Medical Systems B.V., Netherlands).  
These systems are equipped with a finger photoplethysmograph, a small 




changes in arterial blood pressure in the digital arteries (Parati et al., 1989).  
This is based on the volume-clamp method developed by Penaz (Penaz, 
1973).  There is a strong correlation between BP measurements obtained 
using finger photoplethysmography and intra-arterial BP monitoring, offering 
a simple method of obtaining continuous beat-to-beat BP and quantifying 
BRS (Pinna et al., 2000).  
Spontaneous fluctuations in blood pressure can also be used to measure 
BRS without the need for a pharmacological intervention.  Spontaneous BRS 
can be measured using either the sequence method or by calculating 
spectral indices.  These have the advantage of being completely non-
invasive with no adverse effects caused by artificial perturbations in BP.  The 
sequence method uses linear regression analysis of sequences of ≥ 3 
cardiac cycles where there is a change in systolic blood pressure (an 
increase or decrease) coinciding with a simultaneous change in the duration 
of the RR-interval (Parati et al., 2000, La Rovere et al., 2008).  Spectral 
analysis of BRS can include measurement of the alpha index or the averaged 
transfer gain function of systolic pressure variability and the RR interval 
variability (Robbe et al., 1987, Parati et al., 2000).  However spectral 
methods of spontaneous BRS analysis should only be performed in 
individuals who are in sinus rhythm, as methods of spectral BRS analysis are 
highly sensitive to the data loss and estimation bias caused by ectopic beats 
(Pinna et al., 2005).  The sequence method can avoid this issue through the 
automatic exclusion of sequences where there are observable 
haemodynamic changes caused by the presence of ectopic beats (Pinna et 
al., 2015).    
 
1.2.3 Direct measures of cardiovascular autonomic function 
While non-invasive indices such as HRV and BRS can provide useful insights 
into cardiovascular autonomic function, they only provide an indirect estimate 
of autonomic nervous system activity.  At present there is no viable method 
of recording parasympathetic nervous system activity in humans but there 




system activity.  The first of these is the measurement of the plasma 
concentration of norepinephrine, the neurotransmitter released from 
sympathetic nerve terminals (Cohn et al., 1984, Esler, 1993).  However this 
method may be confounded by decreased reuptake of norepinephrine from 
circulation and decreased metabolism (Charkoudian and Rabbitts, 2009).  A 
more sophisticated approach is the norepinephrine spill-over technique, 
which involves the infusion of tritiated norepinephrine into a peripheral vein 
with simultaneous sampling of blood from a catheter inserted into the 
vasculature surrounding a target organ e.g. the venous coronary sinus for the 
heart or the renal vein for the kidney (Esler et al., 1984).  This provides a 
regional estimation of sympathetic nerve activation which is not possible to 
achieve with plasma measurements of norepinephrine, but the invasiveness 
of norepinephrine spillover measurements limits the feasibility of this 
technique.  
A less-invasive method is microneurography, which was first pioneered in the 
late 1960s (Hagbarth and Vallbo, 1968).  Microneurography involves the use 
of high-impedance tungsten microelectrodes inserted percutaneously into a 
superficial nerve such as the common peroneal nerve to directly record 
action potentials in awake humans (Vallbo et al., 2004).  This technique is 
most commonly used to record multi-unit bursts of vasoconstrictor muscle 
sympathetic nerve activity (MSNA) from groups of unmyelinated sympathetic 
postganglionic neurones innervating the intramuscular vasculature (Delius et 
al., 1972, Charkoudian and Rabbitts, 2009).  The microelectrode is carefully 
adjusted within the nerve until a suitable signal-to-noise ratio is obtained.   
Macefield et al. refined the technique to permit recording of single MSNA 
units from individual vasoconstrictor sympathetic neurones, although this is 
more technically challenging than multi-unit recordings (Macefield et al., 
1994, Macefield et al., 1999).   
There is a strong association between the arterial baroreflex and muscle 
sympathetic nervous system activity, with stimulation of the carotid sinus 
nerve eliciting a decrease in MSNA bursts (Wallin et al., 1975).  A decrease 
in blood pressure will elicit a reflexive increase in MSNA to induce peripheral 




synchronous manner, allowing it to be differentiated from skin sympathetic 
nerve activity, which is not associated with the arterial baroreflex and does 
not fire in synchrony with the cardiac cycle (Charkoudian and Rabbitts, 
2009).  MSNA also shows substantial inter-individual variability, but it is 
possible to record repeated measurements in the same individual which are 
reproducible (Fagius and Wallin, 1993). In addition, MSNA has been shown 
to correlate with cardiac norepinephrine spill-over measurements obtained 
from the coronary sinus (Wallin et al., 1992).  This means that 
microneurographic recordings of MSNA from a peripheral site such as the 
common peroneal nerve can provide a less-invasive but informative indicator 
of cardiac sympathetic activation. 
 
1.3 Heart failure and autonomic dysregulation 
Chronic heart failure (CHF) is an increasingly significant public health issue 
affecting an estimated 23 million people worldwide, with 5.3 million of those 
living in the USA (Bui et al., 2011).  The majority of patients living with CHF 
are aged ≥ 65 years and this demographic constitutes 80% of all CHF-
associated deaths, with the mortality rate 5 years after diagnosis reported to 
be greater in men than in women (Levy et al., 2002).  The condition often 
develops from an existing cardiovascular disorder where cardiac output has 
been compromised e.g. due to pathological defects caused by myocardial 
infarction or coronary artery disease.  Inadequate oxygen perfusion 
throughout the body leads to the activation of the sympathetic nervous 
system and renin-angiotensin system, which initially counteract the lack of 
oxygen in body tissues by increasing heart rate and blood pressure (Florea 
and Cohn, 2014).  However, chronic sympathetic activation cannot be 
maintained without degenerative cardiotoxic effects, leading to the 
development of CHF.  The progression of CHF can be determined by 
comparing patient symptoms to the New York Heart Association (NYHA) 










I (Mild) Asymptomatic with no limitations regarding 
physical activity 
II (Mild) No symptoms at rest but patient experiences 
dyspnoea, fatigue or palpitations following 
ordinary physical activity 
III (Moderate) No symptoms at rest but patient experiences 
dyspnoea, fatigue or palpitations after less than 
ordinary physical activity 
IV (Severe) Cardiac insufficiency symptoms at rest with 
patient unable to perform any physical activity 




There is a consensus that increased sympathoexcitation is an integral 
pathophysiological force behind CHF progression (Florea and Cohn, 2014).  
Early evidence for increased sympathetic activation in CHF came from 
analysis of norepinephrine levels in the urine of a group of heart failure 
patients (n = 110) compared to samples from healthy controls (n = 13) 
(Chidsey et al., 1965).  This has further been established by the observation 
of increases in the plasma concentration of norepinephrine as CHF 
progresses (Thomas and Marks, 1978).  MSNA is also significantly increased 
in CHF patients and has been shown to diminish one month after successful 
cardiac transplantation (Leimbach et al., 1986, Rundqvist et al., 1997).  
Macefield et al. obtained multi-unit MSNA recordings in 8 CHF patients 




100 heartbeats) was increased when compared to healthy controls 
(Macefield et al., 1999).  Barretto et al. (2009) also measured MSNA via 
microneurography in 122 heart failure patients (NYHA class II to IV) and 
found that MSNA levels greater than 49 bursts per minute indicated an 
increased mortality rate over one year (Barretto et al., 2009).  This increased 
incidence of sympathetic activation also corresponds with observed 
reductions in HRV and BRS in CHF patients (Mortara et al., 1997, Nolan et 
al., 1998).  In their prospective study of 433 CHF patients, Nolan et al. 
showed that reductions in 24 hour time-domain measures of HRV such as 
the SDNN could provide a useful CHF prognostic assessment (Nolan et al., 
1998).  
Pharmacological treatment strategies for CHF include beta-blockers, which 
can selectively or non-selectively block cardiac β1 and β2-adrenergic 
receptors in order to reduce heart rate, lower blood pressure and thus 
alleviate the effects of chronic sympathetic activation (Brophy et al., 2001).  
Patients with myocardial infarction (MI) who received propranolol, a non-
selective beta-blocker, showed a significant decrease in LF/HF ratio 
compared to a control group of patients who received a placebo (Lampert et 
al., 2003).  This effect suggests that a change in autonomic nervous system 
activity towards parasympathetic predominance occurred in the propranolol-
treated patients.  Further evidence of this has been shown with carvedilol, 
another non-selective beta-blocker which has been shown in 36 CHF 
patients to increase BRS, increase the HF power component of frequency-
domain HRV and reduce cardiac norepinephrine spill-over after 4 months of 
treatment (Kubo et al., 2005).  In this way, the increased vagal activation 
demonstrated by increased HF power and BRS could be as a result of 
removal by beta-blockade of the inhibitory effects of elevated cardiac 
norepinephrine on vagus nerve activity at the sinoatrial node.  However, the 
mortality rate for CHF remains relatively high at around 10% per annum 
despite the use of pharmacological treatments such as beta-blockers (Nolan 
et al., 1998).  This persistently high mortality rate underscores the need for 




Increased sympathetic activation is not solely responsible for CHF 
progression and parasympathetic withdrawal has also been recognised as a 
key pathophysiological feature of the condition (Triposkiadis et al., 2009, 
Sabbah et al., 2011).  The results of a comparative study by Eckberg et al. of 
healthy volunteers (n = 23) and CHF patients (n = 22) showed that the 
patients had impaired parasympathetic activity (Eckberg et al., 1971).  
Atropine was used to induce parasympathetic blockade in both groups and 
the patients displayed an attenuated increase in heart rate, suggesting that 
the patients had a significantly lower level of parasympathetic activity at 
baseline compared to the controls (Eckberg et al., 1971).  This 
parasympathetic withdrawal would suggest that neuromodulation applied with 
the intent of activating the parasympathetic nervous system may be a 
potential method of altering the autonomic dysregulation associated with 
CHF.  One way in which this may be achieved is via electrical stimulation of 
the vagus nerve. 
 
1.4 The vagus nerve 
As the 10th and longest cranial nerve, the vagus nerve is notable for 
providing the main parasympathetic innervation to the thoracic and 
abdominal viscera.  Arising bilaterally as 8 - 10 rootlets between the inferior 
olive and the inferior cerebellar peduncle of the medulla, the vagus nerve 
merges into a common trunk that traverses the jugular foramen to exit the 
cranium (Berthoud and Neuhuber, 2000).  Located within the jugular foramen 
is the jugular (or superior) ganglion, which contains somatic sensory afferent 
cell bodies (Ruffoli et al., 2011).  The larger nodose (inferior) ganglion lies 
distal to the jugular foramen and contains the cell bodies of visceral afferent 
fibres (Ruffoli et al., 2011).  After exiting the cranium, the right and left vagus 
nerves descend inferiorly through the neck within the carotid sheath, 
providing innervation to the soft palate, pharynx and muscles of the larynx 
prior to entering the thorax (Berthoud and Neuhuber, 2000).  At this point, the 




distribution to the heart, lungs, liver, adrenal medulla and the gastrointestinal 
tract up to the splenic flexure of the colon (Berthoud and Neuhuber, 2000). 
While the traditional view is that in humans vagus nerve innervation 
terminates at the splenic flexure of the colon, there is evidence that vagal 
afferents may also innervate the pelvic organs.  In rats, labelled neuronal cell 
bodies were observed in the nodose ganglia following injection of HRP into 
the ovaries (Burden et al., 1983) and the uterine walls (Ortega-Villalobos et 
al., 1990, Collins et al., 1999).  There is evidence that the uterine cervix is 
also innervated by the vagus nerve (Collins et al., 1999).  Transection of both 
the vagus nerve and the sacral pelvic nerves in pregnant rats delayed 
parturition and the associated remodelling of the cervix (Clyde et al., 2011).  
The vagal innervation of the large intestine varies across species, electrical 
stimulation of the cervical vagus nerve in rats has been shown to elicit 
peristaltic contractions in the distal colon (Tong et al., 2010).   
At a histological level, the vagus is a mixed nerve which has been shown in 
cats to consist of 65% to 80% somatic afferent fibres together with a smaller 
amount of visceral and general efferent fibres from the nucleus ambiguus 
and dorsal motor nucleus of the vagus (Foley and DuBois, 1937, Ruffoli et 
al., 2011).  This imbalanced ratio suggests that the vagus is an important 
sensory relay for the regulation of visceral function.  Moreover, there are 
several distinct types of vagal afferent fibres: general visceral afferents which 
transmit information from viscera, mucosa and aortic baroreceptors, as well 
as special sensory afferents, which are involved with taste sensation at the 
root of the tongue and epiglottis.  In addition to the visceral afferents, somatic 
sensory afferents convey sensation from the external ear, pharynx, larynx, 
trachea, cranial meninges and oesophagus to the spinal trigeminal nucleus, 







1.4.1 Vagus nerve stimulation 
The widespread parasympathetic visceral innervation supplied by the vagus 
nerve, as well as its substantial projections to cortical and subcortical sites, 
has led to much interest in the therapeutic effects of modulating vagal activity 
(Clancy et al., 2013).  Vagus nerve stimulation involves the surgical 
implantation of a bipolar electrode cuff around one of the cervical vagus 
nerves, most commonly the left (Groves and Brown, 2005).  This is due to 
the fact that the right vagus nerve provides innervation to the sinoatrial node, 
with the risk that stimulation may elicit bradycardia or asystole, while the left 
vagus nerve innervates the atrioventricular node and thus does not generate 
the same cardiovascular effects (Randall et al., 1985).  Left-sided VNS has to 
date been most commonly implanted in treatment-resistant epilepsy patients 
and has been approved for clinical use in Europe since 1994 and the USA 
since 1997 (Revesz et al., 2016). 
 
Figure 1.2 An example of an implanted vagus nerve stimulation (VNS) 
system.  The right or left cervical vagus nerve is isolated and fitted with a 
bipolar electrode (A).  All VNS systems include a battery generator (B) and 
some designs include an additional intracardiac sensing lead inserted into 
the right ventricle of the heart.   An X-ray is shown of a patient implanted with 


























1.4.2 VNS for the treatment of epilepsy 
The first documented attempt at electrical stimulation of the cervical vagus 
nerves was by the American neurologist James L. Corning, who developed a 
device in the mid-1880s which combined bilateral compression of the carotid 
arteries with transcutaneous direct electrical current (Corning, 1884).  At the 
time it was believed that epileptic seizures were the result of “cerebral 
hyperaemia” and Corning believed this method would reduce cerebral blood 
flow and thus reduce seizure frequency through stimulation of efferent fibres 
in the vagus nerve (Corning, 1884).  He observed transient bradycardia as a 
result of stimulation and presented anecdotal evidence that this method of 
VNS was effective in suppressing seizures (Corning, 1884).  However, 
Corning’s contemporaries proved to be sceptical of his claims and VNS was 
largely forgotten until the mid-20th century (Lanska, 2002).  Work done in the 
1930s using the encéphale isolé technique in vagotomised cats showed that 
VNS applied to the central cut end of the cervical vagus could decrease the 
frequency of strychnine-induced seizures (Schweitzer and Wright, 1937) and 
generate electrical potentials in the orbital region of the frontal lobe (Bailey, 
1938).   Zanchetti et al. found that VNS (2.0V, 50Hz, 0.5ms) in anaesthetised 
encéphale isolé cats evoked widespread desynchronization of cortical activity 
measured using EEG (Zanchetti et al., 1952).  Moreover, this study 
demonstrated that the change in cortical activity was due to the activation of 
vagal afferents, as the cervical vagus nerve was sectioned and stimulation 
was applied to the central cut end of the nerve (Zanchetti et al., 1952).  Later 
work by Zabara et al. found that VNS had an effect on seizure control when 
stimulation of the cervical vagus attenuated strychnine-induced motor 
seizures and pentylenetetrazol-induced tremors (Zabara, 1992).  This seizure 
suppression was proposed to be due to a VNS-induced desynchronization of 
cortical activity, with the seizure suppressive effect persisting following the 
end of stimulation (Zabara, 1992).  
Following on from this preclinical evidence, the first human trial of VNS was 
performed on four treatment-resistant epilepsy patients with refractory partial 
seizures (Penry and Dean, 1990).  Six to twelve months after a stimulator 




connected via an electrode lead to the left cervical vagus, two of the patients 
experienced a complete absence of seizures, with a third patient reporting a 
40% reduction in seizure frequency (Penry and Dean, 1990).  A larger trial 
conducted by DeGiorgio et al. in 164 refractory epilepsy patients observed a 
median reduction in seizure frequency of 45% after 12 months of VNS 
(DeGiorgio et al., 2000).  A retrospective review by Elliott et al. which focused 
on the clinical outcomes of 65 treatment resistant epilepsy patients 10 years 
post-VNS implantation showed improvements in seizure control with 
increasing long-term duration of VNS therapy (Elliott et al., 2011).  A plateau 
in mean seizure reduction was observed at the 2 year mark, after which 
further reductions were modest (Elliott et al., 2011). 
Despite the proven therapeutic efficacy of VNS in patients with treatment-
resistant epilepsy, the mechanisms underlying the seizure-suppressive 
effects of this technique are yet be fully clarified.  However, the activation of 
vagal afferents is known to be critical to the efficacy of VNS.  The afferents in 
the vagus nerve are categorised into myelinated A-fibres and B-fibres as well 
as unmyelinated C-fibres, all of which have different amplitude-duration 
thresholds for excitation (Erlanger, 1930, Groves and Brown, 2005).  The 
unmyelinated C-fibres have the highest excitation threshold (> 2.0mA), 
whereas the excitation thresholds are lower for A-fibres and B-fibres (ranging 
from 0.02 – 0.2mA and 0.4 – 0.6mA respectively).  However, A-fibres and B-
fibres are the most likely to be activated by the VNS stimulation parameters 
as the current is typically at a lower intensity (20 – 30Hz) than the C-fibre 
threshold (DeGiorgio et al., 2000, Ruffoli et al., 2011).  This was directly 
influenced by preclinical evidence from a study of VNS in a rat model of 
pentylenetetrazol-induced seizures (Krahl et al., 2001).  This study showed 
that VNS could reduce seizure severity following the selective capsaicin-
induced destruction of vagal C-fibres, providing further evidence that the 
seizure-suppressive effects of VNS are due to vagal A-fibre and B-fibre 






1.4.3 VNS for the treatment of major depressive disorder (MDD) 
Improvements in mood were observed in many epilepsy patients who 
received VNS treatment.  This phenomenon inspired a pilot study by Harden 
et al. which demonstrated that VNS did have a quantifiable effect on mood 
that was unrelated to its anti-convulsant effects (Harden et al., 2000).  Three 
months of VNS in patients with epilepsy (n = 20) led to significant decreases 
in mood scale scores compared to a control group receiving standard care (n 
= 20).  Moreover, improvements in mood were observed in patients for whom 
there was little improvement in seizure frequency (Harden et al., 2000).  This 
effect led to a number of clinical trials to assess the efficacy of VNS in major 
depressive disorder (MDD) and VNS has subsequently been approved by the 
US Food for Drug Administration (FDA) for the treatment of MDD. 
MDD is a highly disabling condition which is treatment-resistant in around 10 
30% of patients (Al-Harbi, 2012).  An early randomised controlled trial of VNS 
in treatment-resistant MDD patients showed no significant differences 
between the VNS (n = 112) and control groups after 10 weeks (Rush et al., 
2005a).  However, a significant VNS-induced improvement in mood was 
observed from 12 weeks onwards and this sustained at 12 months follow-up, 
suggesting that VNS is more effective over longer time-scales (Rush et al., 
2005b).  Electrophysiological investigation in rats has shown that VNS 
increases the firing rate in the neurones of the locus coeruleus, suggesting 
that VNS can alter noradrenergic signalling: a potential explanation for the 
anti-depressive effects observed with VNS (Dorr and Debonnel, 2006). 
 
1.4.4 VNS for the treatment of chronic heart failure (CHF) 
Given the role of the vagus nerve with regards to cardiac parasympathetic 
innervation, there has been interest in the potential modulatory effects of 
implanted VNS on cardiac function.  In particular, several preclinical animal 
studies provided evidence that VNS may have a therapeutic effect in heart 
failure.  Early work by Vanoli et al. in a canine model of healed myocardial 
infarction (MI) showed that VNS applied to the cervical vagus nerve could 




exercise testing compared to controls (Vanoli et al., 1991).  Following initial 
exercise and ischaemia testing to identify animals susceptible to episodes of 
exercise-induced ventricular fibrillation, 22 out of 24 (92%) of the control 
group animals experienced ventricular fibrillation during a second trial of 
exercise testing compared with just 3 out of 30 (10%) of animals in the VNS 
treatment group (Vanoli et al., 1991).  Additional testing without VNS in the 
treatment group found the incidence rate of ventricular fibrillation increased to 
87% of animals (Vanoli et al., 1991).  This profound reduction in the 
incidence of ventricular fibrillation would suggest that VNS applied to the 
cervical vagus nerve has an anti-arrhythmic effect.   
Following on from this work, Li et al. tested right-sided VNS in a rat model of 
chronic heart failure following left ventricular MI (Li et al., 2004).  A marked 
reduction in mortality rate was found in rats treated with 6 weeks of VNS 
compared to an untreated control group (3 deaths out of 22 for treatment 
group; 15 deaths out of 30 for control group).  This was accompanied by a 
significant reduction in left ventricular end diastolic pressure (LVEDP; 
treatment group = 17.1 ± 5.9 mmHg; control group = 23.5 ± 4.2 mmHg) as 
well as lower plasma norepinephrine levels in the treatment group (426 ± 102 
pg/mL compared to 1182 ± 260 pg/mL in control group).  This latter finding 
suggested that 6 weeks of VNS i.e. vagal activation was capable of 
generating a reciprocal decrease in sympathetic activation.  As the 
progression of CHF is underpinned by a sustained increase in sympathetic 
activation and concurrent withdrawal of parasympathetic activity, this work by 
Li et al. was one of the first to demonstrate that VNS can exert a modulatory 
effect on the cardiovascular autonomic nervous system (Li et al., 2004).  A 
later study by Zhang et al. further assessed the autonomic effects of right-
sided VNS in a canine model of heart failure induced by rapid (220bpm over 
4 weeks) ventricular pacing (Zhang et al., 2009).  The LF/HF ratio decreased 
in the VNS group after 4 weeks of stimulation compared to unstimulated 
controls, suggesting a shift in autonomic nervous system activity towards 
parasympathetic predominance which was reinforced by an increase in HF 
power and a decrease in LF power.  In addition, plasma norepinephrine and 




group compared to control animals, further supporting previous evidence that 
VNS is capable of reducing sympathetic nervous system activity (Li et al., 
2004, Zhang et al., 2009).  A VNS-induced increase in baroreflex sensitivity 
at 4 weeks of stimulation which was sustained at the 8 week time-point was 
also identified, suggesting an enhancement in vagal control had occurred in 
the VNS group over the course of treatment (Zhang et al., 2009).   
The results of these animal studies combined with the established safety 
profile of cervical VNS in human patient groups encouraged investigation into 
the feasibility and tolerability of VNS in CHF patients.  The first of four 
landmark clinical trials to assess the therapeutic efficacy of VNS in heart 
failure was the CardioFit™ non-randomised proof-of-concept phase II safety 
and feasibility trial (Schwartz et al., 2008, De Ferrari et al., 2011).  32 CHF 
patients on optimal medical therapy (e.g. β-blockers, loop diuretics) with a 
NYHA functional classification of II – III and LVEF ≤ 35% were implanted with 
the CardioFit™ VNS system (BioControl Medical Ltd, Israel).  This system 
was a “closed-loop” device with a bipolar electrode cuff positioned around the 
right cervical vagus nerve and an intracardiac sensing lead in the right 
ventricle to monitor heart rate and deliver stimulation at a fixed point in the 
cardiac cycle (Schwartz et al., 2008, Byku and Mann, 2016).  In addition, 19 
patients had already been fitted with an implanted cardioverter defibrillator 
device prior to enrolment (De Ferrari et al., 2011). Six months of chronic 
right-sided VNS led to a significant increase in LVEF and a significant 
reduction in left ventricular end systolic volume.  Improved quality of life 
scores and 6-minute walk test distances were also identified at 6 months and 
19 out of 32 patients were found to have improved by at least one NYHA 
class (De Ferrari et al., 2011).  Crucially, the VNS-induced effects could still 
be observed in 23 patients who were assessed at 12 months such as an 
increase in LVEF from 21% at baseline to 34%, providing strong evidence 
against a placebo effect (De Ferrari et al., 2011).  The promising outcomes 
from this trial led to a series of larger-scale clinical trials of VNS for the 
treatment of chronic heart failure (Premchand et al., 2014, Zannad et al., 




The first of these larger trials was the ANTHEM-HF (Autonomic Neural 
Regulation Therapy to Enhance Myocardial Function in Heart Failure) 
multicentre open-label feasibility study, which compared the safety and 
efficacy of left-sided VNS to right-sided VNS in chronic heart failure patients 
over 6 months (Premchand et al., 2014).  60 CHF patients on optimal 
medical therapy with a NYHA functional classification of II – III and LVEF ≤ 
40% were recruited to the study and implanted with an “open-loop” VNS 
system.  This differed from the CardioFit™ VNS system in that it did not have 
an intracardiac sensing lead and stimulation was delivered at a lower 
intensity (2.0mA on average compared to 4.1mA for the CardioFit trial) (De 
Ferrari et al., 2011, Premchand et al., 2014, Byku and Mann, 2016).  The 
ANTHEM-HF trial reported a significant 4.5% increase in LVEF but no 
significant effect on left ventricular end-systolic volume, the trial’s other 
primary efficacy end-point.  As with the CardioFit trial, quality of life scores 
and exercise tolerance were improved following 6 months VNS (De Ferrari et 
al., 2011, Premchand et al., 2014).  Heart rate variability assessed using 
SDNN was also reported to be higher after 6 months VNS.  No significant 
differences between left and right-sided VNS were reported (Premchand et 
al., 2014).  An extended follow-up at 12 months in 49 consenting patients 
found that there were no serious adverse effects as a result of VNS or 
hardware problems, although some patients reported mild dysphonia or pain 
(Premchand et al., 2016).  Importantly, the effects observed after 6 months of 
either left or right sided VNS were found to have persisted at the 12 month 
time-point and there were no differences in outcomes between the 
stimulation sites (Premchand et al., 2016). 
Another study which used a similar “open-loop” VNS system was the 
NECTAR-HF (Neural Cardiac Therapy for Heart Failure) phase II randomised 
controlled trial (Zannad et al., 2015).  This 12 month trial differed from 
ANTHEM-HF and CardioFit in that it included a sham VNS group as part of 
the study design.  This trial recruited 96 CHF patients with NYHA class II – 
III, LVEF ≤ 35% and left ventricular end-systolic diameter > 55mm.  The 
patients were all implanted with right-sided VNS and randomised 2:1 to 




(stimulator switched off after initial titration visit) for the first 6 months of the 
trial.  All patients then received active VNS treatment for the remaining 6 
months of the trial.  However, the current level achieved through titration in 
the active VNS group was 1.42 ± 0.80mA, lower than CardioFit or ANTHEM-
HF trials.  At 6 months no significant difference was observed between the 
active VNS and sham VNS groups for LV end-systolic diameter, the primary 
efficacy endpoint (Zannad et al., 2015).  Moreover, no significant differences 
were observed between groups at the 6 month time-point for LVEF, LV end-
systolic volume, exercise capacity (peak VO2) or measures of HRV obtained 
from 24 hour ECG Holter recordings, with the exception of SDANN which 
was found to have increased in the active VNS group.  A significant 
improvement in quality of life scores was also reported in the active VNS 
group compared to the sham stimulation and 62% of the active VNS patients 
improved their NYHA class by at least one point compared to 45% of controls 
(Zannad et al., 2015).  While NECTAR-HF was the first and only randomised 
control trial of right-sided VNS for CHF in man, an important limitation of this 
trial was ineffective blinding of patients: 70% of patients in the active VNS 
group correctly guessed their randomisation compared to 31% in the control 
group.  This may have been due to participants perceiving sensations or 
side-effects such as coughing associated with active VNS, which would have 
made it difficult to maintain adequate blinding (Zannad et al., 2015).  
The largest of the four clinical trials for VNS in CHF was the INOVATE-HF 
(Increase of Vagal Tone in Heart Failure) phase III randomised controlled trial 
in 707 CHF patients (NYHA class III; LVEF < 40% and LV end-diastolic 
diameter of 50 – 80 mm).  These patients were randomised 3:2 to receive 
either implanted right sided active VNS plus optimum medical therapy or 
optimum medical therapy alone (control group) (Gold et al., 2016).  A key 
feature of INOVATE-HF was the use of the original CardioFit™ VNS system 
with right ventricular sensing lead.  However, following titration the stimulus 
on-time in the INOVATE-HF trial (5.1 ± 0.8s) was less than in the CardioFit 
trial (7.1 ± 4.8s) (De Ferrari et al., 2011, Gold et al., 2016).  At the outset of 
the trial the primary efficacy end-point was stated to be a composite of all-




failure-associated event which included changes to a patient’s medication 
regimen (Hauptman et al., 2012).  Additional primary safety endpoints were 
>75% freedom from complications associated with VNS in the first 90 days 
following device implantation and comparison between the VNS and control 
groups for all-cause mortality and complications at one year follow-up.  
Patients enrolled in INOVATE-HF were followed up for an average of 16 
months and in some patients up to 4.3 years.  However, the trial was stopped 
early due to statistical futility in the VNS group following an interim analysis, 
with no significant difference in the primary efficacy outcome between the 
VNS and control groups (Gold et al., 2016).  Death or unplanned CHF-related 
hospitalisation occurred in 30.3% of the VNS group versus 25.8% of the 
control group (p = 0.37), with no improvement in left ventricular end-systolic 
volume index (LVESVi) as a result of VNS (Gold et al., 2016).  However, as 
with previous trials there were significant improvements in quality of life, 
NYHA class and 6-minute walking distance after 6 and 12 months of VNS 
treatment, although as the control group received optimum medical therapy 
rather than sham stimulation it is unclear if these improvements were the 
result of a placebo effect (Gold et al., 2016). 
 
1.4.5 Complications associated with VNS 
VNS requires a surgical procedure to implant the electrodes and a 
subcutaneous battery pack in the chest wall, increasing the risk of post-
operative side-effects such as dysphonia, which can occur in up to 62% of 
patients (Handforth et al., 1998, Elliott et al., 2011).  Other common adverse 
effects include stimulation-induced coughing, dyspnoea and neck pain 
(Handforth et al., 1998).  In the longer term, the incidence of adverse effects 
decreases over time with 20% of patients experiencing dysphonia five years 
after VNS implantation and only 5% experiencing other adverse effects (Ben-
Menachem et al., 2015).  There are also a number of hardware issues 
associated with VNS systems.  Patients must avoid machines which emit 
radiofrequency energy such as cardiac defibrillators or high-field MRI 




the vagus nerve and other surrounding tissues (Fahy, 2010).  Hardware 
failure may also require revision surgery to replace faulty electrodes, leaving 
patients at risk of experiencing a relapse in their original symptoms (Dlouhy 
et al., 2012, Spuck et al., 2010). 
 
1.4.6 Non-invasive methods of vagus nerve stimulation  
 
1.4.6.1 Non-invasive cervical vagus nerve stimulation (gammaCore™) 
Given the risk of complications associated with implanted VNS systems, 
there has been emerging interest in non-invasive methods of vagus nerve 
stimulation (nVNS).  One recent development is the handheld gammaCore™ 
device (electroCore LLC, USA) which uses transcutaneous electrical nerve 
stimulation applied to the anterolateral surface of the neck via two stainless 
steel contact electrodes (Figure 1.3) to stimulate the cervical vagus nerve 
without the need for a surgical procedure (Goadsby et al., 2014).  This 
method of non-invasive VNS has been shown in a recent fMRI study with 13 
healthy volunteers to activate the NTS ipsilateral to the stimulation site as 
well other areas associated with vagal central projections such as the insula 
and thalamus (Frangos and Komisaruk, 2017).  Activations were observed 
following cessation of nVNS in sites such as the dorsal raphe nuclei and 
periaqueductal grey, suggesting that the effects of nVNS can persist after 
stimulation has ceased (Frangos and Komisaruk, 2017).  This pattern of 
activation is similar to that observed in fMRI studies of epilepsy and MDD 
patients with implanted VNS (Ko et al., 1996, Narayanan et al., 2002, 
Conway et al., 2012). 
A recent randomised sham-controlled trial with 150 patients with episodic or 
chronic cluster headache patients found that 36% of the episodic cluster 
headache patients responded to nVNS with a substantial reduction in pain 
compared to sham, whereas this effect was not observe in the chronic cluster 
headache group compared to sham (Silberstein et al., 2016).  However 




cluster headache patients found that nVNS may be more effective in 
preventing cluster headaches when combined with a standard care protocol 
compared to a patient group who received standard care alone (Gaul et al., 
2016).  Nonetheless, this new method of cervical VNS, while non-invasive, is 
not without its limitations.  At present the gammaCore™ system is only 
available pre-charged with a maximum of 300 stimulation cycles, meaning 
that a new device needs to be purchased at a cost of £550 to continue 
treatment (Miller et al., 2016).  The electrical current from the device must 
also pass through the tissue overlying the cervical vagus which includes 
branches of the facial nerve as well as nerves originating from the cervical 
plexus.  The activation of other nerve pathways apart from the vagus nerve 
may be responsible for the reports of facial drooping and muscle twitches in a 













Figure 1.3 The gammaCore™ system for non-invasive cervical vagus 
nerve stimulation 




1.4.6.2 The auricular branch of the vagus nerve  
An alternative site of interest for non-invasive vagus nerve stimulation is the 
auricular branch of the vagus nerve (ABVN), the only branch of the vagus 
nerve with a cutaneous distribution.  The ABVN is thought to be a vestigial 
remnant of an embryonic nerve which supplied the first branchial arch (Gupta 
et al., 1986).  In an evolutionary context it may be derived from the cutaneous 
nerve which supplies the lateral line organ in aquatic vertebrates such as 
fish, which use this sensory organ to perceive vibrations and movement in 
their surroundings (Engel, 1979).  In humans, the ABVN innervates the skin 
overlying several cartilaginous structures on the external ear such as the 
tragus, concha and cymba concha as well as the walls of the external 
acoustic meatus (Peuker and Filler, 2002).  The ABVN is mainly composed of 
thick myelinated afferent fibres and a cadaveric study by Safi et al. reported 
averages of 384 axons in the left ABVN and 362 axons in the right ABVN 
(Safi et al., 2016).  The cell bodies of the ABVN afferents are located in the 
jugular ganglion (Safi et al., 2016).  The ABVN contributes to the cutaneous 
innervation of the external ear along with branches from the great auricular 
nerve, the auriculotemporal nerve (V3) and the lesser occipital nerve (Figure 
1.4).  
Peuker and Filler in their study of 14 dissected ears from 7 human cadavers 
found that the ABVN was the only source of innervation to the cymba concha 
(in 100% of specimens dissected; Table 1.2), with this nerve providing 
additional innervation to the antihelix (73%), tragus (45%) and cavity of 
concha (45%)  (Peuker and Filler, 2002).  An interesting clinical case report 
which corresponds with these results described the intracranial sectioning of 
the root of the vagus nerve in a tongue cancer patient to relieve refractory 
pain in the external ear (Fay, 1927).  It was noted that his heart rate 
decreased to 40 beats per minute during the sectioning procedure, while the 
patient later experienced a loss of sensation in the posterior wall of the 
external auditory meatus as well as the concha, antihelix and antitragus (Fay, 
1927).  This pattern of paraesthesia corresponds approximately to the 




2002).  However, there remains some doubt as to the exact arrangement and 









  ABVN GAN ATN 
Crus of helix 20% -  80% 
Spine of helix -  9% 91% 
Tail of helix  - 100%  - 
Scapha  - 100% -  
Crura of antihelix 9% 91% - 
Antihelix 73% 9% 18% 
Antitragus  - 100% -  
Tragus 45% 46% 9% 
Cymba concha 100% -   - 
Cavity of conchae 45% 55%  - 
Lobule of auricle (earlobe) - 100% - 
Table 1.2 Cutaneous distribution of auricular nerves reported by Peuker 
and Filler (2002). 
ABVN = auricular branch of the vagus nerve; GAN = great auricular nerve; 











Figure 1.4 Anatomical landmarks and cutaneous innervation of the 
external ear. 
Three auricular nerves contribute to the cutaneous innervation of the lateral 
aspect of the external ear: the auricular branch of the vagus nerve (ABVN), 
the great auricular nerve (GAN) and the auriculotemporal nerve (ATN). There 
is a variable degree of overlap in the distribution of these cutaneous nerves.  




1.4.6.3 Central projections of the ABVN 
To date there has been just one study with exclusive focus on tracing the 
ABVN central projections to the brainstem, where isolated sections of the 
ABVN were removed from the mastoid canaliculus of the temporal bone in 
seven cats and the transganglionic neuronal tracer horseradish peroxidase 
(HRP) applied to the central cut end of the nerve (Nomura and Mizuno, 
1984).  The study found vagal afferent cell bodies in the jugular ganglion but 
not the nodose ganglion of the vagus nerve, with the ABVN afferent fibres 
projecting to the principal sensory trigeminal nucleus, spinal trigeminal 
nucleus, nucleus tractus solitarius and cuneate nucleus (Nomura and 
Mizuno, 1984).    
A later study by Chien et al. which isolated the rostral, middle and caudal 
internal auricular nerves in 23 dogs found the middle and caudal nerves to be 
composed principally of vagal fibres (88% and 79%) when treated with a 
conjugate of cholera toxin subunit B and HRP, with the neuronal cell bodies 
shown to be located mostly in the jugular ganglion with some retrograde 
labelling present in the geniculate ganglion of the facial nerve (Chien et al., 
1996). The vagal nerve fibres of the middle auricular nerve were found to 
project to the lateral medulla, specifically the spinal trigeminal nucleus and 
nucleus tractus solitarius, with HRP-labelled caudal internal auricular nerve 
terminals located in the paratrigeminal nucleus (Chien et al., 1996).  That 
both studies by Nomura et al. (1984) and Chien et al. (1996) demonstrated 
ABVN projections to the NTS is significant because general visceral afferents 
from the vagus nerve also terminate at this site, suggesting the NTS may act 
as a relay for the ABVN to indirectly influence the autonomic activity of 
visceral organs such as the heart, lungs, liver and stomach.  Further studies 
have found evidence of baroreceptor afferents projecting to a similar region 
as the ABVN on the caudal NTS suggesting that the ABVN could play a role 





1.4.6.4 Auricular reflexes 
There are a number of reports of auricular reflexes which highlight the link 
between the vagal innervation of the external ear and its widespread 
distribution to the thoracic and abdominal viscera (Murray et al., 2016).  Two 
traditional names for the ABVN are the Arnold’s nerve and the Alderman’s 
nerve and these names have been used to describe auricular reflexes.  In 
particular, the Arnold ear-cough reflex was named after the German 
anatomist Friedrich Arnold, who noted that manual stimulation of the 
posterior wall of the external acoustic meatus could lead to coughing in some 
patients.  This reflex is present in approximately 1.7% to 4.2% of the adult 
population (Bloustine et al., 1976, Gupta et al., 1986, Tekdemir et al., 1998) 
and in one third of those individuals can be elicited by stimulating the anterior 
wall of the external acoustic meatus as well (Bloustine et al., 1976).  A recent 
cadaveric study of the myelinated axons in the ABVN in humans found that 
one cadaver had a substantially greater proportion of thickly-myelinated A 
beta class axons in the left ABVN compared to the right ABVN (1007 versus 
289 axons ≥ 7µm) (Safi et al., 2016).  This study proposed that the 
prevalence of the ear-cough reflex may be associated with the number of A-
beta class axons in the ABVN, although no pre-mortem history of ear-cough 
reflex was confirmed in this individual (Safi et al., 2016). 
Related to the ear-cough reflex is gastroauricular phenomenon, which was 
reported in one case study as an itching sensation in the left external 
acoustic meatus which coincided with gastric reflux, both of which were 
relieved by ingesting bicarbonate of soda (Engel, 1979).  In a related case 
study, unilateral ear pain secondary to gastric reflux was resolved with 
administration of ranitidine, a H2 histamine receptor antagonist used to 
decrease stomach acid production (Blau, 1989).  A different form of auricular 
reflex response was reported in a case study involving a female patient who 
perceived a severe pain inside the left ear which coincided with menstruation 
(Engel, 1979).  More recently, Thakar et al. described auricular syncope in a 
young female patient with epilepsy following manual stimulation of the 
posterior wall of the left external acoustic meatus with a cotton-tipped ear 




decrease in heart rate of around 12 bpm.  Interestingly, this response could 
not be elicited via stimulation of the anterior wall of the ear canal or 
stimulation of any point in the right ear canal (Thakar et al., 2008).  In 
addition, there have been reports of pain referred to the ear region as a result 
of angina and myocardial infarction, highlighting a potential neurological 
association between the ear and the heart via visceral afferents (Rothwell, 
1993). 
 
1.4.6.5 Transcutaneous vagus nerve stimulation (tVNS) of the ABVN  
Given the considerable limitations associated with electrical stimulation of the 
cervical vagus nerve, stimulation of the ABVN (tVNS) may offer a convenient 
non-invasive alternative to VNS.  Fallgatter et al. showed that it was possible 
to use transcutaneous electrical stimulation applied to the tragus of the 
external ear to generate vagal sensory evoked potentials (VSEPs) recorded 
using EEG in 6 healthy subjects (Fallgatter et al., 2003).  These VSEPs were 
only reported for stimulation of the tragus and not for other sites such as the 
earlobe, scapha and helix (Fallgatter et al., 2003).  Later fMRI studies 
demonstrated that tVNS (8Hz, 20µs) applied to the tragus could generate 
comparable pattern of cortical activation to invasive VNS (Kraus et al., 2007, 
Kraus et al., 2013).  A later fMRI study in 12 healthy volunteers showed that 
tVNS applied to the left cymba concha could induce significant activation in 
the area of the medulla corresponding to the location of the NTS, with further 
activation in sites such as the dorsal raphe and locus coeruleus (Frangos et 
al., 2015). 
Following on from the VNS for the treatment of refractory epilepsy clinical 
trials, several studies have investigated the anti-convulsant efficacy of tVNS 
(Stefan et al., 2012, He et al., 2013a, Bauer et al., 2016).  A proof-of-concept 
trial by Stefan et al. observed a reduction in seizure frequency after 9 months 
of tVNS in 5 out of the 7 patients who continued stimulation until this time-
point (Stefan et al., 2012).   He et al. showed that TENS (20Hz, 0.4 – 1.0mA, 
30 minutes stimulation 3 times per day) applied using electrode clips to the 




significant reduction in seizure frequency after 24 weeks (He et al., 2013a).  
However, a more recent randomised controlled trial of tVNS in epilepsy 
patients found no difference in seizure frequency between the treatment 
group which received tVNS at 25Hz and the control group which received 
tVNS at 1Hz (Bauer et al., 2016).  This may have been due to the study 
being too underpowered, as seizure frequency was shown to decrease by 
23.4% in the 25Hz tVNS group and increase by 2.9% in the control group 
(Bauer et al., 2016).   
Meanwhile, promising results have been observed in trials of tVNS in patients 
with treatment-resistant MDD (Hein et al., 2013, Rong et al., 2016).  tVNS 
delivered for 15 minutes per day for 2 weeks using a device with electrodes 
inserted into the external acoustic meatus (NET-1000, Auri-Stim Medical Inc., 
USA) showed improvements in mood scores compared to sham stimulation 
(Hein et al., 2013).  A later non-randomised clinical trial in patients with mild 
to moderate MDD compared a treatment group (n = 91) who received tVNS 
applied to the cymba concha and concha with a sham stimulation group who 
received earlobe stimulation (n = 69).  Compared to sham, tVNS could 
reduce depressive symptoms as well as symptoms of anxiety after 4 weeks 
of stimulation (Rong et al., 2016).  An fMRI study of tVNS applied to the 
concha and cymba concha in patients with MDD (n = 17) compared to a 
control patient group (n = 21) who received stimulation of the scapha 
(innervated by cervical spinal afferents) showed that 4 weeks of tVNS 
induced significant activation in the anterior insula compared to controls 
(Fang et al., 2017).  The anterior insula is a cortical site known to be integral 
for the processing of emotional stimuli and is further implicated in the 
neuropathology of MDD (Sprengelmeyer et al., 2011).  In this way, Fang et 
al. proposed that tVNS-induced anterior insula activation assessed using 
fMRI may be a biomarker to identify MDD patients who might respond to 
longer-term treatment with tVNS (Fang et al., 2017). 
Another condition for which there is evidence that tVNS may have 
therapeutic potential is chronic tinnitus.  Tinnitus is associated with 
pathological changes in the central auditory system due to factors such as 




affects up to 16% of the general adult population (Nondahl et al., 2011, 
McCormack et al., 2014).  Invasive VNS paired with acoustic stimulation 
(tones outside of the frequencies associated with tinnitus) has been shown to 
produce improvements in tinnitus severity in a rat model of tinnitus (Engineer 
et al., 2011) and in clinical pilot studies (Vanneste and De Ridder, 2012, De 
Ridder et al., 2014).  Initial safety data for the use of tVNS as a treatment for 
tinnitus showed that tVNS was safe for use in patients without cardiac 
disease (Kreuzer et al., 2012, Kreuzer et al., 2014).  However the efficacy of 
tVNS seemed to be dependent on the use of paired acoustic stimulation, as 
tVNS alone had a minimal effect on tinnitus symptoms.  Another small-scale 
study of tVNS for the treatment of tinnitus included paired acoustic 
stimulation as part of the treatment protocol (Lehtimaki et al., 2013).  
Lehtimaki et al. recruited 10 patients with chronic tinnitus to receive daily 
tVNS applied to the left tragus (25Hz) at the same time as listening to an 
edited piece of classical music over 10 days, with each individual session 
lasting 45 - 60 minutes.  The music was filtered to remove frequencies 
corresponding the individual’s tinnitus frequencies (Lehtimaki et al., 2013).  
Significant improvements in mood were observed as a result of tVNS and the 
loudness of the tinnitus sounds was reported to have diminished (Lehtimaki 
et al., 2013).  The study also reported that tVNS modulated the activity of 
evoked auditory cortical potentials as assessed by magnetoencephalography 











1.4.6.6 The cardiac effects of tVNS 
The retrospective assessments of cardiac safety performed in studies with 
tinnitus patients found that tVNS caused no adverse cardiac effects in 
patients with no prior medical history of cardiac pathology (Kreuzer et al., 
2012, Kreuzer et al., 2014).  Kreuzer et al. reported a decrease in heart rate 
after 30 minutes of tVNS, but no adverse events or side-effects occurred as a 
direct result of stimulation (Kreuzer et al., 2012, Kreuzer et al., 2014).  
However, the investigations of invasive VNS for the treatment cardiovascular 
disease states such as CHF has also led to interest in the potential cardiac 
therapeutic benefits of tVNS. 
Two early tVNS studies were performed in coronary artery disease (CAD) 
patients with angina pectoris who were due to receive a coronary artery 
bypass graft (Zamotrinsky et al., 1997, Zamotrinsky et al., 2001).  
Electroacupuncture was used to deliver tVNS to the inferior concha of both 
ears for 15 minutes daily over the course of 10 days.  This electrical 
stimulation was observed to reduce the incidence of angina pectoris and the 
reduction in symptom severity persisted for several weeks following the 
course of treatment.  In addition, there was also an observed decrease in the 
use of oral vasodilator medication such as glycerol trinitrate (Zamotrinsky et 
al., 1997, Zamotrinsky et al., 2001).  Biopsies of atrial tissue taken during the 
coronary artery bypass procedure showed that patients who had undergone 
tVNS had decreased tissue concentrations of heat shock protein (HSP) 70 as 
well as reduced levels of ATP in the atrial tissue (Zamotrinsky et al., 1997).  
Following the surgical procedure, the patients who had received tVNS had 
improved clinical outcomes compared to a control group, with the tVNS-
treated patients having a reduced prevalence of acute heart failure 
(Zamotrinsky et al., 2001).  In a later study of a 10-day course of tVNS with 
coronary artery disease patients, Popov et al. found a significant reduction in 
the severity of angina attacks in approximately 62.5% of the patients (Popov 
et al., 2013).  While this study did not demonstrate any improvements in 
clinical outcomes of tVNS, an improvement in general quality of life was 
observed (Popov et al., 2013).  However, further analysis of patients who 




ratio from baseline following tVNS, suggesting that in this cohort of patients 
treatment with tVNS may have generated an increase in vagal activation 
(Popov et al., 2013). A larger 15 day trial of daily tVNS (up to 30 minutes per 
day) in patients with chronic heart failure and severe left ventricular 
dysfunction (n = 51) found significant improvements in clinical outcomes for 
the majority of patients who received tVNS compared to a control group 
(Afanasiev et al., 2016).  These improvements included significantly 
increased LVEF and a decrease in LV end-systolic volume, as well as 
reduced dyspnoea and fatigue.  Moreover, these improvements were 
accompanied by a significant increase in exercise tolerance as assessed by 
increased distance covered during a 6 minute walk test (Afanasiev et al., 
2016).  In addition tVNS was observed to evoke bradycardia in the patients 
who received tVNS as well as increased levels of heat shock proteins HSP60 
and HSP70 in patients who had an initial heart rate of less than 80 bpm.  
Patients with a heart rate greater than 80 bpm exhibited increased levels of 
HSP70 alone (Afanasiev et al., 2016). In patients with paroxysmal atrial 
fibrillation, one hour of low level tVNS performed under general anaesthesia 
led to a significant decrease in the duration of atrial fibrillation episodes 
induced by burst atrial pacing (Stavrakis et al., 2015). Moreover, tVNS 
elicited significantly reduction in plasma levels of the inflammatory cytokines 
such as tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and C-
reactive protein (Stavrakis et al., 2015).  Given the promising outcomes of 
these clinical studies and the possibility that tVNS may have a 
cardioprotective effect, further investigation is warranted to identify which 
cardiovascular disease states may potentially benefit most from tVNS. 
The observed efficacy of tVNS in patients with cardiac disease has been 
reinforced by preclinical evidence in animal models.  In a canine model of 
atrial fibrillation induced under general anaesthesia, tVNS (20Hz, pulse width 
1ms, duty cycle 5s on/5s off) applied using electrodes clipped onto the right 
tragus had a significant effect on atrial remodelling and inhibited the induction 
of atrial fibrillation elicited by 3 hours of rapid atrial pacing prior to stimulation 
(Yu et al., 2013).  Additional studies where tVNS the right or left tragus 




pacing by preventing the loss of the atrial connexin gap junction proteins 
Cx40 and Cx43 (Chen et al., 2015b, Chen et al., 2015a).  Another study 
using the same stimulation parameters in conscious dogs with healed 
myocardial infarction showed that 90 days of tVNS (4 hours per day) applied 
bilaterally to the tragus could increase LVEF, reduce left ventricular dilatation 
and improve left ventricular contractility (Wang et al., 2014).  In addition, 
tVNS was shown to reduce the plasma concentration of norepinephrine 
compared to controls, suggesting that the cardiac effects observed as result 
of chronic tVNS were accompanied by a reduction in sympathetic nerve 
activity (Wang et al., 2014).   
 
1.4.6.7 The effects of tVNS on cardiovascular autonomic function 
A number of studies have examined the effects of tVNS on measures of 
cardiovascular autonomic function in humans.  La Marca et al. identified a 
significant increase in respiratory sinus arrhythmia (an indirect marker of 
parasympathetic nervous system activity) following auricular acupuncture in 
14 healthy male volunteers (La Marca et al., 2010).  This effect was observed 
only with electroacupuncture and no significant changes in RSA were 
observed in these volunteers during manual acupuncture, sham acupuncture 
(using a false needle) or during quiet rest with no needle insertion (La Marca 
et al., 2010).  In 15 female patients with chronic pelvic pain, no significant 
change in heart rate or heart rate variability was detected as a result of tVNS 
gated to the exhalation phase of respiration (Napadow et al., 2012).  A study 
in 34 healthy volunteers by Clancy et al. found that 15 minutes of tVNS (10 – 
50mA, 30Hz, 200µs) applied bilaterally to the tragus led to a decrease in the 
LF/HF ratio from baseline (Clancy et al., 2014).  This was further 
accompanied by a decrease in MSNA measured using microelectrodes 
inserted into the common peroneal nerve in 10 volunteers, suggesting that 
the change in autonomic function was due to a decrease in sympathetic 
nervous system activity (Clancy et al., 2014).  Further work using the same 
stimulation parameters in a cohort of young healthy male volunteers (n = 13) 




increase in spontaneous baroreflex sensitivity (BRS) measured using the 
sequence technique (Antonino et al., 2017).  This effect was not observed in 
either sham tVNS (electrical current switched off) or earlobe stimulation 
(Antonino et al., 2017). 
However, a recent study by De Couck et al. did not find a significant effect on 
cardiovascular autonomic function as a result of tVNS applied to cymba 
concha of the ear (De Couck et al., 2017).  This study occurred in two stages 
and the first stage compared the effects on HRV of 10 minutes tVNS applied 
to the left cymba concha to tVNS applied to the right cymba concha in a 
cohort of 30 healthy volunteers.  Right-sided tVNS increased SDNN from 
baseline whereas left-sided tVNS caused no significant changes in HRV.  
However, when right-sided tVNS was investigated in the second stage over 
the course of one hour, no significant changes in HRV were observed after 
correction for confounding variables (De Couck et al., 2017).  A key 
difference between this study and the studies by Clancy et al. and Antonino 
et al. is that De Couck et al. employed different stimulation parameters 
(250µs, 25Hz, duty cycle of 30s on/ 30s off) in addition to stimulating the 
cymba concha rather than the tragus.  As both of these sites are known to 
receive innervation from the ABVN, the choice of stimulation site should in 
theory not matter so long as the electrodes are still positioned within the 
range of the ABVN dermatome (Peuker and Filler, 2002).  However, the 
presence of other nerves innervating the tragus but not the cymba concha 
such as the auriculotemporal nerve and great auricular nerve may suggest 
that tVNS applied to the tragus could also be activating trigeminal and 








1.5 Non-invasive trigeminal nerve stimulation (TNS) 
While the invasive and non-invasive forms of vagus nerve stimulation have 
shown promise as adjunctive treatments for a wide range of disorders, other 
forms of electrical neuromodulatory therapies are currently under 
investigation.  One of these is non-invasive trigeminal nerve stimulation 
applied to the supraorbital branches (V1) located under the skin of the 
forehead (DeGiorgio et al., 2006).  This alternative method of non-invasive 
cranial nerve neuromodulation has been trialled in several conditions such as 
treatment resistant epilepsy (DeGiorgio et al., 2006, DeGiorgio et al., 2013), 
MDD (Cook et al., 2013) and migraine (Schoenen et al., 2013). 
  
1.5.1 Neuroanatomy of the trigeminal nerve  
While the vagus nerve is the longest and most widely-distributed of the 12 
cranial nerves, it is the trigeminal nerve (cranial nerve V) which is physically 
the largest (Go et al., 2001). It emerges bilaterally as a single large sensory 
root and a smaller motor root from the ventrolateral aspect of the pons, which 
both cross anteriorly through the prepontine cistern and enter Meckel’s cave, 
a cerebrospinal fluid-filled extension of the subarachnoid space (Borges and 
Casselman, 2010).  At this point lies the trigeminal sensory ganglion, 
containing somatic afferent cell bodies and from here the three major 
branches of the trigeminal nerve divide: the ophthalmic (V1), maxillary (V2) 
and mandibular (V3) divisions.  The respective divisions then exit the skull 
and are distributed to the face via the superior orbital fissure (V1), the 
foramen rotundum (V2) and foramen ovale (V3) (Go et al., 2001).   
As with the vagus, the trigeminal nerve is a mixed nerve but the motor 
efferent component is confined to the V3 division in order to innervate the 
anterior belly of the digastric muscle, tensor veli palatini, tensor tympani and 
the four muscles of mastication: temporalis, masseter and the medial and 
lateral pterygoids (Go et al., 2001).  The V1 and V2 divisions are composed 
exclusively of somatic afferents which transmit information about orofacial 
touch, pain and temperature sensation, as well as intracranial sensation from 




external ear via the auriculotemporal nerve, where its receptive field overlaps 
with the auricular branch of the vagus nerve (Peuker and Filler, 2002).   
The trigeminal ganglion, located in Meckel’s cave, projects to a bilaterally-
arranged trigeminal tract containing three sensory nuclei – the 
mesencephalic nucleus, major trigeminal sensory nucleus and spinal 
trigeminal nucleus – as well as a smaller motor nucleus (Borges and 
Casselman, 2010).  The trigeminal sensory nuclei have reciprocal projections 
to other brainstem structures such as the paratrigeminal nucleus, NTS, locus 
coeruleus and the extensive network of diffuse nuclei known as the reticular 
formation (Grzanna et al., 1987, Caous et al., 2001).  These sites are known 
from studies in animal models of epilepsy to be critical to the inhibition of 
seizures and there is evidence that electrical stimulation of the trigeminal 
nerve and associated nuclei can suppress seizure activity.   In a feline model 
of chronic seizures induced by stimulating electrodes implanted in the 
amydala, stimulation of the NTS delayed or suppressed the onset of seizure 
activity (Magdaleno-Madrigal et al., 2002).  Similar effects were observed 
with stimulation of the locus coeruleus in rats following induction of seizures 
by intracerebral infusion of 6-hydroxydopamine and electrical stimulation of 
the amydala (Jimenez-Rivera et al., 1987).  The locus coeruleus in particular 
is known to be involved in catecholaminergic neurotransmitter synthesis (e.g. 
norepinephrine) and is known to be a critical pathway for the anticonvulsant 










1.5.2 Non-invasive TNS for the treatment of intractable epilepsy 
The anti-epileptic effects of implanted VNS formed the basis for an 
investigation by Fanselow et al. (2000) into the therapeutic benefits of 
trigeminal nerve stimulation in a rat model of generalised tonic-clonic 
seizures (Zabara, 1992, Penry and Dean, 1990, Fanselow et al., 2000).  
Intraperitoneal injection of pentylenetetrazol was used to induce acute 
seizures in awake adult female rats (n = 8).  The duration and severity of the 
seizures was assessed using field potentials recorded from the thalamus and 
somatosensory cortex via implanted microwire electrode arrays.  Stimulating 
electrode cuffs were also implanted around the infraorbital nerves (V2 
division) to deliver either unilateral or bilateral stimulation.  Fanselow and 
colleagues found continuous unilateral stimulation of the infraorbital nerve 
reduced seizure activity (a reduction of around 36% to 58% in seizure 
frequency), with the effect becoming stronger with increasing levels of current 
(3 – 11mA in 2mA increments).  For these experiments the stimulus pulse 
duration and frequency were kept constant (0.5ms and 333Hz respectively).   
However a frequency-dependent effect was also observed when current was 
held at 9mA, with stimulation at greater frequencies (100Hz, 125Hz, 200Hz 
and 333Hz) leading to fewer seizures than lower frequencies (≤ 50Hz) or 
control (no stimulation).  Bilateral stimulation was also found to be more 
effective at reducing seizure activity than unilateral stimulation, with the 
additional benefit of being able to apply a lower level of current using bilateral 
stimulation to achieve a similar level of seizure reduction (Fanselow et al., 
2000).   
This study by Fanselow et al. informed a proof-of-concept clinical study which 
investigated the safety and efficacy of TNS applied bilaterally to the 
infraorbital and supraorbital nerves in seven intractable epilepsy patients 
(DeGiorgio et al., 2003, DeGiorgio et al., 2006).  Stimulation was well-
tolerated and four patients experienced a ≥50% reduction in the frequency of 
their seizures after three months of chronic TNS (≥12 hours stimulation per 
day), an effect which was maintained at six months.  The patients also 
reported that they preferred to apply TNS to the supraorbital stimulation site 




hat (DeGiorgio et al., 2006).  It is nonetheless important to note that none of 
the observed reductions were reported as significant, likely due to the small 
number of patients recruited to the study (DeGiorgio et al., 2006).  A 
subsequent, larger scale phase II randomised clinical trial (n = 42) of 
supraorbital TNS for intractable epilepsy compared a treatment group which 
received TNS based on stimulation parameters used in the previous studies 
(120Hz, pulse duration <250µs, ≥12 hours stimulation per day) against a 
group which received lower-intensity stimulation (2Hz, 50µs, duty cycle 2 
seconds on and 90 seconds off).  This trial reported a significant 25% 
decrease in seizure frequency at 12 weeks in the treatment group (n = 23) 
compared to a 1.2% increase in seizure frequency in the low intensity 
stimulation group (n = 19).  After 18 weeks, 40.5% of the treatment group 
exhibited a ≥ 50% reduction in seizure frequency compared to 15.6% of the 
low intensity stimulation group at the same time point (DeGiorgio et al., 
2013).  A follow-up study with the same patient cohort after 12 months of 
stimulation found that 7 of the 19 patients assigned to the treatment group 
experienced a ≥ 50% reduction in seizure frequency while only 4 out of 16 
patients in the low-intensity stimulation group achieved the same level of 
seizure reduction (Soss et al., 2015). 
The potential mechanism behind this reduction in seizure activity was 
hypothesised to be due to the cortical desynchronisation produced by TNS, a 
change in cortical excitability which can disrupt seizure activity, which may be 
due to a generalised activation of midbrain nuclei and not solely through 
activation of the trigeminal tract.  Furthermore this would indicate that 
multiple cranial nerves other than the vagus may be used to elicit the anti-
epileptic effects described by invasive VNS and tVNS studies (Fanselow et 








1.5.3 Non-invasive TNS for treatment-resistant major depressive 
disorder 
The phase II randomised clinical trial of supraorbital TNS for intractable 
epilepsy (n = 42 patients) also reported an improvement in mood in the 
treatment group compared to the active control (low intensity stimulation) 
group, as assessed using the Beck Depression Inventory (DeGiorgio et al., 
2013).  Given the neuroanatomy of the trigeminal nerve and the documented 
effects of VNS on mood, a proof-of-concept study of supraorbital TNS in 
patients with treatment-resistant major depressive disorder (MDD) was 
performed (Schrader et al., 2011, Cook et al., 2013).  Eleven MDD patients 
received 8 hours of TNS each night while asleep over the course of 8 weeks, 
with fortnightly assessment of depressive symptoms using the 28-item 
Hamilton Depression Rating Scale (HDRS28).  TNS was well-tolerated in 
these patients apart from mild skin irritation due to the electrode pads.  By 
week 8, six of 11 patients had experienced a significant reduction of ≥ 50% in 
depressive symptoms from baseline, with remission of symptoms in 4 of 11 
patients (Cook et al., 2013).  A similar trend was observed in a second study 
in 12 adult patients with comorbid MDD and posttraumatic stress disorder 
assessed using the HDRS17.  Five out of 12 patients experienced a ≥ 50% 
reduction in depression severity, of which three achieved remission of 
symptoms (Cook et al., 2016).  A significant improvement in quality of life 
scores was also identified at 8 weeks using the Q-LES-Q Quality of Life 
Enjoyment and Satisfaction Questionnaire (Cook et al., 2016). 
 
1.5.4 Non-invasive TNS for the treatment of migraine  
The limited treatment and preventative options available to patients with 
chronic migraine has inspired several trials to assess the efficacy of TNS for 
this disabling primary headache condition.  An initial pilot study of TNS over 3 
months in episodic migraine patients (n = 9) found a significant reduction 
from baseline in the frequency of migraine attacks per month using the 
Cefaly supraorbital nerve stimulation system (STX-Med., Belgium) to deliver 




randomised sham-controlled trial where 67 migraine patients (≥ 2 migraine 
attacks per month) received either active TNS (250µs, 60Hz) or sham 
stimulation (30µs, 1Hz) for 20 minutes each day over 3 months (Schoenen et 
al., 2013).  In the first month of treatment, the number of days per month 
where a migraine occurred (monthly migraine days) decreased by 20% for 
both the active TNS and sham TNS groups.  However, only the active TNS 
group exhibited a further decrease in monthly migraine days by the end of 
the trial, with a significant decrease at 3 months for active TNS of 29.7% 
(Schoenen et al., 2013).  In addition this trial did not report any serious or 
adverse side-effects as a result of TNS and the few contraindications for use 
(unsuitable for patients with recent brain or facial trauma) are in marked 
contrast to the frequent adverse effects of existing pharmacological anti-
migraine treatments (Schoenen et al., 2013).   
A more recent controlled trial by Przeklasa-Muszynska et al. (2017) 
compared the effects of ten 20 minute sessions of supraorbital TNS in a 
cohort of patient with either migraine with aura, migraine without aura or 
another primary headache condition (n = 57).  The effects of TNS in these 
patients were then compared with another group of migraine patients who 
received optimum pharmacological therapy (n = 30).  Patients who received 
TNS reported a significant reduction in pain intensity (36 – 37%) migraine 
attacks, whereas no decrease in pain intensity was observed for the control 
group (Przeklasa-Muszynska et al., 2017).  A study of the acute effects of 
TNS in 30 migraine patients who had the stimulus applied during a migraine 
attack found that 76% of patients experienced a ≥ 50% reduction in pain 









1.5.5 Cardiovascular effects of trigeminal nerve stimulation  
Almost all of the clinical trials of supraorbital TNS included non-invasive 
assessments of heart rate and blood pressure to monitor for adverse 
cardiovascular effects in response to stimulation.  DeGiorgio et al. (2006) 
assessed HR, blood pressure and ECG changes every five minutes when 
TNS was applied for one hour on the first day of stimulation.  No significant 
changes in any of these measures were reported as a result of TNS during 
this observation period or at a subsequent observation period 24 hours later 
(DeGiorgio et al., 2006).  The later phase II clinical trial of TNS in epilepsy 
also failed to detect any significant changes in heart rate, diastolic BP or 
systolic BP either between or within groups (treatment versus control) over 
the course of the 18 week stimulation period (DeGiorgio et al., 2013).  The 
TNS for MDD trials also failed to detect any significant changes in HR or BP, 
although Cook et al. (2016) detected a small but insignificant decrease in HR 
from 76.7bpm to 74.9bpm after 30 min of stimulation at the first visit to the 
clinic (Cook et al., 2013, Cook et al., 2016).  The lack of any observed TNS-
induced changes in cardiovascular function is perceived to be a major benefit 
to this form of neuromodulation, which broadens its potential clinical utility 
compared to invasive techniques such as implanted VNS.  However, a safety 
study in epilepsy patients by Pop et al. did detect a small (4%) significant 
decrease in heart rate after 15 minutes of TNS applied to the supraorbital 
nerves, suggesting that some changes in cardiovascular autonomic function 
may occur as a result of TNS (Pop et al., 2011).  
There is preclinical evidence that TNS may indeed be able to have an effect 
on the cardiovascular system.  In a rat model of traumatic brain injury (n = 
12), intermittent TNS (25 Hz, 1 second on/1 second off duty cycle, 1.0V, 1.0 
ms) applied directly to the anterior ethmoidal nerve (V1) caused a significant 
increase in heart rate from baseline during the first minute of stimulation (340 
± 26 bpm to 351 ± 26 bpm) as well as a significant increase in mean arterial 
pressure (118.6 ± 10.7 to 129.5 ± 9.1 mmHg).  Both HR and MAP returned to 
baseline levels within 10 minutes of cessation of the stimulus (Chiluwal et al., 
2017).  In the same study, electroacupuncture stimulation applied for 1 




second on/1 second off duty cycle, 3.0V, 0.5ms) elicited a similar increase in 
HR and MAP as direct stimulation of the anterior ethmoidal nerve (Chiluwal 
et al., 2017).  This may have been due to increased activation in the RVLM 
as a result of TNS applied to V1, which corresponds with the additional 
observation of a 70.4% increase in cerebral blood flow due to TNS-induced 
cerebral vasodilation. 
 
1.6 General hypothesis 
Non-invasive cranial nerve stimulation will alter autonomic nervous system 
activity.  Both transcutaneous vagus nerve stimulation and trigeminal nerve 
stimulation will induce changes in cardiovascular autonomic function. 
 
1.7 Aims and Objectives 
The primary aim of this thesis was the investigation of two non-invasive 
methods of electrical cranial nerve neuromodulation – transcutaneous vagus 
nerve stimulation (tVNS) and transcutaneous trigeminal nerve stimulation 
(TNS).  The objectives for the tVNS studies included in this thesis were: 
1. To investigate the effects on HRV and BRS of tVNS applied to the 
tragus and compare these effects with those elicited through electrical 
stimulation of the cymba concha (ABVN), earlobe (cervical spinal 
afferent innervation) and helix (trigeminal nerve) in healthy volunteers. 
2. To determine the effects of tVNS applied to the tragus on HRV, BRS 
and MSNA in an aged healthy volunteers 
3. To determine the effects of tVNS on HRV and BRS in a cohort of heart 
failure patients 
The objectives for the TNS study were: 
1. To investigate and compare the effects on HRV and BRS of low 



































2.1 Human research participants 
All experiments with human research participants conformed to the standards 
outlined in the Declaration of Helsinki.  Informed written consent was 
obtained voluntarily from all research participants and their data were 
anonymised and stored securely according to the Data Protection Act (1998).  
Most experiments were carried out in a dedicated human physiology study 
room at University of Leeds between the hours of 8am and 11am in order to 
minimise the impact of circadian rhythm variations on the autonomic nervous 
system.  For some participants it was not possible to perform experiments 
during this time or in the same room and these exceptions are highlighted in 
the appropriate chapters. The ambient temperature of the study rooms where 
experiments took place was maintained at 21 ± 2°C.  
Prior to taking part in experiments, all participants were asked to complete a 
basic health questionnaire.  Physical activity level was assessed using the 
Godin Leisure Time Exercise Questionnaire (Amireault and Godin, 2015).  
Inclusion criteria varied according to each study and these criteria are 
detailed in the respective chapters. Exclusion criteria were a prior medical 
history of hypertension, cardiac disease, diabetes mellitus or epilepsy.  
Female participants were asked to indicate if they were receiving hormonal 
replacement therapy (HRT) for treatment of menopausal symptoms, as HRT 
has been shown to independently alter cardiac autonomic activity (Yildirir et 
al., 2001).  All participants were required to abstain from caffeine, alcohol, 
nicotine and strenuous exercise for a minimum of 12 hours prior to their visit.  
They were further required to consume a light breakfast and use the toilet 










2.2 Experimental protocol 
 
2.2.1 General protocol  
Participants reclined semi-supine on a couch for the duration of each 
experiment while recordings of their heart rate, finger arterial blood pressure 
and respiration rate were obtained.  In Chapter 4 a smaller cohort of 
participants returned for an additional visit where microneurography was 
performed to record MSNA in addition to the non-invasive measures.  
Participants rested for 10 minutes during experimental set-up and before 
recordings commenced.  Three 10 minute recordings were obtained at each 
visit: at baseline (pre-intervention), during the final 10 minutes of the 15 
minute stimulation period and during recovery (post-intervention).  Brachial 
blood pressure was determined using a digital monitor (Omron Intellisense 
M7, Omron Healthcare, Netherlands) at the end of each recording to validate 
the finger arterial blood pressure measurements.  The number of 
experiments the participants were asked to attend depended on the particular 
study and this information is detailed in each chapter. 
 
2.2.3 Transcutaneous vagus nerve stimulation 
In Chapters 3, 4 and 5 tVNS was applied for 15 minutes to the tragus and 
anterior wall of the external acoustic meatus via a TENS machine (V-TENS 
Plus, Body Clock Health Care Ltd, United Kingdom; Figure 2.1) with 
customised auricular electrode clips (Auricular Clips, Body Clock Health Care 
Ltd, UK; Figure 2.1).  In all tVNS experiments the participants wore the 
electrode clips throughout the three experimental recordings obtained at 
each visit.  Following the baseline recording, the electrical current was 
increased by small increments until the participant’s threshold of sensory 
perception was reached and the individual could perceive the stimulus, often 
reported as a ‘pin-prick’ or ‘tingling’ sensation in the tragus (10-50mA; Table 
2.1).  The current was then decreased until the stimulus was borderline 




2.2.3.1 Sham tVNS 
Chapter 4 included a sham tVNS visit in addition to an active tVNS visit.  The 
sham tVNS protocol involved positioning the electrode clips on the tragus of 
the ear and titrating the stimulus amplitude as normal until the participant 
could perceive any sensation from the clips.  The participant was then 
informed that the amplitude would be reduced to prevent any discomfort and 
the electrode leads were disconnected from the TENS machine without the 
participant’s knowledge. 
 
2.2.3.2 Stimulation tolerability questionnaire 
In Chapter 5, the heart failure patients were invited to complete a tolerability 
questionnaire following completion of their experiment.  The purpose of this 
questionnaire was to assess their experience of receiving short-term tVNS 
and identify potential discomfort and other stimulus-associated sensations.  
Each question on the questionnaire was accompanied by a Likert-type scale 
ranging from 0 (“not at all”) to 5 (“extremely”).  Patients were further asked to 
rate the comfort of the couch itself and also to report any anxiety or chest 
palpitations they might have experienced during the experiment.  Space was 
provided on the questionnaire for additional comments from the participants. 
 
2.2.4 Trigeminal nerve stimulation 
In Chapter 6, TNS was applied for 15 minutes to supraorbital nerve branches 
of the ophthalmic division (V1) of the trigeminal nerve using two adhesive 
TENS pads positioned approximately one inch apart (see Figure 2.2).  
Participants wore the electrodes throughout all three experimental 
recordings.  Following the baseline recording, the electrical current was 
increased by small increments until the participant’s threshold of sensory 
perception was reached and the individual could perceive the stimulus, often 
reported as a ‘tingling’ sensation running superiorly from the forehead across 




The current was then decreased until the stimulus was borderline perceptible 
and not uncomfortable.   
 
2.2.4.1 Stimulation parameters for TNS 
Two active TNS parameters were investigated in Chapter 6 – low frequency 
TNS (L-TNS, 30Hz, 200µs, continuous current) and high-frequency TNS (H-
TNS, 120Hz, 250µs, 30s on/30s off duty cycle).  The L-TNS parameters were 
identical to those used for tVNS and were delivered using a V-TENS Plus 
TENS device (V-TENS Plus, Body Clock Health Care Ltd, United Kingdom).  
The H-TNS parameters were derived from clinical studies by DeGiorgio and 
colleagues (UCLA, USA) and were delivered using an EMS DE7500 device 
which was capable of delivering the current on an adjustable on/off duty cycle 
(DeGiorgio et al., 2006).   
 
2.2.4.1 Sham TNS 
For the sham TNS experiments in Chapter 6 (n=10), participants were told 
that a separate set of stimulation parameters would be tested involving a 
reduction in the current below the participant’s level of sensory perception.  
The parameters described in the previous section for L-TNS were used again 
in the initial sham TNS titration stage.  The amplitude was briefly (10-30 
seconds) titrated up to the threshold of sensory perception before being 
reduced and the electrode leads were then disconnected from the TENS 






       Table 2.1 Overview of the stimulation parameters included in this thesis. 
Intervention Stimulation site Method Stimulation parameters  
tVNS Tragus of external 
ear (bilateral) 
Two auricular electrode clips 
with V-TENS Plus device 
15 minutes, 10-50mA, 30Hz, 200µs, continuous 
current  
Sham tVNS Tragus of external 
ear (bilateral) 
Two auricular electrode clips 
with V-TENS Plus device 
10-20 seconds exposure to continuous current (10-
50mA, 30Hz, 200µs) followed by 15 minutes of no 
current (electrodes disconnected from TENS machine) 
L-TNS Supraorbital 
region 
Two adhesive TENS 
electrodes with V-TENS Plus 
device 




Two adhesive TENS 
electrodes with EMS 
DE7500 device 
  
15 minutes 10-50mA, 120Hz, 250µs, 30 seconds on/ 
30 seconds off duty cycle  
Sham TNS Supraorbital 
region 
Two adhesive TENS 
electrodes with V-TENS Plus 
device 
10-20 seconds exposure to continuous current (10-
50mA, 30Hz, 200µs) followed by 15 minutes of no 








Figure 2.1 Transcutaneous vagus nerve stimulation (tVNS) applied to 
the tragus of the ear.  The technique uses a TENS machine and modified 
auricular electrode clips to stimulate cutaneous nerve endings in the tragus. 
Figure 2.2 Non-invasive trigeminal nerve stimulation applied to the 
supraorbital nerves of the forehead.  This technique uses a TENS 
machine and adhesive electrode pads to stimulate the supraorbital branches 




2.4 Heart rate variability 
Heart rate was recorded using a three lead ECG where electrodes (Ambu 
BlueSensor SP, UK) were placed on the right and left costal margins and the 
right clavicle in order to detect a prominent R peak (lead II) for HRV analysis 
with Spike2 software (Cambridge Electronic Design, UK).  The ECG was 
monitored throughout all experiments for the presence of signal artefacts or 
ectopic beats (premature ventricular contractions or ventricular 
extrasystoles).  
Offline analysis was carried out using Spike2 (version 7.1; CED, UK) and 
Labchart (version 8.1.5; ADInstruments, Bella Vista, Australia) software.  
Mean heart rate was derived from the final five minute segment of each ECG 
recording.  The R-R intervals from this time period were used to produce a 
tachogram which was inspected manually to ensure all R-peaks had been 
detected.  Occasional R-R interval abnormalities due to ectopic beats (≤ 2 
events in the five minute ECG segment) were corrected by averaging the R-
R intervals immediately before and after the event.  The R-R interval 
tachogram was resampled at 5 Hz a DC removal process applied to change 
the channel offset to zero.  The tachogram then underwent 512 point Fast 
Fourier Transform with a Hanning window (50% overlap) to calculate the 
HRV power spectrum.  The LF power and HF power components were 
normalised as a percentage of the total frequency power (0 - 0.4 Hz) minus 

































Figure 2.3: An example of heart rate variability analysis.  An R-R interval 
tachogram is derived from the ECG channel (Lead II).  Fast Fourier transform 
(512 point) is used to calculate the HRV power spectrum and obtain values 




















Participants were allowed to breath spontaneously during all experiments, 
but their respiration rate was closely monitored using a piezo-electric 
transducer (Pneumotrace, UFI, USA).  A respiration rate of < 8 breaths per 
minute has a negative effect on the reliability of frequency-domain heart rate 
variability analysis, as the HF power peak (which is associated with 
respiration rate) may merge with the LF power peak (Malliani, 2005).  
Participants were thus assessed at the start of their first experiment to ensure 
they had a minimum respiration rate of ≥ 10 breaths per minute.  Where 
participants failed to meet the minimum respiration rate, their breathing was 
paced using a custom metronome set at 12 breaths per minute. 
 
2.6 Finger arterial blood pressure 
A Finometer PRO (Finometer Medical Systems B.V., Arnhem, Netherlands) 
with finger cuff attachment and height-correction unit was used for 
continuous photoplethysmographic recording of finger arterial blood pressure 
in all experiments.  The Finometer PRO device uses the volume clamp 
method (Penaz, 1973), whereby an inflatable cuff is positioned around the 
middle phalanx of digit three on one hand.  Changes in the intensity of 
infrared light emitted by the finger cuff are detected using a sensor to identify 
changes in blood volume (photoplethysmography).  The systolic and diastolic 
values obtained were validated against readings from a digital brachial blood 
pressure monitor on the same arm.  These brachial values were determined 
before and after each experimental recording to ensure Finometer accuracy 
within 10 mmHg.  In the event of increased disparity in blood pressure values 
between the two sites, one or more measures were taken: 
 
 The finger cuff was positioned on another finger or the opposite hand 
 The participant’s hand was wrapped in a towel for warmth 





If these steps failed to correct for the difference in BP between the two sites, 
finger arterial pressure was not recorded for that participant.  Automatic 
calibration of finger arterial blood pressure was performed continuously using 
PhysioCal software.  Offline analysis was performed using Spike2 software 
and values for systolic pressure, diastolic pressure and mean arterial 
pressure were derived from the same five minute time period of the 
experimental recording as the R-R interval tachogram.  
 
2.7 Baroreflex sensitivity 
The sequence method was used to provide a spontaneous estimate of 
spontaneous cardiac baroreflex sensitivity (BRS).  The RR interval and 
systolic BP waveforms were exported into Labchart (version 8.1.5, 
ADInstruments, Bella Vista, Australia) and custom scripts were used to 
detect sequences of three or more consecutive cardiac cycles where systolic 
pressure and R-R interval changed in the same direction e.g. an increase in 
systolic pressure of at least 1 mmHg coinciding with an increase in R-R 
interval.  The slope of each individual sequence was calculated using linear 
regression analysis and slopes were averaged over 5 minutes to determine 
BRS.  Minimum thresholds of 1 mmHg for systolic pressure and 2 ms for R-R 
interval were applied and all individual sequences were required to have an 
R2 value ≥ 0.85 to be accepted for inclusion.  All accepted sequences in the 
last five minute data block from each recording were averaged to calculate a 
mean value for BRS (ms/mmHg). 
 
2.8 Microneurography 
In Chapter 4, seven participants who had previously received active tVNS 
and experienced a decrease in LF/HF ratio were asked to return for an 
additional visit where microneurography was performed along with tVNS.  
Simultaneous recording of single-unit muscle sympathetic nerve activity 
(MSNA) was obtained from the common peroneal nerve of the leg (Figure 




keep the knee joint flexed.  The skin overlying the common peroneal nerve 
was cleaned using an antibacterial wipe and the nerve was palpated at the 
level of the neck of the fibula.  If the skin was intact and free of lesions, an 
active recording tungsten microelectrode (FHC Inc., USA) insulated with a 
high impedance epoxy resin coat was inserted percutaneously into the nerve.  
A second reference electrode was inserted subcutaneously 2 cm away from 













Figure 2.4 An example of the needle-insertion for microneurography.   
Microneurography was performed using two tungsten microelectrode needles: 
one inserted percutaneously into the common peroneal nerve (active electrode, 
white colour) and the second inserted into the subcutaneous fascia 2cm distal 
(reference electrode, blue colour).  The course of the common peroneal nerve 





The microelectrodes were connected to a headstage (Neurolog NL100AK, 
UK) and an AC pre-amplifier with x50 k amplication (Neurolog NL104A, UK).  
A bandpass filter was applied (0.7 – 2.0 kHz) and a Humbug Noise Eliminator 
unit (Quest Scientific, Canada) was used to remove 50 Hz mains 
interference.  The signal was sampled at 16 kHz, digitised using a Power 
1401 (CED, UK) and displayed on a laptop using Spike2 (version 7.1) to 
allow the raw neurogram to be inspected in real time.  The recording 
electrode was manipulated within the nerve until a candidate action potential 
was detected.  Manipulations were small and restricted to 45 minutes 
following microelectrode insertion according to microneurography guidelines 
(Mano et al., 2006).  A candidate single-unit was deemed to have originated 
from a sympathetic vasoconstrictor axon if it fulfilled the following criteria: 
 
1. There was no change in single-unit activity in response to brushing the 
skin of the lateral surface of the leg and dorsum of the foot 
2. The unit occurred only during diastole on the finger arterial blood 
pressure trace 
3. There was an increase in single unit activity during the second half of 
the cold pressor test (one hand submerged in 4 degrees celsius ice water for 
one minute) or isometric handgrip test (handgrip squeezed by one hand at 
50% maximal voluntary contraction for two minutes). 
 
Units which fulfilled these criteria were manually inspected offline and 
superimposed to determine if they were genuine muscle sympathetic 
vasoconstrictor units from a single axon i.e. they shared a near-identical 
amplitude and morphology (Figure 2.5).  Single-unit MSNA frequency (units 
detected per minute) and MSNA incidence (units detected per 100 
heartbeats) were calculated to assess changes in sympathetic 
vasoconstrictor activity as a result of active tVNS.  Due to high baseline 
variability between subjects, the baseline data were normalised to 1 and 

























Figure 2.5 An example of a raw neurogram from one volunteer, with 
associated ECG and finger arterial blood pressure (BP) traces.  Single-unit 
MSNA from one vasoconstrictor sympathetic axon is marked with an asterisk 
(A).  Each candidate unit was inspected and superimposed to confirm the 






2.8.1 Cold pressor test 
Prior to the start of the test, participants were asked to rest quietly while 
baseline data were recorded for one minute.  At the end of this minute, 
participants were then asked to submerge their left hand up to the wrist in ice 
water (4°C).  Cold pressor test data were then recorded for one minute 
unless the participant reported too much discomfort.  At the end of the test 
the participant’s hand was removed from the water, wrapped in a towel and 
the participant rested while a further minute of recovery data was obtained.   
The cold pressor test can be used to discriminate between MSNA and skin 
sympathetic nerve activity (SSNA).  The cold pressor test evokes an increase 
in blood pressure that correlates well with an increase in MSNA firing rate 
(Fagius et al., 1989, Kregel et al., 1992).  In addition, there is a time delay of 
approximately 30 seconds between the onset of the test and the onset of 
MSNA firing – the last 30 seconds of the test was thus compared to the 
baseline period to determine the participant’s response to the cold pressor 
test. The slight variation in the onset of MSNA firing may be due to the 
participant’s perceived level of discomfort (Victor et al., 1987, Kregel et al., 
1992)) whereas skin sympathetic activity does not change in this respect. 
 
2.8.2 Isometric handgrip test 
Maximal voluntary contraction (MVC) was determined during the 
experimental set up by asking the participant to squeeze a handgrip as hard 
as possible for 10 seconds. The handgrip was connected to a dynamometer 
(MIE Medical Research Ltd, UK) which provided a numerical display.  As with 
the cold pressor test, baseline data were recorded for one minute and the 
participant was asked to squeeze the handgrip at 50% of their MVC level.  
The participant was asked to maintain this level as best as they could for two 
minutes in total.  Participants were asked to keep all muscles apart from 
those in their upper limb involved in the test as relaxed as possible and they 
were further instructed to maintain a normal breathing rhythm throughout the 
test. After two minutes the participants were asked to release the handgrip 




handgrip test evokes a rapid and continuous increase in blood pressure, 
initially mediated by tachycardia and subsequently sustained by an increase 
in MSNA (Seals et al., 1988). This exercise is useful in differentiating 
between muscle and skin SNA as SSNA increases abruptly at the start of 
exercise and remains constant whereas the increase in MSNA is delayed for 
30 - 60 seconds and then gradually increases throughout the exercise (Seals 
et al., 1988, Saito et al., 1990).  This time delay in firing meant that only the 
second minute of each isometric handgrip test was compared to the one 
minute baseline recording. 
 
2.9 Data acquisition 
Three separate data channels (ECG, finger arterial pressure and respiration) 
were fed into a data amplification system (Neurolog NL104A, CED, UK).  An 
additional data channel was included for experiments in Chapter 4 for 
microneurographic recording of nerve activity.  Data channels were sampled 
at 16 kHz and stored on hard drives. Channels were independently calibrated 
before digitisation and storage on PCs. Data channels were then displayed 
on monitors using Spike2 (CED, UK) software.   
 
2.10 Statistical analysis 
All statistical analyses were performed using SPSS (version 24).   Shapiro-
Wilk tests were performed on each variable to assess normality.  Participant 
subgroup characteristics were compared using independent t-tests or Mann 
Whitney U-tests.   One-way repeated measures ANOVA was used to analyse 
effect of time (baseline, stimulation and recovery) for each group and 
Bonferroni post-hoc correction applied.   Linear mixed model analysis was 
performed to compare the effect of time (baseline, stimulation and recovery) 
between different visits (e.g. stimulation sites or stimulation parameters) 
where sample sizes of groups were unequal.  Two-way repeated measures 
ANOVA was used to analyse the effect of time (baseline, stimulation and 




Non-parametric Friedman test was used to analyse effect of time for groups 
where data were not normally distributed and post-hoc analysis was 
performed using Wilcoxon-signed rank tests with Bonferroni correction 
applied.  Spearman’s Rank correlation test was used to identify possible 
relationships between variables and linear regression was used to further 
explore these correlations.  All data are presented as group mean ± standard 























An investigation of the autonomic effects of transcutaneous electrical 
nerve stimulation applied to different sites on the external ear in healthy 
























Transcutaneous vagus nerve stimulation (tVNS), involving the use of either 
percutaneous electroacupuncture or specialised surface electrodes to 
transmit current across the skin, has been shown to be safe in both healthy 
volunteers and in a clinical context (Murray et al., 2016).  However, there is a 
high degree of heterogeneity in the literature in terms of stimulus parameters 
and sites of application on the ear.  The principle sites of interest for 
delivering electrical stimulation to the ABVN have been the tragus (Busch et 
al., 2013, Kraus et al., 2013, Clancy et al., 2014, Weise et al., 2015, 
Stavrakis et al., 2015, Zhou et al., 2016), the concha (He et al., 2013a, Liu et 
al., 2013, Ay et al., 2015b, Fang et al., 2015), and the cymba concha 
(Kreuzer et al., 2014, Frangos et al., 2015).  These regions are known to 
correspond with the ABVN dermatome, but there is overlap at the tragus and 
concha from the great auricular nerve which is derived from the second and 
third cervical spinal nerves which contribute to the cervical plexus (Peuker 
and Filler, 2002).  In addition, the lateral (outer) side of the tragus is known to 
receive innervation from the anterior auricular branch of the auriculotemporal 
nerve, which originates from the mandibular (V3) division of the trigeminal 
nerve (Shankland, 2001, Peuker and Filler, 2002).  While the cutaneous 
innervation supplied by these nerves overlaps at the tragus, the cadaveric 
study by Peuker and Filler (2002) found a number of specific locations on the 
external ear where these nerves were the sole or predominate innervation.  
Examples of these locations are the cymba concha for the ABVN, the earlobe 
for the GAN and the spine of the helix for the auriculotemporal nerve.  
 
3.1.1 Overview of the great auricular nerve and its central projections 
The GAN is a superficial sensory branch of the cervical plexus which 
emerges through the superficial cervical fascia at the posterior border of 
sternocleidomastoid and courses superiorly over the lateral surface of the 
muscle towards the mandibular angle.  As it ascends it divides into an 
anterior branch which supplies the skin overlying the parotid gland and a 




process and inferior portion of the external ear (Ginsberg and Eicher, 2000).   
In humans, cadaveric dissection of the external ear has located branches of 
the GAN primarily in the earlobe, tail of helix and scapha as well as the 
posterior aspect of the ear (Peuker and Filler, 2002, Yang et al., 2015). 
Following application of HRP to the central cut end of the GAN in rabbits, 
HRP labelling was identified in the afferent cell bodies of the great auricular 
nerves in the ipsilateral C2 and to a lesser extent C3 dorsal root ganglia, as 
well as the ipsilateral superior cervical ganglia (Liu and Hu, 1988).  In the 
spinal cord, transganglionically-labelled GAN fibres were found in the 
cuneate fasciculus, laminae I – IV at C2 level and laminae II – IV at C3 level.  
From here, GAN fibres were found to project to medullary nuclei such as the 
medial and lateral cuneate nuclei, the NTS and the spinal trigeminal nucleus 
(Liu and Hu, 1988).  The convergence of GAN fibres on the NTS is of 
particular interest as electrical neuromodulation applied to branches of the 
GAN may thus be able to influence autonomic function.  However, an fMRI 
study in 12 healthy volunteers by Frangos et al. found that electrical 
stimulation of the left earlobe using the Cerbomed NEMOS® system 
produced no activation in cortical or subcortical sites associated with 
autonomic nervous system activity (Frangos et al., 2015).  Activation was 
localised instead to spinal trigeminal nucleus and cuneate nucleus, 
consistent with previous HRP-labelling in rabbits (Liu and Hu, 1988).  Further 
activation was observed in the contralateral insula and contralateral primary 
somatosensory cortex associated with the head and facial region (Frangos et 
al., 2015).  This activation pattern was in marked contrast to that produced by 
electrical stimulation of the left cymba concha, which is innervated 
exclusively by the ABVN (Peuker and Filler, 2002).  Widespread activation 
was observed in the region of the left medulla corresponding to the location 
of the NTS, known from neuroanatomical tracing work with cats to be 
consistent with the afferent distribution of the ABVN (Nomura and Mizuno, 






3.1.2 Overview of the auriculotemporal nerve and its central projections 
The auriculotemporal nerve is a sensory nerve originating from the posterior 
division of mandibular (V3) trigeminal nerve, with afferent cell bodies located 
in the dorsal half of the trigeminal ganglion (Jacquin et al., 1983, Shankland, 
2001).  It emerges from the infratemporal fossa deep to the parotid gland and 
ascends posterior to the temporomandibular joint and anterior to the tragus of 
the external ear.  From this point it travels superiorly along the lateral aspect 
of the cranium deep to the superficial temporal artery (Shankland, 2001).  
Along its course the auriculotemporal nerve divides into eight major branches 
which provide cutaneous innervation to a large area of the lateral aspect of 
the head, with two branches supplying innervation to the external ear.   
These are the anterior auricular nerve, whose branches supply innervation to 
the skin of the tragus along with part of the helix, and the external acoustic 
meatus nerve (Shankland, 2001).  In addition, the auriculotemporal nerve is 
known to have communications with the facial nerve trunk which allow 
auriculotemporal afferent fibres to innervate upper facial muscles such as 
orbicularis oculi and receive proprioceptive information during muscle 
movement (Cobo et al., 2017).   
The central projections of the auriculotemporal nerve have been 
demonstrated in the rat (Jacquin et al., 1983, Takemura et al., 1987).  
Jacquin et al. compared projections of different sensory branches of the 
mandibular division by applying HRP to the central cut end of the 
auriculotemporal nerve in 5 adult rats (Jacquin et al., 1983).  Widespread 
labelling was identified throughout the trigeminal nuclei including the 
ipsilateral principal trigeminal nucleus, subnucleus oralis, subnucleus 
interpolaris and the dorsal horn of C1 – C4.  A later study by Takemura et al. 
which also compared the central projections of mandibular nerve branches 
using HRP reported a similar pattern of labelling at these sites when HRP 
was applied to the left auriculotemporal nerve in 4 adult rats (Takemura et al., 
1987). Interestingly, Jacquin et al. identified sparse labelled projections from 
the auriculotemporal nerve to the NTS, although Takemura et al. did not 
observe any HRP labelling at this site.  Both studies reported labelling in the 




(Jacquin et al., 1983, Takemura et al., 1987).  These findings suggest that 
neuronal components of the mandibular division may be able to influence 
activity in the NTS, although it is not clear if stimulation of auriculotemporal 
nerve afferents can exert a modulatory role on NTS activation and thus 
autonomic nervous system activity. 
In recent years there has been interest in using implanted electrodes to 
stimulate the auriculotemporal nerve as a treatment for pain disorders such 
as chronic migraine and temporomandibular joint syndrome (Simopoulos et 
al., 2010, Rodriguez-Lopez et al., 2015).  However, there is limited 
information on the wider physiological effects of electrical stimulation of the 
auriculotemporal nerve beyond its potential as an analgesic therapy.  A study 
where the auriculotemporal nerve in rats was stimulated to identify the effects 
of selective muscarinic M1 and M2 receptor antagonists on parotid salivary 
secretion showed no change in femoral intra-arterial blood pressure when 
stimulation was performed prior to application of the pharmacological agents 
(Tobin, 1998).  A comparison of the autonomic effects of manual auricular 
acupuncture versus electroacupuncture at different ear sites in rat found that 
manual acupuncture of the A1 site at the apex of the helix, innervated by the 
auriculotemporal nerve, elicited a significant depressor response in mean 
arterial pressure (Gao et al., 2008).  This effect was similar to that observed 
with high frequency (100Hz) electroacupuncture at the same site. 
 
3.1.3 Knowledge gap 
There have been a number of studies which have compared the effects of 
transcutaneous electrical stimulation at different sites on the ear in man.  
Kraus et al. compared electrical stimulation of the inner tragus and posterior 
wall of the external acoustic meatus with earlobe stimulation, which was 
considered by the study authors to be a sham stimulation site (Kraus et al., 
2013).  The activation pattern observed by Frangos et al. suggests that 
stimulation of the ABVN dermatome (cymba concha) may be able to 
influence autonomic centres such as the NTS (Frangos et al., 2015).  




the same sites as cymba concha stimulation.  A more recent study by 
Yakunina et al. applied electrical stimulation to the cymba concha and 
earlobe as well as the inner tragus and inferoposterior wall of the external 
acoustic meatus in 37 healthy volunteers.  Cymba concha stimulation 
produced the strongest activation in the area of the medulla corresponding to 
the NTS (Yakunina et al., 2017). 
The present study employed non-invasive measures of cardiovascular 
autonomic function (heart rate variability and baroreflex sensitivity) to 
compare the effects of transcutaneous electrical nerve stimulation (TENS) 
applied to both ears at four different locations: tragus, cymba concha, helix 
and earlobe (Figure 3.1).  
 
3.2 Hypothesis  
Transcutaneous electrical stimulation of the tragus of the external ear will 
have a similar effect on cardiovascular autonomic function as cymba concha 
stimulation as both of these areas are innervated by the ABVN.  The 
autonomic effects of tragus and cymba concha stimulation will differ from 
those observed with earlobe and helix stimulation.  
 
3.3 Aims and objectives 
The present study investigated the cardiovascular autonomic effects of 
transcutaneous electrical nerve stimulation (TENS) at four different sites on 
the external ear.  The study aimed to identify stimulation-induced changes in 
cardiovascular autonomic activity in healthy participants using non-invasive 








3.4 Materials and Methods 
 
3.4.1 General protocol  
University of Leeds ethical approval was secured (Ethics Reference: BIOSCI 
16-009) and the all experiments conformed to the standards outlined in the 
Declaration of Helsinki.  Informed written consent was obtained voluntarily by 
all research participants and their data were anonymised and stored securely 
according to the Data Protection Act (1998).  All experiments were carried 
out in a dedicated human physiology study room at University of Leeds.  
These experiments occurred between the hours of 8am and 10am in order to 
minimise the impact of circadian rhythm variations on the autonomic nervous 
system.  The ambient temperature of the study room was maintained at 21 ± 
2°C. Inclusion criteria were male or female volunteers aged ≥ 18 years old. 
Exclusion criteria were a prior medical history of hypertension, cardiac 
disease, diabetes mellitus or epilepsy.  Female participants were asked to 
indicate if they were receiving hormonal replacement therapy (HRT) for 
treatment of menopausal symptoms, as HRT has been shown to 
independently alter cardiac autonomic activity (Yildirir et al., 2001).  All 
participants were required to abstain from caffeine, alcohol, nicotine and 
strenuous exercise for a minimum of 12 hours prior to their visit.  They were 
further required to consume a light breakfast and use the toilet prior to 
attending for the experiment.   
All participants were asked to attend for four visits to apply bilateral 
transcutaneous electrical nerve stimulation (TENS) to one of the following 
sites per visit in a randomised order: the tragus, the cymba concha, the helix 
and the earlobe.  Both left and right ears were stimulated simultaneously at 
these sites.  Stimulation of the tragus, helix and earlobe was delivered using 
a V-TENS Plus (Body Clock, U.K.) device and customised auricular electrode 
clips as used previously for tragus stimulation in healthy human volunteers 
(Clancy et al., 2014).  The protocol for delivering stimulation was the same as 
described for active tVNS in Chapter 2 with the exception of cymba concha 




without causing potential discomfort to the participant, two carbon fibre 
electrodes used to manufacture the auricular clips were applied separately to 
the skin of the cymba concha and positioned approximately 5 millimetres 
apart (Figure 3.1).  The electrodes were held securely in place for the 
duration of the experiment using a non-conductive silicone putty ear plug 
moulded to the shape of the participant’s cymba concha.  This putty was then 
held in position using a lightweight headset to ensure good contact between 
the electrodes and the skin.  
Participants were asked to report the sensations described during the initial 
titration of the stimulus at each site.  Once the stimulus could be clearly 
detected by the participant, the current was reduced to a level where it was 
remained perceptible without any discomfort.  Participants were asked to 
inform the investigator if they perceived a change in the strength of the 
current, which was then immediately adjusted back to a comfortable but 





























Figure 3.1 Overview of the stimulation sites used in the present 
study.  Four sites were chosen based on the cutaneous distribution 
of the auricular nerves described by Peuker and Filler (Peuker and 
Filler, 2002). The stimulation sites were the helix (auriculotemporal 
nerve or ATN), earlobe (great auricular nerve or GAN), cymba 
concha (ABVN) and the tragus (which can be innervated by the ATN, 




3.4.2 Cardiovascular autonomic measurements and data acquisition 
Recordings of heart rate, respiration, blood pressure and MSNA were 
obtained as described in Chapter 2.  The data acquisition protocol and 
analyses of HRV and BRS were performed as described in Chapter 2.  In 
some participants it was not possible to obtain reliable finger arterial blood 
pressure recordings or to detect BRS sequences and the sample sizes for 
these analyses are included in Table 3.10 for BP and Table 3.7 for BRS.  
 
3.4.3 Statistical Analysis 
All statistical analyses for this study were performed using SPSS (version 
24).   Shapiro-Wilk tests were performed on each variable to assess 
normality.  Participant subgroup characteristics were compared using 
independent t-tests or Mann Whitney U-tests.  One-way repeated measures 
ANOVA was used to analyse effect of time (baseline, stimulation and 
recovery) for each visit (active tVNS or sham tVNS) and Bonferroni post-hoc 
correction applied.  Non-parametric Friedman test with Bonferroni correction 
for multiple pairwise comparison tests was used where data were not 
normally distributed.  Friedman test with Bonferroni correction for multiple 
pairwise comparison tests was also used to compare effects between 
stimulation parameters (tragus, earlobe, helix and cymba concha) at a 
specific time-point for measures of HRV e.g. at baseline.  Two-way repeated 
measures ANOVA was used to analyse the effect of stimulation (tragus, 
earlobe, helix and cymba concha) on BRS over time (baseline, stimulation, 











3.5.1 Baseline characteristics 
24 participants with no previous medical history of cardiovascular disease, 
diabetes or epilepsy were enrolled at the study and written informed consent 
was obtained at the first visit.  One male participant (age = 28 years) was 
excluded from the study due to a slow respiration rate (< 8 breaths per 
minute) and non-compliance with a breathing metronome following coaching.  
One female participant (age = 62 years) was excluded from the study due to 
post-menopausal hot flashes (2 - 3 per visit, mean duration = 2 minutes) 
which produced extensive signal artefacts in the ECG channel and disrupted 
the HRV and BRS analyses.  The baseline characteristics of the remaining 
22 participants (n = 11 female and n = 11 male) included in the study are 
presented in Table 3.1.  There were no significant differences in age, BMI or 
physical activity level as assessed by the Godin Leisure-Time Exercise 
questionnaire.  There was no significant difference in LF/HF ratio at baseline 
between the male and female participants (male = 1.32 ± 0.22; female 
participants = 1.36 ± 0.27). No significant differences were detected at 
baseline between male and female participants for other measures of HRV, 
mean HR or mean BP.   
Three participants (2 male, 1 female) were found prior to experimental 
recording at their first visit to have a respiratory rate < 10 breaths per minute.  
These participants were consequently required to breath to a metronome set 
at 12 breaths per minute at all four visits, as a respiration rate < 8 breaths per 
minute can affect frequency-domain HRV analysis (Malliani, 2005).  
However, the participants who were allowed to continue spontaneous 
breathing (n = 19) showed no significant changes in respiration as a result of 


























32.86      
± 2.04 
(range = 
24 – 59) 
 24.66      
± 0.84 
84.83      
± 2.79 
67.05      
± 2.18 






33.73       
± 3.42 
(range = 
26 – 59) 
24.12      
± 0.90 
81.88      
± 3.79 
64.39      
± 2.58 





 32.00      
± 2.37 
(range = 
24 – 47) 
25.20      
± 1.44 
88.08      
± 3.47 
69.72      
± 3.44 




3.5.2 Heart rate variability 
When the 22 included participants were compared at baseline between the 
stimulation parameters, no significant differences were detected between 
parameters at each time point (baseline, stimulation and recovery) for any 
measure of frequency-domain HRV (Friedman test, p > 0.05).  This may 
have been due to the relatively small sample size and the skewed non-
normal distribution of data.  HRV was then analysed for each stimulation 
parameter in all 22 participants (Table 3.2).  However, the sole significant 
change detected was an increase in LF power which occurred following 
earlobe stimulation during the recovery period (Friedman test, p = 0.048), but 
Table 3.1 Baseline characteristics of participants enrolled in the study.  
No significant differences were detected between male and female 




without any simultaneous significant difference from baseline for HF power 
(Friedman test, p = 0.186) or LF/HF ratio (Friedman test, p = 0.544) at this 
time-point.   
To determine if the lack of significant changes in frequency-domain HRV 
were due to a high degree of inter-individual variation in resting cardiac 
autonomic activity, the dataset of 22 participants was split into participants 
who responded with a decrease in LF/HF ratio during tragus stimulation 
(tragus responders; n = 12; Figure 3.2, Table 3.3), implying either a reduction 
in sympathetic nervous system activity or an increase in parasympathetic 
predominance, and participants who exhibited no change or an increase in 
LF/HF ratio (tragus non-responders; n = 10; Figure 3.2, Table 3.4).  The 
participants who responded to tragus stimulation had a greater LF/HF ratio 
during the baseline recording of their tragus stimulation visit than the non-
responder group (responders = 1.68 ± 0.24; non-responders = 0.99 ± 0.20; p 
= 0.036).  This disparity in baseline values corresponded with increased 
values of normalised LF power (p = 0.036) and normalised HF power (p = 
0.036) at baseline in the tragus responder group compared to non-
responders.  A significant decrease in LF/HF ratio was observed during 
tragus stimulation in the responder group from baseline (repeated measures 
ANOVA; p = 0.001) whereas a significant increase in LF/HF ratio occurred in 
the non-responder group during tragus stimulation (repeated measures 
ANOVA; p = 0.032).  Normalised LF power decreased during tragus 
stimulation in the responder group (repeated measures ANOVA; p = 0.001), 
while normalised HF power increased during stimulation (repeated measures 
ANOVA; p = 0.001).  For the non-responder group, normalised LF power was 
observed to increase during tragus stimulation (Friedman test; p = 0.030) and 
remained elevated during the recovery period (Friedman test; p = 0.016), 
while a significant decrease in normalised HF power from baseline was 
detected during tragus stimulation (Friedman; p = 0.030) and during recovery 
(Friedman test; p = 0.016). 
When data from the other stimulation sites was analysed for the tragus 
responder group, a significant decrease in LF/HF ratio of a similar magnitude 




test; helix visit baseline LF/HF ratio = 1.71 ± 0.33; helix stimulation LF/HF 
ratio = 0.95 ± 0.16; p = 0.013) but not for earlobe or cymba concha 
stimulation at the same time point.  This was accompanied by a decrease in 
normalised LF power and an increase in normalised HF power during helix 
stimulation (Friedman test; p = 0.013 for both normalised LF power and 
normalised HF power; Figure 3.3).  No significant changes in LF/HF ratio 
were observed in the tragus non-responders during helix stimulation.  No 
significant changes were observed in either response group for LF/HF ratio 
during earlobe stimulation (Figure 3.5) or cymba concha stimulation (Figure 
3.6).  However an increase in HF power was observed in the tragus 
responder group in the recovery period after stimulation of the cymba concha 
(Friedman test; p = 0.013; Figure 3.5) but this effect was not reflected in a 
change in normalised HF power (repeated measures ANOVA; p = 0.790).   
The dataset of all 22 participants was also divided into male and female 
participants to determine if there were any sex-associated differences in 
cardiac autonomic control and subsequent responses to stimulation.  No 
significant differences were observed between male and female participants 
at baseline for any measure of HRV and the male and female participant data 
were then analysed separately to identify within-group trends (Table 3.5 and 
Table 3.6).  The only observed sex-associated effect was a significant 
increase in LF power in female participants during the recovery period 
following earlobe stimulation (Friedman test; p =0.025).  No changes in HRV 
were detected for male participants.  This was likely due to the small sample 






Table 3.2 HRV data for all participants (n = 22) for the different 
stimulation sites.  The sole significant change observed in data from all 
participants was an increase in LF power from baseline after earlobe 
stimulation (Friedman test, p = 0.048). 
Table 3.3 HRV data for the tragus responder subgroup (n = 12) for the 
different stimulation sites.  A significant decrease in LF/HF ratio was 
observed during tragus stimulation in the responder group from baseline 
(repeated measures ANOVA; p = 0.001). Normalised LF power decreased 
during tragus stimulation in the responder group (repeated measures 
ANOVA; p = 0.001), while normalised HF power increased during 
stimulation (repeated measures ANOVA; p = 0.001).  Helix stimulation 
also caused a decrease in LF/HF ratio (Friedman test; p = 0.013), 
normalised LF power (Friedman test; p = 0.013) and normalised HF power 
(Friedman test; p =0.013). 
Table 3.4 HRV data for the tragus non-responder subgroup (n = 10) 
for the different stimulation sites.  A significant increase in LF/HF ratio 
from baseline was observed during tragus stimulation in the tragus non-
responder group (repeated measures ANOVA; p = 0.001). 
Table 3.5 HRV data for the female participants (n = 11) at the different 
auricular stimulation sites.  A significant increase in LF power was 
observed from baseline in the recovery period following earlobe 
stimulation (Friedman test; p = 0.025). 
Table 3.6 HRV data for the male participants (n = 11) at the different 
auricular stimulation sites.  No significant changes were detected for 






  Tragus Helix Cymba Concha Earlobe 











































































1639.99    
± 401.69 










0.52        
± 0.04 
0.50        
± 0.04 
0.51          
± 0.04 
0.51        
± 0.04 
0.50        
± 0.04 
0.54          
± 0.04 
0.52        
± 0.04 
0.52          
± 0.03 
0.51           
± 0.04 
0.53         
± 0.03 
0.51        
± 0.04 




0.48        
± 0.04 
0.50        
± 0.04 
0.49          
± 0.04 
0.49        
± 0.04 
0.50        
± 0.04 
0.46          
± 0.04 
0.48        
± 0.04 
0.48         
± 0.03 
0.49          
± 0.04 
0.47        
± 0.04 
0.49        
± 0.04 
0.47          
± 0.04 
LF/HF 
1.33        
± 0.17 
1.21        
± 0.16 
1.32          
± 0.18 
1.38        
± 0.21 
1.29        
± 0.22 
1.56          
± 0.26 
1.37        
± 0.19 
1.36          
± 0.21 
1.25          
± 0.16 
1.42         
± 0.21 
1.38        
± 0.24 
1.54         
± 0.27 






  Tragus Helix Cymba Concha Earlobe 





3866.08   
± 1419.63 
4039.45   
± 1090.60 
4984.97   
± 1712.94 
4296.14   
± 1538.01 
3781.52     
± 884.88 
5783.56     
± 1918.17 
3798.96   
± 964.94 
5371.84    
± 1684.05 
5898.28   
± 1729.82 
3489.95   
± 965.92 
4158.59   
± 1152.05 






1817.49   
± 682.94 
1482.31   
± 435.80 
1981.71   
± 735.91 
1974.61   
± 795.75 
1315.13   
± 360.75 
2364.37   
± 779.44 
1597.66   
± 480.31 
2646.84   
± 928.47 
2331.25   
± 831.97 
1663.00   
± 513.75 
1726.35   
± 532.21 






1627.74   
± 554.12 
1905.10   
± 557.51 
2593.35   
± 1030.58 
1627.74   
± 554.12 
1905.10   
± 557.61 
2593.35   
± 1030.58 
1552.99   
± 449.89 
1997.99   
± 674.85 
2464.67   
± 861.62 








0.56         
± 0.06* 
0.45         
± 0.05* 
0.54         
± 0.05 
0.56         
± 0.06* 
0.45         
± 0.05* 
0.54         
± 0.05 
0.55         
± 0.05 
0.52         
± 0.04 
0.52         
± 0.05 
0.58         
± 0.04 
0.51        
± 0.05 




0.44         
± 0.06* 
0.55         
± 0.05* 
0.46         
± 0.05 
0.44         
± 0.06* 
0.55          
± 0.05* 
0.46          
± 0.05 
0.45         
± 0.05 
0.48         
± 0.05 
0.48         
± 0.05 
0.42        
± 0.04 
0.49        
± 0.05 
0.48         
± 0.05 
LF/HF 
1.68          
± 0.24* 
1.03          
± 0.16* 
1.21         
± 0.23 
1.71         
± 0.33* 
0.95         
± 0.16* 
1.50         
±  0.33 





























  Tragus Helix Cymba Concha Earlobe 






2785.35    
± 532.59  
3100.77    
± 721.88 
2979.98    
± 573.92 
2230.17   
± 437.09 
2239.43    
± 541.85 
2410.32    
± 446.11 
3090.68    
± 697.57 
2845.09   
± 523.60 
2484.44   
± 584.69 
2611.08   
± 429.37 
3110.05   
± 890.10 






970.79     
± 202.89 
1416.86   
± 501.11 
1369.78   
± 396.64 
829.66     
± 181.07 
1137.42   
± 415.89 
947.40     
± 215.47 
1277.82    
± 352.76 
1094.76   
± 218.16 
1033.88   
± 361.56 
988.76     
± 200.86 
1237.03   
± 481.48 






1477.41   
± 397.74 
1286.71   
± 333.95 
1183.07   
± 276.05 
1113.87   
± 302.39 
793.56     
± 211.58 
839.21     
± 243.24 
1551.81   
± 372.43 
1210.39   
± 350.32 
1015.15   
± 243.11 
1331.22   
± 286.65 
1257.84   
± 357.05 




0.43          
± 0.06* 
0.53         
± 0.07* 
0.53         
± 0.06 
0.46         
± 0.05 
0.55         
± 0.06 
0.54         
± 0.06 
0.48          
± 0.05 
0.51          
± 0.05 
0.49          
± 0.05 
0.46          
± 0.05 
0.51          
± 0.06 




0.57         
± 0.06* 
0.47                  
± 0.07* 
0.47          
± 0.06 
0.54          
± 0.05 
0.45          
± 0.06 
0.46          
± 0.06 
0.52         
±  0.05 
0.49          
± 0.05 
0.51              
± 0.05 
0.54               
± 0.05 
0.49          
± 0.06 
0.45          
± 0.06 
LF/HF 
0.93         
± 0.20* 
1.46           
± 0.29* 
1.46             
± 0.29 
0.99            
± 0.20 
1.69              
± 0.43 
1.62           
± 0.42 
1.15          
± 0.27 
1.37            
± 0.36 
1.15           
± 0.22 
1.06                
± 0.22 
1.43          
± 0.41 
1.72         
± 0.47 
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4234.57    
± 1525.09 
3738.23   
± 1078.66 
4652.79    
± 1771.65  
3772.64   
± 1502.44 
3433.63   
± 915.90 
5435.72    
± 2096.47 
3347.21   
± 934.52 
4900.25    
± 1648.17 
4715.09   
± 1787.47 
3303.22   
± 988.40 








1639.37    
± 745.60 
1159.18    
± 406.70 
1761.32    
± 770.51 
1636.16   
± 742.95  
1158.52   
± 347.17 
2140.70   
± 864.38 
1225.45   
± 396.27 
2154.00   
± 893.32 
1681.92   
± 853.50 
1355.95   
± 534.28* 
1478.14   
± 442.25 






2061.15    
± 697.95 
2120.21    
± 618.13 
2267.17    
± 722.82 
1609.37    
± 572.63 
1807.61   
± 595.91 
2735.49   
± 1124.16 
1703.16   
± 473.55 
2238.43   
± 750.75 
2512.41   
± 930.15 
1568.12   
± 444.25 
1900.18   
± 529.11 




0.49          
± 0.06 
0.42          
± 0.05 
0.44          
± 0.06 
0.53         
±  0.05 
0.44          
± 0.05 
0.49         
± 0.06 
0.49         
± 0.06 
0.47         
± 0.05 
0.42         
± 0.06 
0.50        
± 0.06 
0.50        
± 0.06 




0.51          
± 0.06 
0.58          
± 0.05 
0.56          
± 0.06 
0.47         
± 0.05 
0.56         
± 0.05 
0.51         
± 0.06 
0.51         
± 0.06 
0.53         
± 0.05 
0.58         
± 0.06 
0.50        
± 0.06 
0.50        
± 0.06 
0.50        
± 0.07 
LF/HF 
1.27          
± 0.26 
0.89          
± 0.20 
1.02          
± 0.25 
1.42         
± 0.29 
0.92         
± 0.17 
1.38         
± 0.38 
1.25         
± 0.27 
1.11         
± 0.25 
0.99         
± 0.25 
1.31          
± 0.29 
1.44        
± 0.42 
1.60        
± 0.51 






  Tragus Helix Cymba Concha Earlobe 










3494.43   
± 885.43 
2941.49 
± 956.38  
2727.50 
± 658.76  
3064.81   
± 682.67  
3606.82 
± 814.63 
3546.38   
± 1065.85 
3977.98    












± 258.43  
1745.93 
± 500.95  
1645.80   









1728.69   
± 621.12 





















992.11   
± 287.66  




1041.55   
± 205.98 




1147.63   
± 295.44 




0.55       
± 0.04 
0.58       
± 0.04 
0.59         
± 0.03 
0.50       
± 0.06 
0.55       
± 0.06 
0.59         
± 0.04 
0.55       
± 0.05 
0.56         
± 0.04 
0.59         
± 0.03 
0.56      
± 0.04 
0.52        
± 0.05 




0.45       
± 0.04 
0.42       
± 0.04 
0.41         
± 0.03 
0.50       
± 0.06 
0.45       
± 0.06 
0.41         
± 0.04 
0.45       
± 0.05 
0.44         
± 0.04 
0.41         
± 0.03 
0.44      
± 0.04 
0.48        
± 0.05 
0.43         
± 0.03 
LF/HF 
1.40       
± 0.24 
1.56       
± 0.21 
1.62         
± 0.24 
1.34       
± 0.31 
1.66       
± 0.39 
1.74         
± 0.35 
1.49       
± 0.27 
1.60         
± 0.34 
1.51         
± 0.16 
1.53      
± 0.30 
1.31        
± 0.24 
1.48         
± 0.18 
















Figure 3.2: LF/HF ratio response trends for tragus stimulation.  Participants were divided into the tragus responder subgroup 
(A; decrease in LF/HF ratio during to tragus stimulation; n = 12) and the tragus non-responder subgroup (B; no change or an 
increase in LF/HF ratio during tragus stimulation; n = 10) for the different stimulation sites.  A significant decrease in LF/HF ratio was 
observed for the tragus responders during tragus stimulation (p = 0.001), whereas a significant increase in LF/HF ratio occurred in 








Figure 3.3: LF/HF ratio response trends in the tragus responder (A) and tragus non-responder (B) subgroups during 
helix stimulation.  A significant decrease in LF/HF ratio occurred due to helix stimulation (p = 0.013).  No significant changes 
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Figure 3.4: LF/HF ratio response trends in the tragus responder (A) and tragus non-responder (B) subgroups during 








Figure 3.5: LF/HF ratio response trends in the tragus responder (A) and tragus non-responder (B) subgroups during 




3.5.3 Baroreflex sensitivity 
BRS data was obtained from 14 out of 22 participants and baroreflex 
sequences had to be detected in each recording (baseline, stimulation and 
recovery) at all four visits in order to include that participant’s data in the 
subsequent analysis.  Data were initially analysed irrespective of response or 
sex and no significant difference was observed at any time-point (baseline, 
stimulation or recovery) between the stimulation sites (two-way repeated 
measures ANOVA; p = 0.418).  A significant increase in BRS was detected 
during tragus stimulation (one-way repeated measures ANOVA; p = 0.039; 
Table 3.7).  Repeated measures ANOVA failed to detect any significant 
change in BRS during cymba concha stimulation (p = 0.191), helix 
stimulation (p = 0.612) or earlobe stimulation (p = 0.742).  The BRS data was 
separated into male participants (n = 9) and female participants (n = 5), 
although no differences were observed between groups for the different 
stimulation sites (independent t-tests; p > 0.05 for all) or within groups for any 
stimulation site.   
Eleven of the 14 participants for whom BRS data was available had 
previously been included in the tragus responders group (determined by a 
decrease in the LF/HF ratio).  In these participants, a significant increase in 
BRS was detected during tragus stimulation (repeated measures ANOVA; p 
= 0.009; Table 3.8) but during the recovery period BRS had begun to 
decrease to baseline level (p = 0.370).  No significant changes from baseline 
were identified as a result of stimulation at the cymba concha, helix or 
earlobe.  BRS data was obtained for only 3 participants in the tragus non-
responder (no change or increase in LF/HF ratio during tragus stimulation) 
















 N Baseline Stimulation Recovery 




Tragus 14 13.60 ± 1.04 16.55 ± 1.51 15.36 ± 1.24 0.039 0.688 
Helix 14 15.00 ± 1.59 15.57 ± 1.22 16.26 ± 1.58 1.0 0.565 
Cymba 
Concha 
14 15.02  ±  1.79 15.51  ± 1.24 17.56 ± 1.64 1.0 1.0 
Earlobe 14 14.92 ± 1.35 14.82 ± 1.80 15.60 ± 1.85 1.0 1.0 
Table 3.7 BRS data for all participants (n = 14) during stimulation at different sites on the ear.  A 
significant increase in BRS from baseline was observed during tragus stimulation (p = 0.001), but no other 















 N Baseline Stimulation Recovery 
p (Baseline -  
Stimulation) 
p (Baseline - 
Recovery) 
Tragus 11 13.11 ± 1.17 17.07 ± 1.73 15.86 ± 1.45 0.009 0.370 
Helix 11 14.70 ± 1.84 15.91 ± 1.23 16.60 ± 1.62 0.995 1.0 
Cymba 
Concha 
11 14.42 ± 2.05 15.63 ± 1.35 18.03 ± 1.75 1.0 0.389 
Earlobe 11 14.76 ± 1.59 14.92 ± 1.67 14.96 ± 1.60 1.0 1.0 
Table 3.8 BRS data for participants in the tragus responder subgroup (n = 11) during stimulation at 
different sites on the ear.  A significant increase in BRS from baseline was observed during tragus 




3.5.4 Heart rate and blood pressure 
Heart rate data was obtained for all 22 participants and the baseline values 
for mean HR were not significantly different for each stimulation site 
(Friedman test; p = 0.106).  A significant decrease in mean HR was observed 
during tragus stimulation (Figure 3.6; repeated measures ANOVA; p < 0.001) 
and during the recovery period (p < 0.001).  Mean HR also decreased during 
earlobe stimulation (repeated measures ANOVA; p < 0.001), helix stimulation 
(repeated measures ANOVA; p = 0.001) and cymba concha stimulation 
(Friedman test; p = 0.048).  This decrease in mean HR was sustained into 
the post-stimulation recovery period for all stimulation sites (Figure 3.6; p < 
0.001 for cymba concha, helix and earlobe stimulation).   
When the dataset was divided into male and female participants, one-way 
repeated measures ANOVA revealed a significant decrease in mean HR 
during tragus stimulation for both male (p = 0.015) and female (p = 0.033) 
participants.  This decrease in heart rate from baseline was sustained during 
the post-stimulation recovery period (male p = 0.038; female p = 0.008; see 
Table 3.9).  A significant decrease in mean HR also occurred during cymba 
concha stimulation (repeated measures ANOVA; male p = 0.013; female p = 
0.019) and during earlobe stimulation (repeated measures ANOVA; male p = 
0.001; female p = 0.008).  However, a significant decrease in mean HR was 
detected during helix stimulation only in the female participants (repeated 
measures ANOVA; p = 0.007).  There was no significant change in mean HR 























Figure 3.6 Participant HR responses as a result of stimulation at different sites on the ear (n = 22).  Group 
mean and SEM shown in green.  A small but significant decrease in mean HR from baseline was observed during 







































Male participants (n = 11) Female participants (n = 11) 
Baseline Stimulation Recovery Baseline Stimulation Recovery 
Tragus 64.4 ± 2.5*† 61.30 ± 2.9* 61.3 ± 2.6† 73.1*† ± 3.0 68.7* ± 2.3 66.4 ± 2.2† 
Helix 64.4 ± 2.6 62.7 ± 2.8 62.4 ± 2.7 72.8*† ± 3.9 69.2 ± 3.2* 68.0 ± 3.1† 
Cymba 
Concha 
64.1 ± 3.0*† 61.8 ± 2.7* 60.3 ± 2.6† 75.8 ± 4.1*† 70.5 ± 3.0* 69.4 ± 2.9† 
Earlobe 62.3 ± 1.8*† 60.4 ± 2.1* 59.5 ± 2.2† 71.2 ± 3.3*† 68.8 ± 3.0* 67.9 ± 2.9† 
Table 3.9 Male and female participant HR responses as a result of stimulation at different sites on the ear.   
Both male and female participants showed a small but significant decrease in mean HR from baseline during 
stimulation at the tragus, earlobe and cymba concha (p < 0.05), which was sustained into the recovery period (p < 









  Tragus Helix Cymba Concha Earlobe 
  Baseline Stim Rec Baseline Stim Rec Baseline Stim Rec Baseline Stim Rec 
Systolic BP 
(mmHg) 
115.47    
± 3.33*  
118.80   
± 3.11 
125.82    
± 3.34* 
113.59     
± 2.92* 
119.05     
± 3.59 
126.65   
± 3.53* 
117.55   ± 
3.56* 
119.20   
± 2.92 
124.05   
± 2.91* 
120.42   ± 
2.73 
122.33   
± 3.00 




63.86     ± 
2.20* 
66.12     
± 2.53 
67.81     
± 2.64* 
63.90     ± 
2.31* 
67.00     
± 2.54 
70.58      
± 2.60* 
64.74     ± 
2.37* 
64.60     
± 1.89 
67.08     
± 1.94* 
69.27     ± 
2.63 
68.25     
± 2.24 




81.07     ± 
2.40* 
81.07     
± 2.56 
87.15     
± 2.73* 
80.46     ± 
2.42* 
84.35      
± 2.73 
89.36     
± 2.79* 
82.34     ± 
2.69* 
82.96     
± 2.69 
86.07     
± 2.12* 
86.32     ± 
2.49 
86.47     
± 2.37 
87.80     
± 2.24 
Table 3.10: BP responses during stimulation at different sites on the ear in participants with 
successful finger arterial pressure recordings (n = 21).  Significant increases in systolic BP, diastolic BP 
and mean BP were recorded in the recovery period after stimulation was applied to the tragus, cymba concha 





































118.95       
± 1.66* 
115.90       
± 1.66* 
115.10       
± 1.17 
118.57       
± 1.70 
116.95       
± 1.85 
116.71       
± 2.19 
118.00        
± 1.77 




68.14         
± 1.27* 
65.17         
± 1.14* 
64.24         
± 1.25 
65.19         
± 1.10 
74.00         
± 1.21 
74.14         
± 1.41 
74.38         
± 1.37 




85.75         
± 1.14* 
82.11         
± 1.14* 
81.19         
± 1.20 
82.98         
± 1.10 
88.32         
± 1.25 
88.33         
± 1.49 
88.92         
± 1.34 
88.45         
± 1.44 
Table 3.11: BP responses measured using a brachial BP cuff immediately after the baseline period and 
immediately after the stimulation period at different sites on the ear (n = 21).  A small but significant decrease was 
observed from baseline at the end of tragus stimulation in brachial systolic BP (paired t-test; p = 0.039), brachial diastolic 




Finger arterial blood pressure was recorded in all but one participant (n = 21) 
across all four visits.  Small but significant increases in systolic BP, diastolic 
BP and mean BP were recorded after stimulation applied to the tragus, 
cymba concha and helix (see Table 3.10, with the exception of earlobe 
stimulation, where there was no significant change in blood pressure over 
time.  To investigate if this effect was due to recording BP using a finger 
arterial NIBP device, data was compared with BP data obtained using a 
digital brachial BP monitor in the two 5 minute rest periods between the 
baseline, stimulation and recovery recordings (Table 3.11).  A significant 
decrease was observed from baseline at the end of tragus stimulation in 
brachial systolic BP (paired t-test; p = 0.039), brachial diastolic BP (paired t-
test; p = 0.027) and brachial mean BP (paired t-test; p = 0.012).  Significant 
differences were detected between finger arterial diastolic pressure and 
brachial systolic pressure at baseline and at the end of stimulation for all four 
stimulation sites (p < 0.05).  This was also reflected in significant differences 
between finger arterial diastolic pressure and brachial diastolic pressure at 
baseline and at the end of stimulation for all four stimulation sites (p < 0.05).  
No significant differences were detected between methods of measurement 














3.5.5 Reported sensations during electrical stimulation 
During the brief stimulus titration stage at each visit where the electrical 
current was adjusted to a comfortable but perceptible level, the participants 
were asked to describe as best they could the sensations associated with the 
electrical stimulation.  The only further prompting from the investigator was to 
ask the participant to report if the sensation was localised to the area 
immediately in contact with the electrode or if the stimulus could be perceived 
elsewhere.  The electrical current was typically described at all stimulation 
sites as being a “tingling”, “tickling”, “pins and needles” or “sharp” sensation 
before the current was adjusted to a lower level, with the sensation being 
localised to the stimulation site.  However, a number of participants reported 
sensations at other sites on the ear or on nearby facial regions.  The 
sensation evoked by helix stimulation was reported by some participants to 
travel posteriorly along the helix of the ear from the stimulation site (n = 5) or 
travel inferiorly towards the tragus on one or both ears (n = 3) or along the 
ipsilateral mandible (n = 2).  In two participants the sensation caused by 
earlobe stimulation was felt to radiate inferiorly along the neck, while one 
participant reported an itching sensation along their left zygomatic arch which 
was not present on the right zygomatic arch.  Tragus stimulation was 
reported in three participants to produce a tingling sensation which radiated 
inferiorly along the mandible on one or both sides.  Lastly, in two participants 
cymba concha stimulation evoked a tingling or tickling sensation which 
radiated laterally from the cymba concha towards the helix of the ear and one 
participant reported a “vague sensation of current” travelling inferiorly from 
the ear along the neck.  One participant reported a sensation of “warmth” in 
their chest for the duration of cymba concha stimulation, which ceased when 









The results of the present study of transcutaneous electrical nerve 
stimulation applied to different sites on the external ear are mixed with 
regards to the effects on cardiovascular autonomic function.  On the one 
hand, this study provides further evidence that transcutaneous electrical 
nerve stimulation applied to the tragus of the ear can induce a change in 
autonomic function similar to that described by Clancy et al., whereby tragus 
stimulation in healthy adults elicited a decrease in LF/HF ratio (Clancy et al., 
2014).  However, in the present study this effect was only observed in 12 out 
of 22 individuals recruited (54.5%), who were termed tragus responders as 
they exhibited a decrease in LF/HF ratio as opposed to the tragus non-
responder group who did not have this response to tragus stimulation. Clancy 
et al. reported a significant decrease in LF/HF ratio for the whole group as a 
result of tragus stimulation although that study had a larger sample size (n = 
34 versus n = 22 in the present study).  In addition, Clancy et al. showed a 
decrease in MSNA from baseline as a result of tragus stimulation, 
characterising the change in cardiovascular autonomic function as 
sympathoinhibitory (Clancy et al., 2014).  
Where the present study provides additional insight is firstly through the 
significant increase in spontaneous BRS observed during tragus stimulation 
in 14 participants who had detectable BRS sequences.  Clancy et al. did not 
report BRS data although recordings of continuous beat-to-beat finger arterial 
pressure were obtained as part of the experimental protocol (Clancy et al., 
2014).  In addition, the observed increase in BRS in the present study only 
occurred during tragus stimulation, with no significant differences in BRS 
detected as a result of stimulation applied to the cymba concha, helix or 
earlobe.  This outcome would suggest that tragus stimulation may have a 
unique effect on cardiovascular autonomic function compared to stimulation 
at the other three sites.  A recent study by Antonino et al. in 13 young (mean 
age = 23 ± 1 years) healthy male volunteers also assessed the effect of 15 
minutes of tragus stimulation on spontaneous BRS using the sequence 
method and observed a significant increase in BRS along with a 




Antonino et al. compared tragus stimulation with 15 minutes control 
stimulation applied to the earlobe in the same volunteers and found no 
significant difference in BRS during earlobe stimulation (earlobe baseline 
BRS = 13.6 ± 1 ms/mmHg; earlobe stimulation BRS = 13.9 ± 1ms/mmHg; p = 
0.23).  This is consistent with the findings of the present study, where earlobe 
stimulation elicited no significant effect on BRS (Table 3.7).  Antonino et al. 
attributed the increase in BRS during tragus stimulation to activation of ABVN 
afferents (Antonino et al., 2017).   
However, the present study expands further on the effects of auricular nerve 
stimulation on BRS by including stimulation of the helix and cymba concha, 
with no significant change in BRS for either stimulation site.  While the 
sample size of participants with detectable spontaneous BRS sequences was 
small (n = 14) the lack of an effect at sites such as the cymba concha is 
interesting.  If the increase in BRS observed during tragus stimulation was 
due to activation of ABVN afferents alone, a significant increase in BRS 
should also have been observed during cymba concha stimulation using the 
same stimulation parameters.  This may imply that the cardiovascular 
autonomic effects of tragus stimulation are due to simultaneous activation of 
multiple neural pathways rather than solely activation of ABVN afferents.  It is 
possible that the cardiovascular autonomic effects reported by the present 
study, Clancy et al. and Antonino et al. were influenced by the activation of 
trigeminal and cervical spinal afferent pathways, with subsequent effects on 
medullary nuclei such as the nucleus tractus solitarius (NTS).  However, 
there is less convincing evidence in the present study for the activation of 
cervical spinal pathways as part of the mechanism of tVNS, as earlobe 
stimulation did not significantly alter LF/HF ratio or BRS. 
The lack of an effect on HRV or BRS as a result of cymba concha stimulation 
using the same stimulation parameters as tragus stimulation is an 
unexpected finding.  If the activation of ABVN afferents is responsible for the 
cardiovascular autonomic effects of tVNS, then a similar decrease in LF/HF 
ratio and an increase in BRS should have been observed in the tragus 
responder subgroup as with tragus stimulation.  However, the present study 




HRV.  Napadow et al. (2012) assessed the effects of cymba concha 
stimulation on HRV in female patients with chronic pelvic pain and found no 
significant change in LF/HF ratio.  The recently published study by De Couck 
et al. also applied tVNS to the cymba concha, with no significant effect on 
measures of HRV such as LF/HF ratio (De Couck et al., 2017).  However the 
stimulation parameters used by De Couck et al. (250µs, 25Hz, 30s on/off 
cycle) differed from the present study.  Moreover, De Couck et al. did not 
stimulate both cymba conchae simultaneously, instead performing alternating 
10 minute periods of unilateral right or left cymba concha stimulation at the 
same visit along with sham stimulation.  Nevertheless, the results of the 
present study appear to be consistent with both Napadow et al. and De 
Couck et al. regarding the lack of changes in HRV as a result of cymba 
concha stimulation. 
 
3.6.1 Central mechanisms 
An interesting result from the present study is that the participants who 
showed a response to tragus stimulation (tragus responders; n = 12) in the 
form of a decrease in LF/HF ratio had a similar response to helix stimulation 
but not to stimulation of the cymba concha or earlobe.  This may implicate 
afferent fibres in the auriculotemporal nerve rather than the ABVN as being 
responsible for the change in cardiovascular autonomic function seen with 
tragus stimulation.  One explanation for this may be auriculotemporal afferent 
fibre projections to the NTS, a key relay point for the processing of 
cardiovascular reflexes and the control of autonomic outflow.  A previous 
neuroanatomical tracing study by Jacquin et al. showed some evidence of 
auriculotemporal nerve projections to the NTS in rats, although a later study 
by Takemura et al. did not report any projections to this site (Jacquin et al., 
1983, Takemura et al., 1987).  In addition, Chien et al. reported some HRP-
labelled nerve terminals in the canine NTS from the rostral internal auricular 
nerve, the canine equivalent of the auriculotemporal nerve (Chien et al., 
1996).  The study also observed HRP-labelling from the middle and caudal 




to have their cell bodies in the jugular ganglion of the vagus nerve, consistent 
with the ABVN (Chien et al., 1996).  Evidence of NTS activation has also 
been found in an fMRI study where electrical stimulation was applied to the 
inner surface of the tragus in human volunteers (Kraus et al., 2013).  In this 
way, activation of the NTS by afferent fibres from one or both of the ABVN or 
the auriculotemporal nerve could be responsible for the autonomic effects of 
tragus stimulation.  Activation of the NTS could then also activate the nucleus 
ambiguus and dorsal motor nucleus of the vagus to elicit an increase in 
parasympathetic outflow via the vagus nerve (Izzo et al., 1993).  This is 
consistent with the observation that the tragus responder subgroup of 
participants exhibited a significant increase in normalised HF power during 
both tragus and helix stimulation, with an additional increase in BRS 
observed during tragus stimulation.  However, as it is not possible to perform 
direct recordings of vagus nerve activity in humans, further preclinical in vivo 
experiments are necessary to clarify the effects of tragus stimulation on 
parasympathetic activity. 
A limitation of the present study is the lack of a direct method of assessing 
stimulation-induced changes in sympathetic nervous system activity.  One 
approach may be to use microneurography to record MSNA, as MSNA has 
been previously shown in healthy volunteers to decrease as a result of tragus 
stimulation (Clancy et al., 2014).  The effects observed in the present study 
could also in part be due to activation of the caudal ventrolateral medulla 
(CVLM) via the NTS, which in turn would lead to inhibition of the rostral 
ventrolateral medulla (RVLM) and a subsequent generalised reduction in 
sympathetic activity (Guyenet, 2006).  Some evidence of this may potentially 
be found in the decrease in both LF power and LF/HF ratio observed during 
both tragus stimulation and helix stimulation in the tragus responder group.  
Nevertheless, without a direct measurement of sympathetic nervous system 
activity it is difficult to establish if this change occurred due to a reduction in 






3.6.2 Response to tragus stimulation 
One reason for the variable response rate to tragus stimulation in the healthy 
participants included in this study is evidence that the auriculotemporal nerve 
is not found at the tragus in all individuals.  The cadaveric dissection study by 
Peuker and Filler found the auriculotemporal nerve at the tragus in only 55% 
of the 14 ears investigated, with the GAN providing sole innervation to the 
tragus in the remaining 45% (Peuker and Filler, 2002).  The response rate to 
tragus stimulation in terms of a decrease in LF/HF ratio in the present study 
was 54.5% of participants, which may be related to the reported innervation 
pattern at the tragus.  In the present study, no significant changes in HRV or 
BRS were observed for great auricular nerve stimulation at the earlobe.  
Thus, individuals with a greater distribution or exclusive innervation of the 
GAN at the tragus may not exhibit the same stimulation-induced 
cardiovascular autonomic effects as individuals with a greater distribution of 
ABVN or auriculotemporal nerve fibres at the tragus.  Nevertheless, it is 
difficult to establish which nerve may be responsible for the autonomic effects 
of tragus stimulation without further clarification of anatomical variations of 
the cutaneous nerves of the external ear.   
 
3.6.3 Distribution of the cutaneous nerves of the external ear 
A potential explanation for the outcomes of the present study is that the 
distribution of the cutaneous nerves of the external ear described by Peuker 
and Filler may not be entirely accurate (Peuker and Filler, 2002).  In that 
study, the ramifications of the ABVN, GAN and auriculotemporal nerve were 
dissected in 7 human cadavers (14 ears in total) with the aid of magnifying 
glasses and the results depicted on a generic template of the external ear.  
This approach may have led to inconsistencies in the innervation pattern due 
to inter-individual variation in the shape and size of the cadaveric ears and no 
data pertaining to this is reported as part of the study (Peuker and Filler, 
2002).  The small sample size of that study may be an additional issue, as 
some relatively common variations in the cutaneous innervation of the 




for dissection.  This is especially key with regards to the cymba concha, as 
Peuker and Filler reported it to be innervated exclusively by the ABVN.  As 
such, this warrants further human cadaveric studies with a larger sample size 
of cadaveric specimens to investigate the auricular cutaneous distribution of 
the ABVN, GAN and auriculotemporal nerve.  Nevertheless, the fine nature of 
the terminal branches of these nerves makes dissection technically 
challenging. An alternative approach may be to use a neuronal tracer 
suitable for fixed cadaveric tissue such as DiI, a carbocyanine dye which can 
travel through fixed neuronal tissue in both an anterograde and retrograde 
direction (Lanciego and Wouterlood, 2011).  DiI applied to the cut peripheral 
end of nerves such as the ABVN could be used to visualise the cutaneous 
innervation of the ear using an epifluorescence microscope. 
An approach which may allow the cutaneous distribution of the auricular 
nerves of the ear to be investigated in human volunteers could be the use of 
direct administration of local anaesthetic agents.  Auriculotemporal nerve 
blockade can be used in clinical settings to alleviate temporomandibular joint 
pain or dysfunction, as the auriculotemporal nerve provides the principal 
sensory innervation to the temporomandibular joint (Donlon et al., 1984, 
Nascimento et al., 2013).  In addition, other nerve blocks applied to the 
branches of the mandibular division of the trigeminal nerve such as the 
inferior alveolar nerve can cause a transient loss of sensation to the external 
ear (Ngeow and Chai, 2009).  The auriculotemporal nerve is in close 
proximity to the superficial temporal artery and the course of this vessel can 
be closely identified using Doppler ultrasound.  This approach allows for 
selective blockade of the auriculotemporal nerve via injection of a local 
anaesthetic agent at a site 1cm superior to the tragus, which has been 
performed in patients undergoing awake craniotomy (Bebawy et al., 2014).  
Pinprick-testing could then be used to assess sensory loss ipsilateral to the 
anaesthetic injection site and compared to sensitivity at the same point on 
the contralateral ear.  A similar method has been previously performed in 20 
human volunteers to assess the cutaneous innervation of the great auricular 
nerve (Thallaj et al., 2010).  The great auricular nerve itself was visualised by 




0.1ml mepivacaine 1% as it emerged from the posterior border of 
sternocleidomastoid.  When compared to the contralateral side, GAN 
blockade led to sensory loss in the earlobe, tail of helix and the antitragus in 
all individuals, consistent with the innervation pattern observed in previous 
cadaveric dissection work for these sites (Peuker and Filler, 2002, Thallaj et 
al., 2010).  However, 7 out of 20 participants reported anaesthesia at the 
spine of the helix, which was the stimulation site chosen in the present study 
to stimulate the auriculotemporal nerve, as Peuker and Filler reported it being 
the sole innervation of the spine of the helix in 91% of cadaveric specimens 
examined (Peuker and Filler, 2002, Thallaj et al., 2010).  This inconsistency 
further reinforces the need for larger scale studies which assess variation in 
the cutaneous innervation of the ear either through cadaveric dissection or 
through nerve blockade studies in human volunteers.   
 
3.6.4 Conclusion 
Stimulation of the tragus and helix evoked a similar response in normalised 
LF power, normalised HF power and LF/HF ratio in a subset of healthy 
volunteers.  This suggests that the effects on cardiovascular autonomic 
function induced by tragus stimulation may be due in part to the influence of 
the auriculotemporal nerve.  However, further in-vivo investigation in animals 
as well as greater clarification of the cutaneous innervation of the external 
ear in humans is needed before this influence can be confirmed.  As such, 
tragus stimulation will be referred to as tVNS applied to the tragus for the 











The autonomic effects of transcutaneous vagus nerve stimulation 


























4.1 Introduction     
There are now over 10 million people aged 65 and older living in the UK, with 
this figure expected to increase to 15.5 million by 2030 and 19 million by 
2050 (Cracknell, 2010).  Age is a critical factor in cardiovascular health and it 
is estimated that cardiovascular diseases such as myocardial infarction and 
stroke will cause 40% of deaths in those aged 65 and over by 2030 (North 
and Sinclair, 2012).  Moreover, ageing is strongly associated with changes in 
autonomic nervous system activity, in particular autonomic control of the 
heart (Kuo et al., 1999).  The autonomic nervous system can be altered with 
increasing age towards elevated sympathetic nerve activity and reduced 
parasympathetic activity, hastening the progression of cardiovascular 
disease (Abhishekh et al., 2013).   
It is well-established that there is an age-associated decline in heart rate 
variability across both time domain and frequency domain measures 
(Umetani et al., 1998, Antelmi et al., 2004, Zhang, 2007, Zulfiqar et al., 2010, 
Abhishekh et al., 2013) with a reduction in HRV signifying corresponding with 
an increased risk of mortality (Tsuji et al., 1994)(Tsuji et al., 1994).  Antelmi 
et al. found that time-domain measures of HRV such as RMSSD and pRR50, 
which reflect parasympathetic modulation, decreased with age in a cohort of 
653 patients aged 14 - 82 years with no history of heart disease (Antelmi et 
al., 2004).  Meanwhile, the LF/HF ratio was observed to increase with age 
across both sexes, although it was consistently greater in men (Antelmi et al., 
2004). Abhishekh et al. also identified a positive correlation between age and 
LF/HF ratio (R = 0.19; p < 0.01) (Abhishekh et al., 2013).  A previous study 
by Clancy et al. with a younger cohort of healthy volunteers (n = 48; 24 male, 
24 female; age range = 20 – 62 years) observed a trend whereby a higher 
LF/HF ratio at baseline was associated with both a greater response to tVNS 
applied to the tragus (R2 = 0.58; p < 0.0005) and increasing age (R2 = 0.19; 
p = 0.013), similar to the correlation observed by Abhishekh et al. (Abhishekh 
et al., 2013, Clancy et al., 2014).  The study by Clancy et al. included only 
two individuals aged 60 years and older but linear regression analysis 
identified two trends whereby age was associated with increased LF/HF ratio 




baseline LF/HF ratio.  These correlations suggest that the stimulation 
parameters employed for tVNS could be more effective at altering autonomic 
nervous system activity in older individuals.  
 
4.1.1 Knowledge gap 
There are no other studies in the literature which specifically assess the 
autonomic effects of auricular tVNS in older healthy adults with no prior 
medical history of cardiovascular disease.  La Marca and colleagues (2010) 
found that auricular electroacupuncture of the concha led to increased 
respiratory sinus arrhythmia (a non-invasive index of cardiac vagus nerve 
activity) in a cohort of healthy men (n = 14), although the age range for these 
volunteers was 20 – 40 years with a mean age of 28.2 years (La Marca et al., 
2010).  More recently, De Couck et al. (2017) looked at the effects on tVNS 
applied to the cymba concha of the ear (Cerbomed device, Germany) on 
measures of heart rate variability in two studies with healthy male and female 
participants: one study involving a comparison of the autonomic effects of 10 
minutes left-sided tVNS versus right-sided tVNS (n = 30; mean age = 37 
years; age range = 23 - 58 years) and a second study with slightly older 
participants looking at the effects of right-sided tVNS over one hour (n = 30, 
mean age = 44 years; age range = 30 – 65 years) (De Couck et al., 2017).  
The first study by De Couck et al. failed to detect any significant change in 
HRV apart from an increase in SDNN from baseline during right-sided tVNS.  
As the first study identified minimal effects as a result of 10 minutes tVNS 
and also in comparison with sham stimulation using the earlobe, the second 
study by De Couck et al. trialled right-sided tVNS over one hour.  This study 
found that tVNS increased the LF/HF ratio after one hour, suggesting an 
alteration in cardiac autonomic activity towards elevated sympathetic nerve 
activity and/or reduced vagal tone (De Couck et al., 2017).  The exact 
number of these participants aged 60 and older is not reported, although both 
this study and the stimulation site optimisation trial with participants aged <60 
years did divide the volunteers into groups older and younger than 40 years 




increased age was associated with an increased LF/HF ratio at baseline, but 
neither study saw any tVNS-induced alterations in HRV related to the age of 
the participants.  Thus, the lack of information on the autonomic effects of 
tVNS in research participants aged 60 years and older, coupled with the 
contradictory nature of the results of previous studies in younger individuals, 
reveals a clear knowledge gap. 
 
4.2 Hypothesis  
Transcutaneous electrical stimulation of the tragus of the ear (tVNS) will alter 
cardiovascular autonomic activity in healthy aged volunteers free from 
cardiovascular disease, with an increased LF/HF ratio at baseline associated 
with a greater response to tVNS. 
 
4.3 Aims and objectives  
The present study investigated the effects of tVNS on cardiovascular 
autonomic activity in healthy participants aged 60 years and older by non-
invasive measurements of heart rate and finger arterial blood pressure.  
Microneurography was then performed at an additional visit to record 













4.4 Materials and methods 
 
4.4.1 General protocol 
University of Leeds ethical approval was secured (Ethics Reference: BIOSCI 
13-025) and the study conformed to the standards outlined in the Declaration 
of Helsinki.  Informed written consent was obtained voluntarily by all research 
participants and their data were anonymised and stored securely according 
to the Data Protection Act (1998).  All experiments were carried out in a 
dedicated human physiology study room at University of Leeds.  These 
experiments occurred between the hours of 9am and 11.30am in order to 
minimise the impact of circadian rhythm variations on the autonomic nervous 
system.  The ambient temperature of the study room was maintained at 21 ± 
2°C.  
27 healthy participants were recruited to the study and all participants were 
asked to complete a basic health questionnaire.  Physical activity level was 
assessed using the Godin Leisure Time Exercise Questionnaire (Amireault 
and Godin, 2015).  Inclusion criteria were male or female volunteers aged ≥ 
60 years old. Exclusion criteria were a prior medical history of hypertension, 
cardiac disease, diabetes mellitus or epilepsy.  Female participants were 
asked to indicate if they were receiving hormonal replacement therapy (HRT) 
for treatment of menopausal symptoms, as HRT has been shown to 
independently alter cardiac autonomic activity (Yildirir et al., 2001).  All 
participants were required to abstain from caffeine, alcohol, nicotine and 
strenuous exercise for a minimum of 12 hours prior to their visit.  They were 
further required to consume a light breakfast and use the toilet prior to 
attending for the experiment.  Participants were asked to attend for two visits 
to receive active tVNS and then sham tVNS at an additional follow-up visit.  
The protocols for delivering these stimulation parameters are outlined in 
Chapter 2.  The active tVNS data from included older participants was further 
compared to active tVNS data obtained from the younger participants aged 





4.4.2 Cardiovascular autonomic measurements and data acquisition 
Recordings of heart rate, respiration, blood pressure and MSNA were 
obtained as described in Chapter 2.  In some participants it was not possible 
to obtain reliable finger arterial blood pressure recordings or to detect BRS 
sequences and the sample sizes for these analyses are included in Table 4.6 
for BP and Table 4.4 for BRS.  To characterise if the change in the LF/HF 
ratio observed during tVNS was due to a decrease in sympathetic activity, 
seven participants who responded with a >10% decrease in LF/HF ratio 
during active tVNS (tVNS responders, n = 13) agreed to return for an 
additional visit.  At this third visit, simultaneous recording of single-unit 
muscle sympathetic nerve activity (MSNA) was obtained from the common 
peroneal nerve of the leg (Figure 2.4).  Single-unit MSNA frequency (units 
detected per minute) and MSNA incidence (units detected per 100 
heartbeats) were calculated to assess changes in sympathetic 
vasoconstrictor activity as a result of active tVNS.  Microneurography was not 
performed during sham tVNS as it was inappropriate to implement this 
invasive technique when sham tVNS had been observed to have no effect on 
LF/HF ratio or mean BRS at the first active tVNS visit.   
  
4.4.3 Statistical Analysis 
All statistical analyses for this study were performed using SPSS (version 
24).   Shapiro-Wilk tests were performed on each variable to assess 
normality.  Participant subgroup characteristics were compared using 
independent t-tests or Mann Whitney U-tests.  Linear mixed model analysis 
was performed to compare the effect of time (baseline, stimulation and 
recovery) between the active tVNS and sham tVNS visits.  One-way repeated 
measures ANOVA was used to analyse effect of time (baseline, stimulation 
and recovery) for each visit (active tVNS or sham tVNS) and Bonferroni post-
hoc tests performed.  Two-way repeated measures ANOVA was used to 
analyse the effect of time (baseline, stimulation and recovery) in the 
subgroup of participants (n = 7) who attended for two active tVNS visits 




Friedman test was used where data were not normally distributed with 
Bonferroni correction applied to adjust significance based on the number of 
pairwise comparisons within the test.  Spearman’s Rank correlation test was 
used to identify possible relationships between variables and linear 
regression was used to further explore these correlations.  All data are 




4.5.1 Baseline characteristics of participants 
27 participants with no previous medical history of cardiovascular disease or 
diabetes were enrolled at the study and written informed consent was 
obtained at the first visit.  Seven of the 27 participants (n = 5 male, n = 2 
female) were excluded from the study due to the presence of frequent 
ventricular extrasystoles.  One volunteer (female, age = 88 years) was 
excluded due to poor ECG signal despite repeated attempts at repositioning 
the ECG electrodes and one volunteer (male, age = 62 years) was excluded 
due to an inability to stay awake during the recordings.  The baseline 
characteristics of the remaining 18 participants (n = 12 female and n = 6 
male) included in the study are presented in Table 4.1.   Male participants 
had a higher baseline LF/HF ratio than female participants (male mean 
LF/HF ratio = 2.0 ± 0.16; female = 1.54 ± 0.29; p = 0.016).  None of the 
female volunteers reported receiving hormonal replacement therapy during 
their involvement with the study.  There were no significant differences in BMI 
or in physical activity level as assessed by the Godin Leisure Time Exercise 







The baseline characteristics of the 18 older participants were then compared 
to mean data from the younger participants (< 60 years old, n = 22) in 
Chapter 3.  The older participants had significantly reduced mean values at 
baseline for the HRV measures total power, VLF power, LF power and HF 
power but not normalised LF, normalised HF or LF/HF ratio (Table 2; p < 
0.05).  No significant differences in systolic BP, diastolic BP or mean BP 
were detected between the younger and older groups (p > 0.05).  The older 
participants had significantly reduced mean BRS at baseline compared to the 
younger participants (p < 0.001; older baseline mean BRS = 8.40 ± 0.72 
ms/mmHg; younger baseline mean BRS = 17.29 ± 1.07 ms/mmHg), but there 





















































67.5          
± 1.56 
26.0         
± 4.16 
17.0        
± 3.79 
84.35       
± 2.20 
64.94      
± 1.86 
1.69        
± 0.21 
16 
8.40            
± 0.75 




68.3         
± 3.05 
25.82       
± 2.40 
17.5        
± 7.97 
84.72      
± 1.76 
68.67      
± 4.42 









67.08       
± 1.75 
26.03       
± 1.39 
16.58      
± 4.06 
84.15      
± 3.26 
65           
± 1.67 
1.54        
± 0.29* 
10 
8.02            
± 0.84 





68.31      
± 1.95 
26.21       
± 1.21 
15.77      
± 4.84 
86.12       
± 4.88 
64.69      
± 3.46 










65.4        
± 2.09 
25.32       
± 1.55 
19.80       
± 5.07 
83.33      
± 5.01 
64.6         
± 2.20 
0.86         
± 0.17* 
3 
9.90            
± 0.88 










Older participants  
(≥ 60 years old) 
Younger 
participants        
(< 60 years old) 
p 
N 18 22 - 
Mean age (years) 
67.50 ± 1.60 
Age range = 60 – 
84  
32.86 ± 2.04 
Age range = 24 - 





) 654.44 ± 82.10*  3374.78 ± 803.03* < 0.001 
LF power (ms
2
) 348.71 ± 99.39* 1409.90 ± 388.29* < 0.001 
HF power (ms
2
) 264.86 ± 101.58* 1491.41 ± 373.58* < 0.001 
Normalised LF 
power (n.u.) 
0.58 ± 0.04 0.52 ± 0.04 0.138 
Normalised HF 
power (n.u.) 
0.42 ± 0.04 0.48 ± 0.04 0.118 
LF/HF ratio 1.69 ± 0.22 1.33 ± 0.18 0.081 
BRS (ms/mmHg) 8.40 ± 0.72* 13.60 ± 1.04* < 0.001 
Table 4.2: Baseline characteristics of the older healthy participants 
compared with younger healthy participants from Chapter 3. 
Significant differences between the older and younger healthy participants 
were observed for BRS as well as the HRV measures total power, LF power 




4.5.2 tVNS significantly improved heart rate variability in healthy older 
adults 
18 participants attended for the active tVNS visit and 14 of those 18 
participants attended for a sham tVNS visit a minimum of one week later.  
Baseline mean LF/HF ratio values were similar between the active and sham 
tVNS visits (p = 0.118, see Table 4.3).  A significant decrease in overall 
mean LF/HF ratio from baseline was observed during active tVNS (repeated 
measures ANOVA; p = 0.003) but there was no significant change from 
baseline during sham tVNS (Figure 4.1 and Figure 4.2).  Active tVNS also 
elicited a significant decrease in normalised LF power (Friedman test; p = 
0.023) and an increase in normalised HF power (Friedman test; p = 0.014) 
from baseline, but no significant changes were observed for sham tVNS (p > 
0.05). 
As in Chapter 3, the participants at the active tVNS visit were further divided 
into subgroups based on their response to active tVNS: tVNS responders 
(decrease in LF/HF ratio during active tVNS, n = 13) and tVNS non-
responders (no change or an increase in LF/HF ratio during active tVNS, n = 
5; Figure 4.1 and Figure 4.2).  All six male participants in the study were 
included in the tVNS responder subgroup.  Mean baseline LF/HF ratio was 
significantly higher for tVNS responders than non-responders (independent t-
test; p = 0.011; responder mean LF/HF ratio = 2.02 ± 0.23; non-responder 
mean LF/HF ratio = 0.86 ± 0.17) and the responder subgroup exhibited a 
decrease in LF/HF ratio during active tVNS (repeated measures ANOVA; p = 
0.001; mean percentage change = - 34.27%).  The mean LF/HF ratio of the 
tVNS responder subgroup approached baseline level once stimulation had 
ceased (Figure 4.1 and Figure 4.2).  A significant decrease in normalised LF 
power (repeated measures ANOVA; p < 0.001) and an increase in 
normalised HF power (repeated measures ANOVA; p < 0.001) was also 
observed from baseline during active tVNS.  The tVNS non-responder 
subgroup (n = 5) were all female and the group mean LF/HF ratio did not 
deviate significantly from baseline during or after active tVNS (p > 0.05; 












Active tVNS (n = 18) 
  
Sham tVNS (n = 14) 





654.44         
± 79.79 
625.74         
± 81.54 
860.43          
± 131.01 
570.47 
 ± 69.11 
718.17 ± 
144.10 





348.71         
± 96.59 
278.95         
± 70.32 
454.62         
± 124.36 
230.93              
±  38.71 
276.21              
±  41.48 
321.67              




264.86         
± 98.71 
272.52          
± 73.26 
331.42         
± 97.29 
168.77              
±  57.04 
201.26              
±  30.61 
199.80              
±  30.71 
Normalised LF 
power (n.u.) 
0.58 ± 0.04* 0.50 ± 0.03* 0.59 ± 0.03 0.56 ± 0.04 0.58 ± 0.04 0.61 ± 0.04 
Normalised HF 
power (n.u.) 
0.42 ± 0.04* 0.50 ± 0.03* 0.42 ± 0.03 0.44 ± 0.04 0.42 ± 0.04 0.39 ± 0.04 
LF/HF 1.69 ± 0.21* 1.16 ± 0.11* 1.63 ± 0.20 1.53 ± 0.21 1.67 ± 0.24 1.84 ± 0.24 
Table 4.3: HRV responses to active tVNS and sham tVNS in older healthy participants   Active tVNS elicited a 
significant decreases in normalised LF and LF/HF ratio from baseline (p < 0.05).  A significant increase in normalised 
HF power was observed in the recovery period following active tVNS (p = 0.014). No significant changes were 






























Active tVNS (n = 18)



























tVNS Responder (n = 13)
tVNS Non-Responder (n = 5)
Sham (n = 14)
Figure 4.1 HRV responses to active tVNS and sham tVNS in older healthy participants: (A) Active tVNS elicited a 
significant decrease in LF/HF ratio from baseline (p = 0.003) while no significant change was observed as a result of sham 
tVNS (p > 0.05).  (B) 13 participants experienced a decrease in LF/HF ratio during tVNS (tVNS responder; mean change = 
















































4.5.3 The LF/HF ratio at baseline is correlated with the change in LF/HF 
ratio during active tVNS  
A relationship between baseline LF/HF ratio and the change in LF/HF during 
active tVNS was identified by linear regression analysis, indicating that the 
response to active tVNS can be predicted based on the baseline LF/HF ratio 
(R2 = 0.79; p = 0.001; Figure 4.3).  There was no correlation between 
baseline LF/HF ratio and age (R2 = 0.16; p = 0.052) or with any other 














































Figure 4.3 Relationship between baseline LF/HF ratio and change in 




4.5.4 The tVNS-induced changes in LF/HF ratio were reproducible in 
tVNS responders 
Seven participants (male = 3, female = 4) from the tVNS responder subgroup 
returned for a second active tVNS visit where microneurography was 
performed to assess changes in single-unit MSNA.  The group mean change 
in LF/HF ratio observed as a result of active tVNS in these participants was 
comparable between their first and second active tVNS visits (Figure 4.4) but 



























tVNS responder (first visit)
tVNS responder (second visit)
Figure 4.4 LF/HF ratio change observed as a result of active tVNS in 
participants who returned for microneurography (n = 7).  A decrease in 
LF/HF ratio was observed due to active tVNS at both visits in all 
participants except one. This male participant did not show a decrease in 




4.5.5 tVNS increased baroreflex sensitivity in healthy older adults 
When all participants (responders and non-responders) were considered in 
analyses, there was a small but significant increase in BRS from baseline 
during active tVNS (n = 16; p = 0.031; see Figure 4.5 and Table 4.4), which 
was sustained in the recovery period (p = 0.002).  This effect was not 
observed as a result of sham tVNS (n = 10; p = 0.520; Figure 4.5 and Table 
4.4).  The baseline BRS values for sham and active tVNS did not differ 
significantly (p = 0.701).  No significant change in BRS was detected in the 
male participants during or after active tVNS (baseline BRS = 9.04 ± 1.35; 
tVNS BRS = 12.22 ± 1.75; n = 6; p = 0.096).  This may have been due to the 
small sample size and substantial inter-individual variability.  A significant 
increase in BRS was observed from baseline in female participants (n = 10; 
baseline BRS = 8.02 ± 0.84) in the recovery period (recovery BRS = 10.58 ± 
1.20) but not during tVNS (BRS = 9.25 ± 1.01).  
In participants who responded to tVNS with a decrease in LF/HF ratio (n = 
13), there was an increase in BRS which remained elevated in the recovery 
period (see Table 4.4).  Linear regression analysis showed that the mean 
LF/HF ratio in the recovery period for the tVNS responder group was 
inversely related to the mean BRS in these participants at the same time-
point (R2 = 0.406; p = 0.019).  In the seven tVNS responders who returned 
for an additional visit where active tVNS and microneurography were 
performed, there was no difference in baseline BRS between this visit and 
the original active tVNS visit (first visit = 8.06 ± 1.28; second visit = 8.67 ± 
0.84; p = 0.403).  However, the small sample size at this additional visit (n = 
6) meant that no significant change was detected (p= 0.194; baseline BRS 








































Active tVNS (n = 16)
Sham tVNS (n = 10)
Figure 4.5 BRS response to active tVNS and sham tVNS in the older 
participants. 
A significant increase in BRS was observed from baseline during active 
tVNS (p = 0.031), which was sustained into the recovery period (p = 


















 N Baseline Stimulation Recovery 
p (Baseline -  
Stimulation) 
p (Baseline - 
Recovery) 
Active tVNS 16 8.40 ± 0.75 10.36 ± 1.01 10.97 ± 1.04 0.031 0.011 
Sham tVNS 10 8.96 ± 1.28 9.77 ± 0.98 9.10 ± 0.74 0.805 1.0 
tVNS responders 13 8.06 ± 0.86 10.30 ± 1.16 10.73 ± 1.25 0.011 0.004 
tVNS non-
responders 
3 9.90 ± 0.88 10.61 ± 1.34 12.00 ± 0.64 1.0 1.0 
Active tVNS + 
microneurography 
7 8.67 ± 0.84 9.95 ± 0.86 8.22 ± 0.93 0.078 1.0 
Table 4.4: BRS responses in healthy older participants.   
Active tVNS elicited a significant increase in BRS from baseline, which was sustained in the recovery period. 


















 N Baseline Stimulation Recovery 
p (Baseline -  
Stimulation) 
p (Baseline - 
Recovery) 
Male participants 6 9.04 ± 1.47 12.22 ± 1.91 11.62 ± 2.03 0.140 0.505 
Female participants 10 8.02 ± 0.84 9.25 ± 1.01 10.58 ± 1.20 0.392 0.029* 
Table 4.5: Comparison of BRS responses in male and female healthy older participants.   
Female participants showed a significant increase in BRS from baseline in the post-stimulation recovery period.  




4.5.6 tVNS reduced muscle sympathetic nerve activity in healthy older 
adults 
Simultaneous microneurography recording of single-unit MSNA from the 
common peroneal nerve was performed in five out of seven participants who 
returned for a second active tVNS session.  Active tVNS elicited a significant 
decrease in mean MSNA frequency (p = 0.043; Figure 4.6 and Table 4.6) 
and mean MSNA incidence (p = 0.043; Figure 4.6), alongside a decrease in 
LF/HF ratio.  All five participants experienced a decrease in single-unit MSNA 
frequency and incidence from baseline as a result of active tVNS, which 
remained below baseline level in four out of five participants after active tVNS 
ceased.  Single-unit MSNA in the fifth participant returned to that individual’s 
baseline level of MSNA frequency and MSNA incidence after active tVNS 
ceased, although the LF/HF ratio for this participant remained below baseline 
level. 
 
Baseline Stimulation Recovery 
MSNA Frequency 
(units/min) 
0.60 ± 0.17*† 0.30 ± 0.14* 0.16 ± 0.04† 
Normalised MSNA 
Frequency (units/min) 
1.00*† 0.40 ± 0.14* 0.40 ± 0.16†   
MSNA Incidence 
(units/min) 
1.06 ± 0.31*† 0.56 ± 0.27* 0.28 ± 0.06† 
Normalised MSNA 
Incidence (units/min) 
1.00*† 0.39 ± 0.14* 0.41 ± 0.16† 
Table 4.6: Effect of active tVNS on MSNA in healthy older participants.   
Active tVNS elicited a significant decrease from baseline in mean MSNA 
frequency (p = 0.043) and mean MSNA incidence (p = 0.043).  Data 
normalised to 1.00 due to high degree of inter-individual variability in the 















Figure 4.6 Effect of active tVNS on MSNA frequency and incidence in healthy older participants (normalised data).   
A significant decrease in both MSNA frequency and MSNA incidence were detected as a result of active tVNS (p < 0.05).  
Data have been normalised to 1.00. 
 














































































4.5.7 Effects of active and sham tVNS on heart rate and blood pressure 
A slight but significant decrease in mean heart rate from baseline was 
observed during active tVNS (baseline mean heart rate = 66.4 ± 1.6 beats 
per minute; during tVNS = 65 ± 1.8 beats per minute; p = 0.007), which 
persisted once active tVNS had ceased (mean heart rate after tVNS = 63 ± 
1.9; p = 0.01 compared with mean heart rate at baseline).  This trend was not 
observed in the participants who returned for an active tVNS and 
microneurography experiment (n = 7). There was no change in mean heart 
rate from baseline during sham tVNS, but heart rate decreased in the post-
intervention recovery period (p = 0.004).  An increase in mean systolic blood 
pressure (p = 0.006) and mean diastolic blood pressure (p = 0.034) was 






























Active tVNS (n = 17) 
 
Sham tVNS (n = 11) 
Baseline Stimulation Recovery Baseline Stimulation Recovery 
Systolic BP 
(mmHg) 
122.71 ± 2.64 126.24 ± 2.25 122.76 ± 3.18 116.45 ± 4.19* 116.36 ± 4.32 123.64 ± 4.22* 
Diastolic BP 
(mmHg) 
65.18 ± 2.31 67.35 ± 1.71 66.41 ± 1.61 68.09 ± 1.60* 66.82 ± 1.66 70.91 ± 1.79* 
Mean BP 
(mmHg) 
84.35 ± 2.20 86.98 ± 1.54 85.20 ± 1.88 84.21 ± 1.74 83.33 ± 1.99 88.48 ± 1.92 
Table 4.7: BP responses to active and sham tVNS in healthy older participants.   
Active tVNS did not have a significant effect on systolic, diastolic or mean BP (p > 0.05) but an increase in systolic BP (p = 
0.034) and diastolic BP (p = 0.034) from baseline was observed in the recovery period following sham tVNS.  
 ( 





This study demonstrates that transcutaneous vagus nerve stimulation applied 
to the tragus of the ear can induce changes in autonomic nervous system 
activity in healthy adults aged 60 years and older.  Active tVNS significantly 
decreased the LF/HF ratio from baseline and this observation was 
accompanied by a decrease in single-unit MSNA when measured in a subset 
of subjects during active tVNS and microneurography, characterising this 
change in autonomic activity as one involving a decrease in central 
sympathetic outflow.  However, a small but significant increase in BRS was 
also observed during active tVNS, suggesting that there may be a concurrent 
increase in vagal tone as a result of stimulation too.  As aging is a risk factor 
for cardiovascular dysfunction, tVNS may thus be beneficial to cardiovascular 
health in older people (North and Sinclair, 2012).  
The results of this study contrast with Napadow et al. (2012) where tVNS 
applied to the cymba concha had no effect on HRV, although that study also 
used different stimulation parameters (Napadow et al., 2012).  However, the 
present study lends some support to the conclusion of La Marca et al. (2010) 
that tVNS is able to enhance vagal tone, although that study focused on 
respiratory sinus arrhythmia rather than HRV or BRS and also used 
electroacupuncture of the left inferior concha of the ear rather than bilateral 
cutaneous surface electrodes positioned on the tragus (La Marca et al., 
2010).  The high frequency spectral power component is considered to be a 
quantitative marker of respiratory sinus arrhythmia (Pagani et al., 1986, 
Pomeranz et al., 1985) and although the present study failed to see any 
change in HF power as a result of active tVNS, an increase in normalised HF 
was detected.  This disparity in outcomes between HF power and normalised 
HF power may have been due to the high variability in HF power between the 
older participants, which would have been adjusted and minimised by 
normalisation. This change in normalised HF also coincided with a small but 
significant increase in mean BRS from baseline in the older participants, 




The present study only agrees with the two studies by De Couck et al. (2017) 
insofar as their >40 year old age groups had depressed values of LF and HF 
power at baseline compared to younger participants, as well as a greater 
value for LF/HF ratio in the two >40 year old groups(De Couck et al., 2017).  
No other age-related trends in HRV were associated with this study, although 
the different stimulation sites (right or left cymba concha) and different 
stimulation parameters (1mA, 10 minutes tVNS and 1 hour tVNS) to the 
present study may be responsible for the contrasting results.  
 
4.6.1 tVNS effects on cardiovascular function  
The present study corroborates the conclusions of Clancy et al. (2014) in that 
tVNS is able to induce a decrease in both LF/HF ratio and single-unit MSNA 
frequency and incidence in healthy individuals (Clancy et al., 2014).  In 
addition, the present study provides further insight into this short-term change 
in autonomic function through the detection of a small but significant increase 
in spontaneous baroreflex sensitivity as measured using the sequence 
method.  This is particularly important given the association between lower 
values of BRS and prognosis following myocardial infarction and also in heart 
failure (La Rovere et al., 2011).  Thus, tVNS may be a method of potentially 
increasing BRS where it may be impaired – the participants in the present 
study had a much lower mean BRS value at baseline than the younger 
participant data taken from Chapter 3, although the younger volunteers 
overall (n = 22) did not show a change in BRS as a result of tVNS applied to 
the tragus.  Cardiovagal BRS is known to be inversely correlated with age 
and the reductions in BRS may involve any aspect of the cardiac baroreflex 
arc such as the afferent limb or the efferent limb i.e. the vagus nerve 
(Laitinen et al., 1998; Monahan et al., 2007).  However it is not possible to 
directly record from the vagus nerve in humans and further in-vivo studies 
investigating the effects of tVNS applied to the tragus on spontaneous BRS 
are needed. 
There remains uncertainty as to the residual autonomic effects of tVNS once 




in LF/HF ratio and MSNA following cessation of current, but the present study 
observed this effect for MSNA alone.  The mean LF/HF ratio returned to 
baseline level within 15 minutes of the stimulus being switched off.  This 
suggests that the cardiac autonomic modulation induced by tVNS may be 
short-lived in older individuals, but the reduction in vasoconstrictor 
sympathetic nerve activity to vascular smooth muscle (specifically to the 
smooth muscle of arteries supplying the leg skeletal musculature) may be 
able to persist for a longer duration.  However, the observed change in LF/HF 
ratio in response to tVNS can be reproduced, as demonstrated by data from 
the tVNS responder subjects (n = 7) who returned for an additional 
microneurography visit.  Their group mean LF/HF response to tVNS was 
similar between both active tVNS visits.  Further studies are needed to 
elucidate the autonomic effects of chronic tVNS in older individuals and 
determine if the autonomic modulation induced in the short-term by this 
technique can be maintained over time.   
There has been a number of previous studies performed over a longer time-
scale using an electroacupuncture form of tVNS in patients with coronary 
artery disease (Popov et al., 2013, Zamotrinsky et al., 1997, Zamotrinsky et 
al., 2001).  These studies are especially relevant to the present study given 
the known association between ageing and an increased incidence of 
coronary artery disease (Jousilahti et al., 1999).  Current treatment strategies 
in coronary artery disease (CAD) patients with heart failure include β-
adrenergic blockade to counter the early adverse effects of cardiac 
sympathoexcitation via the modulation of heart rate (Azevedo et al., 2001).  
Zamotrinsky and colleagues trialled a variation of tVNS involving 
electroacupuncture in patients with CAD who were awaiting coronary artery 
bypass surgery.  Bilateral electrical stimulation of the concha for 15 minutes 
over 10 days led to a decrease in vasodilator use and a reduction in the 
frequency of angina pectoris attacks, with effects persisting up to three 
weeks after tVNS (Zamotrinsky et al., 1997, Zamotrinsky et al., 2001).  
Patients in the tVNS group had a significantly reduced incidence of acute 
heart failure post-surgery compared to a control group (Zamotrinsky et al., 




of tVNS over 10 days in a cohort of 48 male CAD patients (mean age = 53.5 
± 4.1 years).  The study found that 62.5% of patients (n = 30) experienced a 
reduction in the severity of their angina attacks with a concurrent and 
significant decrease in LF/HF ratio (baseline mean LF/HF ratio = 2.43 ± 0.78; 
after tVNS = 1.25 ± 0.25; p = 0.001), although the remaining patients 
experienced no significant immediate change in HRV (baseline mean LF/HF 
ratio = 1.85 ± 0.20; after tVNS = 1.71 ± 0.21) (Popov et al., 2013).  A follow-
up examination one month later found improvements in the well-being of the 
responder group with a sustained decrease in LF/HF ratio (mean LF/HF ratio 
= 1.02 ± 0.03), although the non-responder patients also exhibited a 
significant decrease in LF/HF ratio one month on (mean LF/HF ratio = 1.56 ± 
0.15; p = 0.043).  The autonomic effects of chronic tVNS therefore may not 
manifest immediately after the course of stimulation has finished.  Future 
studies with older healthy individuals free from cardiovascular disease should 
also include a follow-up period after tVNS has ceased, to ascertain if there 
are comparable changes in autonomic indices such as the LF/HF ratio and 
especially MSNA, given the sustained decrease in single-unit MSNA 
observed with short-term tVNS in the present study. 
 
4.6.2 tVNS as a therapeutic adjunct for age-associated autonomic 
dysfunction 
The results of the present study suggest that tVNS may be able to exert a 
short-term modulatory effect on the autonomic nervous system in older 
healthy individuals, suggesting that it may be a potential non-invasive method 
of counteracting the deleterious changes in autonomic nervous system 
activity that coincide with normal ageing.  This autonomic dysfunction can 
manifest in chronic cardiovascular conditions such as heart failure, which 
increases in prevalence with age (Levy et al., 2002, Bleumink et al., 2004).  
However, autonomic dysfunction identified using non-invasive measures 
such as heart rate variability and baroreflex sensitivity is also associated with 
an increased risk of developing psychological disorders such as major 




et al. in a cohort of elderly men (n = 2285) free from cardiovascular disease 
found an association between depressive symptoms and increased resting 
heart rate, a sign of potential autonomic dysfunction (Kamphuis et al., 2007).  
The association between autonomic dysregulation and the risk of developing 
poor mental health in old age could be a potential research direction to 
explore with tVNS applied to the tragus, as the changes in cardiovascular 
autonomic function observed with tVNS may elicit a prophylactic effect. 
In addition, problems with memory and cognition are common aspects of 
ageing which can have a profound effect on an individual’s quality of life.  
Episodic memory, for example the ability to equate a face with a name, is 
one particular form of memory which declines with age (Ronnlund et al., 
2005).  There is evidence that tVNS applied to the tragus may have a 
beneficial effect on episodic memory performance in healthy older people 
(Jacobs et al., 2015).  The application of 17 minutes tVNS was found to 
attenuate a decline in performance in a verbal word-learning task which was 
otherwise observed when stimulation was applied to the earlobe as a control 
(Jacobs et al., 2015).  This finding suggests that tVNS may be a potential 
method of ameliorating episodic memory loss, reducing the impact of this 
particularly distressing condition on elderly individuals.  
 
4.7 Conclusion  
The present study supports the use of tVNS as a method of counteracting the 
detrimental age-associated changes in autonomic nervous system activity, 
specifically through the reduction of sympathetic nerve activity as measured 
using MSNA and the increase in baroreflex sensitivity.  Further studies are 
needed to determine the long-term autonomic effects of tVNS in an aged 








The autonomic effects of transcutaneous vagus nerve stimulation 



























Vagus nerve stimulation for the treatment of heart failure was first trialled by 
Schwartz et al., who surgically implanted a modified VNS system (CardioFitTM 
model 5000, BioControl Medical Ltd.) in eight male heart failure patients who 
had already received optimum medical therapy such as beta-blockers and 
ACE-inhibitors for at least one month (Schwartz et al., 2008).  In contrast to 
previous VNS trials in drug-refractory epilepsy, this single-centre phase II 
feasibility study implanted the stimulating electrodes around the right cervical 
vagus nerve rather than the left.  An intracardiac sensing lead was also 
inserted into the right ventricle to monitor heart rate, allowing 1ms VNS pulses 
to be delivered at a fixed time delay (70ms) from the onset of the R wave to 
prevent bradycardia (Schwartz et al., 2008).  At six months follow-up, there 
was a significant reduction in end-systolic left ventricular volume (baseline = 
208 ± 71ml; six months = 190 ± 83ml; p = 0.001) as well as small yet significant 
decrease in resting heart rate (baseline = 87 ± 15bpm; six months = 82 ± 
12bpm; p = 0.02).  This preliminary study also found significant improvements 
in both symptoms and quality of life as assessed by the New York Heart 
Association (NYHA) classification and the Minnesota Living with Heart Failure® 
QoL questionnaire.  An expanded multi-centre phase II trial of the CardioFit 
system with an additional 24 heart failure patients again demonstrated 
improved quality of life scores and NYHA classification at six months follow-
up, plus an increase in left ventricular ejection fraction (baseline = 21.1 ± 7.5%; 
one year = 34.1 ± 12.5%; p<0.0001) and a reduction in heart rate (baseline = 
85 ± 14bpm; one year = 76  ± 11bpm; p < 0.003) in 23 patients at one year 
follow-up (De Ferrari et al., 2011). 
Since publication of the results of this study, subsequent larger-scale trials 
have found VNS to be safe in heart failure but have reported varied outcomes 
in terms of efficacy (Premchand et al., 2014, Zannad et al., 2015, Gold et al., 
2016).  Although measures such as NYHA classification and quality of life 
scores improved in all these later studies, only the ANTHEM-HF trial (n=60) 
reported improved measures of cardiac function after six months.  These 
included increased LVEF (increase after 6 months = 4.5%), reduced left 




decreased left ventricular end-systolic diameter (LVESD; change after 6 
months = -1.7mm).  SDNN, a time domain measure of heart rate variability, 
was also found to increase by 17ms after six months of VNS regardless of 
whether it was applied to the left or right cervical vagus nerve.  However, both 
the randomised controlled NECTAR-HF (n=87) and INOVATE-HF (n=707) 
trials failed to detect differences in echocardiographic measures of cardiac 
function between their respective active and control groups.  
Stimulation of the auricular branch of the vagus nerve, via the tragus and 
lateral wall of the external acoustic meatus, may be a feasible non-invasive 
alternative to cervical VNS.  tVNS has been investigated as a potential therapy 
for epilepsy, depression, pain and tinnitus but has not been investigated as a 
potential therapy to alter autonomic function in heart failure. Following on from 
the promising results of a previous tVNS study in healthy human research 
participants (Clancy et al., 2014), which showed that 15 minutes of tVNS could 
improve HRV and also reduce MSNA, ethical approval was obtained to trial 
tVNS in a small group of patients with chronic heart failure.  Once recruited 
these patients were compared to age-matched and sex-matched healthy 
controls free from diagnosed cardiovascular disease. 
 
5.2 Hypothesis  
Transcutaneous vagus nerve stimulation applied to the tragus of the external 
ear will alter cardiovascular autonomic function in heart failure patients. Based 
on the results of the previous studies of tVNS in healthy human volunteers, 
tVNS will decrease LF/HF ratio and increase BRS, signifying a shift in 








5.3 Aims and Objectives 
The aim of this study was to investigate the effects of tVNS on cardiovascular 
autonomic function in a cohort of patients with chronic heart failure. The 
objectives were:  
1. To determine the effects of tVNS on heart rate variability and baroreflex 
sensitivity in heart failure patients.  




5.4.1 Research subjects 
National Research Ethics Service ethical approval was secured to recruit 
heart failure patients (Ethics Reference: 12/YH/0354 and 14/YH/0178) and 
University of Leeds ethical approval was secured to recruit healthy volunteers 
as controls (Ethics Reference: BIOSCI 13-025) the study conformed to the 
standards outlined in the Declaration of Helsinki.  Informed written consent 
was obtained voluntarily from all research participants and their data were 
anonymised and stored securely according to the Data Protection Act (1998).  
The heart failure patients were recruited from a weekly heart failure 
outpatient clinic at Leeds General Infirmary and eligible patients were 
identified and screened by the clinical care team.  Inclusion criteria for heart 
failure patients were: 
 
 Male or female with diagnosis of heart failure 
 Aged 18 years and older 








Exclusion criteria for heart failure patients were: 
 Cardiac arrhythmia 
 Bradycardia 
 Postural hypotension 
 Unable to transfer onto a couch without assistance 
 
All heart failure patients were receiving optimal medical therapy at the time of 
participation in the study including ACE-inhibitors, angiotensin receptor 
blockers, beta-blockers and loop diuretics. Three of the included heart failure 
patients also had cardiac resynchronisation therapy (CRT) using an 
implanted pacing device but none of these patients were atrially-paced.  
None of the female participants (patients or controls) reported receiving 
hormonal replacement therapy during their involvement with the study.  
Participants reclined semi-supine on a couch for the duration of each 
experiment while recordings of their heart rate, finger arterial blood pressure 
and respiration rate were obtained as previously described in Chapter 2. 
 
5.4.2 Experimental protocol 
All experiments with the heart failure patients were carried out in a vacant 
clinical consultation room or in the Human Physiology lab of the 
Cardiovascular Clinical Research Facility at Leeds General Infirmary.  
However, the time of day when experiments took place was not controlled as 
most of the patients were recruited directly from the outpatient clinic.  In 
addition, for the patients it was not possible to control for the influence of 
medication, nicotine, caffeine, or exercise levels prior to participation in the 
study.  All experiments with healthy controls occurred under the controlled 
conditions detailed in Chapter 4.  Participants reclined semi-supine on a 
couch for the duration of each experiment while recordings of their heart rate, 
finger arterial blood pressure and respiration rate were obtained as 





Ten minute recordings of heart rate (lead II ECG), respiration and finger 
arterial blood pressure were obtained at baseline, during active tVNS and 
following cessation of stimulation (recovery period) as described in Chapter 
2.  The heart failure patients were further asked to complete a stimulation 
tolerability questionnaire (Chapter 2). 
 
5.4.4 Data analysis 
Offline analysis was carried out using Spike2 (version 7.1; CED, UK) and 
Labchart (version 8.1.5; ADInstruments, Bella Vista, Australia) software.  Five 
minute samples of data from each recording were analysed in Spike2 to 
obtain frequency-domain HRV and mean blood pressure. The same five 
minute samples of the R-R interval tachogram were then exported from 
Spike2 as a text file and imported into Labchart, where spontaneous 
baroreflex sensitivity was calculated using custom scripts in Labchart 
(version 8.1.5, ADInstruments, Bella Vista, Australia) from each five minute 
sample of data using the sequence method. 
 
5.5.7 Statistical Analysis 
All statistical analyses for this study were performed using SPSS (version 
24).   Shapiro-Wilk tests were performed on each variable to assess 
normality.  The effect of tVNS compared to baseline on HRV, BRS, heart 
rate, blood pressure and respiration was analysed using paired t-tests or 
Wilcoxon signed ranks tests.  Independent t-tests and Mann-Whitney U-tests 
were used to compare baseline characteristics of the heart failure patients to 
a cohort of age and sex-matched healthy controls.  Levene’s test was used to 
assess the equality of variances for variables compared between groups and 








5.6.1 Baseline characteristics  
A total of 28 heart failure patients were recruited for this study but 20 were 
excluded for the following reasons: 
 
 14 had frequent ectopic beats or other cardiac arrhythmia 
 2 had frequent coughing during the experiment  
 2 had pre-existing pain conditions (arthritis of back and shoulder) that 
made lying on the couch for long periods of time uncomfortable  
 1 had poor ECG signal-to-noise ratio and numerous ECG signal 
artefacts 
 1 reported pain in their left arm 
 
The baseline characteristics of the included eight patients alongside eight 
healthy age-matched controls selected from previous studies are presented 
in Table 5.1.  Compared to the patients, the healthy controls were not 
significantly different at baseline with respect to the LF/HF ratio (patient mean 
LF/HF = 3.09 ± 0.61, healthy control mean LF/HF = 1.99 ± 0.52).  However, 
the patients had a reduced LF power and HF power at baseline compared to 
healthy controls (Table 5.2).  There were no significant differences in 
baseline mean HR between the two groups, but mean systolic blood 
pressure, mean diastolic blood pressure and mean blood pressure were all 
lower in the patients at baseline compared to the controls (Table 5.3).  BRS 
was also greater in the healthy controls than the patients at baseline (healthy 















Patients Controls p 
Number 8 8 - 
Age (years) 66.25 ± 4.16 64.0 ± 3.56 0.69 
LVEF (%) 29.63 ± 3.63 - - 
NYHA 
classification 
2 class I; 4 class II;                




27.0 ± 7.12 - - 
Baseline LF/HF 
ratio 
3.09 ± 0.62 1.99 ± 0.52 0.20 
Mean heart rate 
(bpm) 
68.29 ± 3.34 65.15 ± 3.64 0.38 
Baseline BRS 
(ms/mmHg) 
5.36 ± 1.18* 9.34 ± 1.17* 0.03 
Mean BP 
(mmHg) 
64.85 ± 5.81* 84.02 ± 2.21* 0.01 
Table 5.1: Baseline characteristics of heart failure patients and healthy 
controls.  The patients had a significantly reduced baseline BRS (p = 0.03) 




5.6.2 tVNS reduced LF/HF ratio and increased BRS in heart failure 
patients 
A significant decrease in LF/HF ratio was observed in the heart failure 
patients compared to baseline (p = 0.05; Table 5.2).  This effect was not 
observed in the healthy controls (p = 0.121) and may be due to the small 
sample size.  No significant changes in LF power or HF power alone were 
detected for either group.  BRS increased in the heart failure patients from 












Table 5.2: Mean HR and HRV data for heart failure patients and 
healthy controls.  The heart failure patients experienced a 
significant reduction in LF/HF ratio during tVNS (p = 0.05).  The 
healthy volunteers experienced a small but significant decrease in 








Patients (n = 8) Controls (n = 8) 
Baseline Stimulation p Baseline Stimulation p 
Mean heart rate 
(bpm) 










64.19 ± 17.27 63.59 ± 16.83 0.889 236.49 ± 64.09 262.18 ± 112.11 1.0 
LF power (ms
2
) 148.77 ± 43.73 136.01 ± 41.76 0.479 510.48 ± 209.01 408.97 ± 149.99 0.263 
HF power (ms
2
) 51.90 ± 11.63 88.78 ± 32.15 0.093 414.88 ± 225.40 371.10 ± 164.84 1.0 
LF/HF ratio 3.09 ± 0.62* 2.08 ± 0.61* 0.05 1.99 ± 0.52 1.32 ± 0.15 0.121 


















Patients (n = 8) Controls (n = 7) 
Baseline Stimulation p Baseline Stimulation p 
Mean Systolic BP 
(mmHg) 
98.34 ± 8.09 97.68 ± 8.60 0.836 120.21 ± 3.44 118.13 ± 4.59  0.266 
Mean Diastolic BP 
(mmHg) 
48.11 ± 5.19* 45.19 ± 5.20* 0.026 65.92 ± 1.94 65.56 ± 3.00 0.789 
Mean BP      
(mmHg) 
64.85 ± 5.81 62.69 ± 5.98 0.228 84.02 ± 2.21 83.34 ± 3.23 0.640 
Mean BRS 
(ms/mmHg) 
5.36 ± 1.18* 7.33 ± 1.57* 0.017 9.34 ± 1.17 10.63 ± 1.94 0.494 
Table 5.3: Blood pressure and BRS data for heart failure patients and healthy controls.  The heart failure 
patients had a significant reduction from baseline in mean diastolic BP (p = 0.026) and an increase in mean BRS 





























































Figure 5.1: The effects of tVNS on LF/HF ratio in individual heart failure patients and healthy controls.  
A significant decrease in LF/HF ratio occurred during tVNS only in the heart failure patients (A; n = 8; p = 0.05).  No 































































Figure 5.2: The effects of tVNS on spontaneous BRS in individual heart failure patients and healthy 
controls.  A significant increase in BRS occurred during tVNS only in the heart failure patients (p = 0.017).  No 





5.6.3 Effects of tVNS on HR and BP 
There was no difference between patients and healthy controls in terms of 
baseline mean heart rate (p=0.382).  A slight but significant decrease in 
mean heart rate from baseline was observed in the healthy controls during 
tVNS (p = 0.005; Table 5.2, but not in the heart failure patients (p=0.141).  
Systolic blood pressure was significantly lower in the patient group at 
baseline and these effects may have been the result of CHF medication such 
as beta-blockers (p = 0.033, see Table 5.3 for BP values).  This was further 
reflected in decreased values for diastolic BP (p = 0.011) and mean BP (p = 
0.013) compared to the control group.   
 
5.6.4 Tolerability questionnaire results 
All heart failure patients enrolled in the study were asked to complete a 
tolerability questionnaire which asked if they experienced any discomfort or 
other sensations during tVNS.  The patients were also asked if they 
experienced any dizziness, anxiety or chest palpitations during stimulation.  
In terms of the tolerability questionnaire, none of the patients reported any 




















Question Mean Score 
Did you find the ear stimulation uncomfortable 0 
Did you experience any pins and needles during the ear stimulation? 0.63 ± 0.39 
Did you experience any warmth sensation at the stimulation site 0.13 ± 0.12 
Did you feel any dizziness during the experiment? 0.25 ± 0.23 
Did you feel anxious during the experiment? 0 
Did you experience any palpitations during the experiment? 0 
Did you find lying on the couch uncomfortable 0.13 ± 0.12 
Table 5.4: Results of the tVNS tolerability questionnaire.  Questions were rated from 0 – 5 with 





This case-control study demonstrates that tVNS can decrease LF/HF ratio in 
heart failure patients, indicating a shift in cardiac autonomic control towards 
parasympathetic predominance.  This alteration was also shown to coincide 
with an increase in baroreflex sensitivity in the patient group.  Given that all of 
the patients were receiving optimal medical therapy (including beta-blockers) at 
the time of participation in the study, the results suggest that tVNS may be able 
to influence cardiac autonomic nervous system activity when it is already to an 
extent impaired.  Some evidence of this impairment may be in the reduced total 
power, LF power, HF power and reduced BRS exhibited by the patients 
compared to the healthy controls free from cardiovascular disease.  Decreased 
parasympathetic activity, indicated by reduced HRV and BRS, is known to be 
associated with an increased risk of mortality after myocardial infarction and in 
patients with heart failure (La Rovere and Schwartz, 1997, La Rovere et al., 
1998, La Rovere et al., 2011).  
In the clinical trials with heart failure patients, cervical VNS was shown to elicit 
alterations in autonomic activity as indicated by time-domain HRV measures 
(Premchand et al., 2014, Zannad et al., 2015, Gold et al., 2016).  However, it 
should be noted that the majority of patients enrolled in these trials were NYHA 
class III, indicating at least moderate symptoms such as breathlessness 
following mild physical exertion e.g. walking.  This was exemplified by 
INOVATE-HF, where all 707 heart failure patients enrolled were NYHA class III 
(Gold et al., 2016).  In the present study, the majority of the included patients 
were NYHA class I or II (n=6), with only one NYHA class III patient and one 
NYHA class IV patient.  The severity of heart failure symptoms may thus have 
an influence on the efficacy of tVNS and a larger sample size is needed to 
identify if there is any correlation.  
In the present study, the heart failure patients had a greater baseline mean 
LF/HF ratio compared to the aged healthy control group, although because of 
the small sample size and wide variation in baseline LF/HF ratios this was not 
found to be significantly different (p = 0.414).  In Chapter 4, linear regression 
analysis revealed a significant relationship between baseline LF/HF ratio and 




cardiovascular disease.  A greater decrease in LF/HF ratio was observed in 
healthy participants who had an elevated baseline LF/HF ratio.  This trend was 
not observed in the heart failure patients, again potentially due to a small 
sample size.  A larger controlled study of the effects of tVNS in heart failure 
should be carried out to clarify differences in response to tVNS between 
patients and healthy controls.  In addition, further studies with heart failure 
patients should be controlled for the potential confounding effects of time of day 
and also caffeine and nicotine intake.  This was not feasible with the present 
cohort of patients due to time constraints. 
As a result of the time constraints with some patients, it was not possible to 
evaluate the presence of any immediate residual effects following short-term 
stimulation i.e. within 15 minutes of the stimulus being switched off.  Clancy et 
al. (2014) reported a sustained reduction in LF/HF ratio and single-unit MSNA in 
healthy younger participants following tVNS (Clancy et al., 2014), although 
Chapter 4 of this thesis found only a sustained reduction in single-unit MSNA in 
healthy older participants, with the LF/HF ratio returning to baseline level 15 
minutes after stimulation had ceased.  The cardiovascular benefits of repeated 
daily exposure to tVNS in coronary artery disease patients has been previously 
demonstrated (Zamotrinsky et al., 1997, Zamotrinsky et al., 2001) and as such 
there may be potential for similar residual effects to be observed in heart failure.    
The primary advantage for tVNS is its ease of application, followed by a lack of 
side-effects and complications from using the technique (Ben-Menachem et al., 
2015).  The present study found acute tVNS to be well-tolerated in the heart 
failure patients and no side-effects such as chest palpitations were reported as 
a direct result of the stimulation.  For these patients, the most commonly 
reported sensation was paraesthesia or a ‘tingling’ sensation before the 
electrical current was titrated to a comfortable level.  In addition, none of the 
patients asked for tVNS to be stopped as a result of these sensations and did 
not report any further stimulus-associated discomfort.  This is in contrast to 
VNS, which although safe and also generally well-tolerated is known to cause 
adverse effects in some patients as a direct result of stimulation (Beekwilder 
and Beems, 2010, Ben-Menachem et al., 2015).  VNS requires a surgical 
procedure under general anaesthesia to implant the electrodes and a 




side-effects such as dysphonia and infection (Elliott et al., 2011).  In the longer 
term, hardware failure may require revision surgery to replace faulty electrodes, 
leaving patients at risk of experiencing a relapse in their symptoms (Spuck et 
al., 2010, Dlouhy et al., 2012). Furthermore, the invasiveness of VNS poses an 
issue in particular for very ill or elderly patients, for whom surgery may not be 
advisable. This severely constrains the potential clinical utility of VNS.   
The case for trialling tVNS in cardiovascular disease states rather than VNS 
may be furthered by the ineffective outcomes of the recent clinical trials 
investigating the efficacy of right-sided VNS in heart failure (Zannad et al., 2015, 
Gold et al., 2016). In particular, INOVATE-HF was stopped due to statistical 
futility when patients in the treatment arm of the trial did not see a significant 
improvement in all-cause mortality or unplanned HF-related hospitalisations 
(Gold et al., 2016). The lack of efficacy reported in these trials may be due in 
part to the complex mixed fibre composition of the human cervical vagus nerve 
along with the potential activation of sympathetic nerve fibres transmitted within 
the cervical vagus, which may have a confounding effect (Seki et al., 2014, 
Verlinden et al., 2016).  Indeed, when the cervical vagus nerve was stimulated 
in anesthetized dogs, activity of neurones in the stellate ganglion increased; this 
increased sympathetic nerve activity would clearly be detrimental to patients 
suffering from cardiovascular disease (Rhee et al., 2015).  Given the drawbacks 
inherent to cervical VNS, a simpler, more practical alternative without the need 
for a surgical procedure may be offered by tVNS. 
 
5.7.1 tVNS as a potential anti-arrhythmic agent 
The present study excluded 14 out of the 28 enrolled heart failure patients 
(50%) due to frequent ventricular extrasystoles or premature ventricular 
complexes (PVCs), which if uncorrected can cause spectral abnormalities in the 
low-frequency and high frequency power bandwidths for frequency-domain 
HRV analysis (Wen and He, 2011).  PVCs are arrhythmic events which are 
commonly asymptomatic, occurring in around 6% of 45 - 65 year olds 
(Sapoznikov et al., 1992).  The frequency of these PVCs is known to increase 
with age, although they are perceived to be harmless in individuals with no 




people aged 65 and over (n = 1139) with normal left ventricular ejection fraction 
(LVEF) at baseline and no history of congestive heart failure showed that an 
elevated frequency of PVCs may be associated with a reduction in LVEF, an 
increased risk of developing heart failure and increased mortality (Dukes et al., 
2015).  Previous longitudinal studies have also found that men with frequent 
PVCs have an increased risk of developing coronary artery disease (Hirose et 
al., 2010, Bikkina et al., 1992) and PVC frequency may be an independent risk 
factor for ischaemic stroke (Agarwal et al., 2015).  Moreover, there is an 
association between frequent PVCs and the development of atrial fibrillation in 
adults aged ≥50 years old (Watanabe et al., 2006), indicating that these 
frequent disruptions in normal cardiac rhythm may have a deleterious effect on 
the cardiac conduction system. 
A study with CAD patients by Popov et al. demonstrated that tVNS is able to 
influence the frequency of PVCs, as measured by 24 hour ECG recording 
(Popov et al., 2013).  Ten days of tVNS led to a significant reduction in PVC 
frequency one month after the course had been completed.  A number of other 
studies have found tVNS to have a pronounced anti-arrhythmic effect.  Yu and 
colleagues (2013) used tVNS of the right tragus to inhibit the induction of atrial 
fibrillation from three hours of rapid atrial pacing in anaesthetised dogs (Yu et 
al., 2013).  Further tVNS studies associated the tVNS-induced suppression of 
atrial fibrillation (AF) with reduced loss of connexin 40 and connexin 43 in the 
atrial myocardium (Chen et al., 2015c, Chen et al., 2015a) and improved 
cardiac function and reduced ventricular remodelling (Wang et al., 2015b, Wang 
et al., 2014).  The results observed in animal models informed a study where 
one hour of tVNS under general anaesthesia was trialled in 20 patients with 
paroxysmal atrial fibrillation and the effects compared to a control group of AF 
patients who received sham tVNS (n = 20).  Active tVNS significantly decreased 
the duration of atrial fibrillation and also reduced serum levels of pro-
inflammatory cytokines such as tumour necrosis factor, C-reactive protein and 
interleukin-6, suggesting that tVNS is able to modulate immune system activity 
(Stavrakis et al., 2015).  These studies suggest that tVNS may be able to 
benefit patients with a range of cardiac arrhythmias by reducing the frequency 
of arrhythmic events through modulation of the cardiac conduction system, 





These preliminary results suggest that tVNS may be able to influence 
autonomic activity in conditions such as heart failure which are associated with 
autonomic dysfunction. Moreover, tVNS is an inexpensive and non-invasive 
method of activating similar neural pathways to cervical VNS that may be 
utilised by a much greater number of patients.  Further investigation is needed 
in both clinical and animal studies to elucidate the efficacy of tVNS as an 
























The autonomic effects of supraorbital trigeminal nerve stimulation in 



























6.1 Introduction  
The anti-epileptic effects of VNS led to the investigation of trigeminal nerve 
stimulation (TNS) as a potential therapeutic and minimally-invasive alternative 
form of neuromodulation (Penry and Dean, 1990, DeGiorgio et al., 2006).  
Subsequent trials sought to establish a standardised method of non-invasively 
applying TNS to the supraorbital and supratrochlear nerves of the ophthalmic 
division (V1) of the trigeminal nerve using adhesive surface electrode positioned 
on the forehead (DeGiorgio et al., 2006; see Figure 2.2 in Chapter 2).  These 
trials have shown TNS to be safe and well-tolerated, with no significant effect on 
blood pressure although there is some evidence that short-term (60 minutes) 
exposure to TNS can exert a mild (4%) decrease in heart rate (Cook et al., 
2013, Pop et al., 2011, Schrader et al., 2011).  However, heart rate and blood 
pressure are crude measures of autonomic function and it is unclear what effect 
TNS may have on other measures such as heart rate variability and baroreflex 
sensitivity.  Acute stimulation of trigeminal afferents can induce cardiovascular 
effects such as bradycardia, a phenomenon variously reported in the literature 
as the trigeminal depressor response or the trigeminocardiac reflex (Kumada et 
al., 1975, Shelly and Church, 1988, Lang et al., 1991).  This has been reported 
to occur during surgical procedures where blunt contact between surgical 
instruments and a trigeminal nerve branch can cause bradycardia and a 
decrease in mean arterial pressure by as much as 20% (Schaller et al., 2009).  
A related trigeminal reflex is the mammalian diving reflex, where exposure of 
facial skin to cold water also leads to increased vagal tone but in this instance 
there is a simultaneous increase in sympathetic nervous system activity (Alboni 
et al., 2011).  However microneurographic recordings of MSNA and SSNA in 
humans during exposure to cold water showed that this sympathetic activation 
was primarily directed towards the skeletal muscle vasculature rather than the 
cutaneous vascular beds (Fagius and Sundlof, 1986).  A later study in young 
healthy men found that stimulation of trigeminal afferents via facial cooling led 







6.1.1 Knowledge gap 
There have been few studies which have specifically investigated the 
cardiovascular autonomic effects of electrical TNS.  In anaesthetised rabbits, 
non-invasive electrical stimulation (10Hz, 0.5 ms, 5V) of the nasal mucosa 
generated an increase in cerebral blood flow as assessed by laser Doppler 
flowmetry (Gurelik et al., 2004).  The nasal mucosa are densely innervated by 
trigeminal afferents from the nasociliary nerve (V1) and this study failed to 
detect any changes in mean heart rate or mean arterial blood pressure as a 
result of stimulation.  A later study by Hanamoto et al. investigated the 
autonomic effects of lingual nerve (V3) stimulation in cats (n = 38) sedated using 
controlled doses of pentobarbital sodium, a widely-used anaesthetic for animal 
studies (Hanamoto et al., 2012).  A light dose of anaesthetic caused an 
increase in HR and BP when 10 seconds of TNS (10Hz, 5ms, 2Ma) was 
applied.  This may have been due to sympathetic activation, whereas a 
moderate dose with TNS produced a depressor reflex response, suggesting 
that the reflex may be dependent on the depth of anaesthesia and the type of 
anaesthetic agent used (Hanamoto et al., 2012).  It is less clear how stimulation 
of trigeminal afferents using TENS, such as the TNS protocols employed in 
clinical trials, may alter autonomic nervous system activity in awake humans.  A 
recent study in healthy volunteers (n = 16) by Waki et al. found that 
electroacupuncture delivered at 100Hz (compared to 120Hz for the TNS in 
epilepsy patient trials) for 5 minutes to the supraorbital region elicited a 
significant decrease in heart rate along with an increase in HF power during 
stimulation (Waki et al., 2017).  A bilateral increase in cerebral blood flow to the 
prefrontal cortices was also detected using near-infrared spectroscopy 
compared to a control group who did not receive stimulation and rested quietly 
(Waki et al., 2017).   
Anatomical tracing studies have demonstrated that the trigeminal nerve projects 
to similar brainstem structures at the ABVN such as the nucleus tractus 
solitarius and spinal trigeminal nucleus (Jacquin et al., 1983, Nomura and 
Mizuno, 1984, Chien et al., 1996), suggesting that transcutaneous electrical 
nerve stimulation applied to a site such as the tragus may stimulate the 
trigeminal nerve as well as the ABVN.  Chapter 3 of this thesis provides some 




autonomic effects seen with tVNS applied to the tragus, as participants in the 
tragus responder subgroup (n = 12; participants who experienced a decrease in 
LF/HF ratio during tragus stimulation) experienced a decrease in LF/HF ratio in 
response to helix (auriculotemporal nerve) stimulation.  It should be noted that 
the auriculotemporal branch of the trigeminal nerve which innervates the 
external ear and overlaps with the cutaneous innervation of the ABVN is derived 
from the mandibular V3 division as opposed to the ophthalmic V1 or maxillary V2 
divisions, which have been previously targeted in the TNS clinical trials with 
refractory epilepsy patients (DeGiorgio et al., 2006).  However, if the trigeminal 
nerve is involved in the alteration in cardiovascular autonomic function observed 
during tragus stimulation, then stimulation at an alternative site to the tragus 
e.g. the supraorbital region may elicit a similar autonomic effect if the same 
stimulation parameters are used (30Hz, 200µs, continuous current for 15 
minutes).  There may also be a frequency-dependent effect whereby stimulation 
at a higher frequency e.g. 120Hz as per the stimulation protocols used by 
DeGiorgio et al. might alter cardiovascular autonomic function in a different way 
to stimulation at a lower frequency (DeGiorgio et al., 2006).  As none of the TNS 
for treatment-resistant epilepsy trials have assessed the effects of TNS on 
autonomic measures such as HRV or BRS, this data could be useful for the 
optimisation of future trials with this treatment-resistant population. 
 
6.2 Hypothesis  
Transcutaneous electrical nerve stimulation applied to the supraorbital branches 
of the trigeminal nerve (TNS) in healthy research participants will alter 
cardiovascular autonomic function. 
 
6.3 Aims and objectives 
The present study investigated the effects of TNS on cardiovascular autonomic 
activity in healthy participants by non-invasive measurements of heart rate and 
finger arterial blood pressure.  Two different stimulation parameters (low or high 
frequency TNS) were employed to assess if there were any frequency-




6.4 Materials and methods 
 
6.4.1 General protocol 
University of Leeds ethical approval was secured (Ethics Reference: BIOSCI 
13-025) and the all experiments conformed to the standards outlined in the 
Declaration of Helsinki.  Informed written consent was obtained voluntarily by all 
research participants and their data were anonymised and stored securely 
according to the Data Protection Act (1998).  All experiments were carried out in 
a dedicated human physiology study room at University of Leeds.  These 
experiments occurred between the hours of 8am and 10am in order to minimise 
the impact of circadian rhythm variations on the autonomic nervous system.  
The ambient temperature of the study room was maintained at 21 ± 2°C. 
Inclusion criteria were male or female volunteers aged ≥ 18 years old. Exclusion 
criteria were a prior medical history of hypertension, cardiac disease, diabetes 
mellitus or epilepsy.  Female participants were asked to indicate if they were 
receiving hormonal replacement therapy (HRT) for treatment of menopausal 
symptoms, as HRT has been shown to independently alter cardiac autonomic 
activity (Yildirir et al., 2001).  All participants were required to abstain from 
caffeine, alcohol, nicotine and strenuous exercise for a minimum of 12 hours 
prior to their visit.  They were further required to consume a light breakfast and 
use the toilet prior to attending for the experiment.  Participants were asked to 
attend University of Leeds to receive low-frequency TNS (L-TNS, 30Hz) or high-
frequency TNS (H-TNS, 120Hz) at separate visits.  The protocols for delivering 
these stimulation parameters are outlined in Chapter 2.  Ten participants were 
selected at random from the group to return for an additional visit where sham 
TNS was performed and this visit was included into the randomisation order. 
 
6.4.2 Cardiovascular autonomic measurements and data acquisition 
Recordings of heart rate, respiration, blood pressure and MSNA were obtained 
as described in Chapter 2.  The data acquisition protocol and analyses of HRV 
and BRS were performed as described in Chapter 2.  In some participants it 




detect BRS sequences and the sample sizes for these analyses are included in 
Table 6.3 for BP and Table 6.4 for BRS.  
 
6.4.3 Statistical Analysis 
All statistical analyses for this study were performed using SPSS (version 24).  
Shapiro-Wilk tests were performed on each variable to assess normality.  
Participant subgroup characteristics were compared using independent t-tests 
or Mann Whitney U-tests.  One-way repeated measures ANOVA was used to 
analyse effect of time (baseline, stimulation and recovery) for each visit (L-TNS, 
H-TNS or sham TNS) and Bonferroni post-hoc correction applied.  Non-
parametric Friedman test with Bonferroni post-hoc test for pairwise comparisons 
was used where data were not normally distributed.  All data are presented as 




6.5.1 Baseline characteristics 
30 participants with no previous medical history of cardiovascular disease, 
diabetes or epilepsy were enrolled at the study and written informed consent 
was obtained at the first visit.  Two participants (n = 2 male) were excluded from 
the study due to elevated blood pressure (> 140 mmHg systolic BP) at rest as 
measured using a brachial cuff and digital blood pressure monitor.  One 
volunteer (female, age = 21 years) was excluded due to frequent ectopic beats.  
One volunteer (female, age = 38 years) was excluded due to discomfort 
unrelated to the experiments.  The baseline characteristics of the remaining 26 
participants (n = 11 female and n = 15 male) included in this arm of the study 
are presented in Table 6.1.  No significant differences in baseline characteristics 
such as age, BMI, mean heart rate or mean blood pressure were identified 








6.5.2 Cardiovascular autonomic measurements 
There was no significant difference in baseline mean LF/HF ratio values 
between the L-TNS and H-TNS visits for the entire group (p = 0.118, Table 6.2).  
When the 26 included participants were compared at baseline between the 
stimulation parameters, no significant differences were detected between 
parameters at each time point (baseline, stimulation and recovery) for any 
measure of HRV (Friedman test, p > 0.05).  This may have been due to the 
relatively small sample size and the skewed non-normal distribution of data.  
There were no significant differences between participants who received L-TNS 
first due to the order of randomisation compared to those who received H-TNS 
first for any measure.   
No significant changes were observed in respiration rate, BRS or blood 
pressure for any of the stimulation parameters (Table 6.5 for BP data and Table 
6.6 for BRS data).  Mean HR was observed to decrease from baseline during L-
TNS (Figure 6.1; repeated measures ANOVA; p = 0.02) and in the recovery 
period (p < 0.001).  Mean HR decreased only in the recovery period for H-TNS 



















































1.03  ± 
0.20  
Table 6.1: Baseline characteristics of participants enrolled in the TNS study.  




(Figure 6.1; repeated measures ANOVA; p = 0.017) and no significant changes 
were observed for sham TNS (repeated measures ANOVA; p = 0.157). 
Within-groups HRV analysis of the entire sample (n = 26) failed to detect any 
changes in HRV as a result of L-TNS, H-TNS or sham TNS.  However, several 
differing sex-specific effects were identified when the sample was divided into 
male (n = 11; Table 6.3) and female (n = 15; Table 6.4) participants.  While no 
significant differences from baseline were detected for L-TNS or sham TNS for 
either sex, H-TNS reduced HF power in females during stimulation (Friedman 
test; HF power change from baseline p = 0.001).  Both HF power and LF power 
were found to have decreased from baseline in females following H-TNS in the 
recovery period (HF power recovery period p = 0.005; LF power recovery period 
p = 0.006).  However no significant change was observed in LF/HF ratio for the 
female participants as a result of H-TNS (Friedman test; p = 0.420).  In addition, 
neither normalised LF power or normalised HF power were found to be 
significantly reduced for the female participants as a result of H-TNS. This 
disparity between the normalised and absolute measures may be due to the 
relatively small sample size.  The observed changes in the female participants 
for measures of frequency-domain HRV were not seen with the male 
participants.  Both male and female participants experienced a significant 
decrease in mean heart rate following L-TNS in the recovery period (repeated 
measures ANOVA; female mean HR p = 0.001; male mean HR p = 0.005).  A 
significant decrease in mean HR was also observed in the recovery period 
following H-TNS (repeated measures ANOVA; p = 0.035), but no significant 
change in mean heart rate was detected in the male participants as a result of 






























Figure 6.1: Mean HR data for all participants (n = 26).  A significant 
reduction in mean HR from baseline was observed during L-TNS (Repeated 
measures ANOVA; p = 0.02) and in the recovery period (p < 0.001).  A 
significant decrease in mean HR from baseline was only observed in in the 
recovery period for H-TNS (Repeated measures ANOVA; p = 0.017).  No 
significant changes in mean HR were observed for sham TNS (Repeated 
measures ANOVA; p = 0.157). 
* * * 
Table 6.2: HRV data for all participants (n = 26).  No significant 
differences were observed as a result of any stimulation parameter (L-







 L-TNS H-TNS Sham TNS 
 Baseline Stimulation Recovery Baseline Stimulation Recovery Baseline Stimulation Recovery 
Total Power 
(ms2) 
6508.19        
± 1678.64 
6205.75        
± 1651.53 
4678.31        
± 1093.27 
5619.14        
± 1519.89 
4882.91        
± 1219.30 
3712.59        
± 719.95 
6568.30        
± 1485.87 
6182.53        
± 1324.43 
5986.90        
± 1479.20 
LF Power (ms2) 
2575.18        
± 590.69 
2729.97        
± 780.38 
2094.72        
± 548.45 
2105.69        
± 489.00 
1977.43        
± 514.19 
1428.37        
± 266.73 
3030.20        
± 926.23 
2427.15        
± 622.95 
2350.34         
± 667.37 
HF Power (ms2) 
3313.81        
± 1029.02 
2677.17        
± 707.48 
2108.05        
± 577.30 
2896.32        
± 952.40 
1250.51        
± 329.08 
1130.46       
± 264.51 
2743.99        
± 698.31 
2710.92       
± 738.01 




0.48 ± 0.03 0.50 ± 0.03 0.51 ± 0.03 0.49 ± 0.03 0.49 ± 0.03 0.49 ± 0.03 0.51 ± 0.05 0.53 ± 0.05 0.51 ± 0.04 
Normalised HF 
power (n.u.) 
0.52 ± 0.03 0.50 ± 0.03 0.50 ± 0.03 0.51 ± 0.03 0.51 ± 0.03 0.51 ± 0.03 0.49 ± 0.05 0.47 ± 0.05 0.49 ± 0.04 
LF/HF 1.13 ± 0.15 1.15 ± 0.13 1.19 ± 0.14 1.12 ± 0.13 1.12 ± 0.11 1.16 ± 0.13 1.25 ± 0.23 1.25 ± 0.19 1.14 ± 0.14 


















  L-TNS H-TNS 
  
Baseline Stimulation Recovery Baseline Stimulation Recovery 
Total Power (ms
2








































Normalised LF Power 0.56 ± 0.03 0.57 ± 0.03 0.57 ± 0.04 0.59 ± 0.03 0.59 ± 0.03 0.62 ± 0.03 
Normalised HF power 0.44 ± 0.03 0.43 ± 0.03 0.44 ± 0.03 0.41 ± 0.03 0.41 ± 0.03 0.38 ± 0.03 
LF/HF 1.46 ± 0.24 1.48 ± 0.24 1.51 ± 0.27 1.57 ± 0.17 1.57 ± 0.17 1.71 ± 0.18 











  L-TNS H-TNS 
  Baseline Stimulation Recovery Baseline Stimulation Recovery 
Total Power (ms
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Table 6.4: HRV data for female participants (n = 15). HF power decreased from baseline during H-TNS (p = 0.001).  
Both HF power and LF power were found to have decreased from baseline in females following H-TNS in the 





  L-TNS H-TNS Sham TNS 
  
Baseline Stimulation Recovery Baseline Stimulation Recovery Baseline Stimulation Recovery 
Systolic BP 
(mmHg) 
111.69         
± 2.85  
111.96         
± 3.41 
113.09        
± 3.49 
108.31        
± 3.01 
110.18        
± 3.90 
111.65        
± 3.13 
108.45       
± 2.66 
115.72        
± 2.17 




66.10         
± 1.98 
65.96          
± 2.67 
67.95         
± 2.60 
66.93         
± 3.05 
67.16         
± 3.58 
67.87         
± 2.42 
63.22         
± 2.49 
65.29         
± 1.90 




81.30         
± 2.06 
81.29          
± 2.68 
82.99         
± 2.68 
80.72         
± 2.53 
81.50         
± 3.56 
82.46          
± 2.40 
78.29         
± 1.93 
82.10         
± 1.73 
82.10         
± 3.09 
Table 6.5: Blood pressure data for all participants included in the study (n = 24).  It was not possible to obtain reliable BP 
recordings in two participants.  No significant differences in BP were observed for systolic BP, diastolic BP or mean BP as a 







6.5.3 Reported sensations due to trigeminal nerve stimulation 
L-TNS and H-TNS were well-tolerated by all subjects and all participants 
reported a tingling sensation on their forehead and scalp as a result of the 
stimulus.  Some participants reported an additional mildly uncomfortable 
“wiggling” or “worm-like” sensation under the skin of the forehead (n = 7) 
during the electrical current titration stage, but this sensation diminished once 
a more comfortable stimulus intensity was achieved.  During this initial stage 
four participants also reported piloerection of the anterior scalp hair, which 






 N Baseline Stimulation Recovery 
L-TNS 18 20.29 ± 1.78 19.29 ± 1.74 21.61 ± 2.29 
H-TNS 18 19.35 ± 1.90 21.56 ± 1.85 21.73 ± 2.44 
Sham 
TNS 
7 19.41 ± 2.94 21.10 ± 2.95 21.91 ± 2.90 
Table 6.6: Baroreflex sensitivity data for all participants with 
detectable BRS sequences.  No significant changes in BRS were 






The present study is the first reported investigation of the effects of non-
invasive TNS using TENS on heart rate variability and baroreflex sensitivity in 
healthy humans.  It provides evidence that transcutaneous electrical nerve 
stimulation applied to the supraorbital branches of the trigeminal nerve has a 
minimal effect on cardiovascular autonomic function in healthy human adults.  
While no significant differences in blood pressure were observed for the 
trigeminal stimulation parameters, a small but significant decrease in mean 
HR was observed as a result of both L-TNS and H-TNS.  A safety study by 
Pop et al. (2011) reported a small but significant (p = 0.01) 4% decrease in 
heart rate as a result of 60 minutes of stimulation and this decrease was only 
observed to occur following at least 15 minutes of stimulation (Pop et al., 
2011).  Interestingly, the present study observed a 4% decrease in mean HR 
10 – 15 minutes after stimulation had been switched off (25-30 minutes after 
the onset of stimulation), but no change was observed during the 15 minutes 
in which H-TNS was applied.  This may suggest a residual effect of H-TNS 
on mean HR and a slightly longer on-time for stimulation e.g. 20 minutes H-
TNS may produce an observable effect on mean HR during H-TNS.  A small 
reduction in mean HR (4.61%) was observed during L-TNS, suggesting that 
the mild bradycardic effects on heart rate may be frequency-dependent in the 
short-term.  Further investigation is needed to clarify if a reduction in mean 
HR can still be observed for both L-TNS and H-TNS over the course of one 
hour of stimulation, as per the protocol used by Pop et al. to assess the 
cardiac safety of the H-TNS parameters (Pop et al., 2011).    
The observed effects on mean HR in the present study may have been the 
result of a mild form of the oculocardiac reflex, a variant of the 
trigeminocardiac reflex involving the branches of V1 such as the supraorbital 
nerves as the afferent limb (Schaller et al., 2009, Kim et al., 2012).  The 
oculocardiac reflex has been reported as bradycardia of 10 – 20% during 
ophthalmic or neurosurgical procedures where surgical instruments come 
into accidental peri-operative physical contact with branches of V1, as well as 





(Kim et al., 2012, Kasi et al., 2014, Meuwly et al., 2015).  This bradycardic 
effect is thought to be elicited by increased vagal activation and thus the 
trigeminocardiac reflex can also be referred to as the trigeminovagal reflex 
(Meuwly et al., 2015).  However, the present study failed to detect any 
changes in HRV or BRS which might indicate some level of vagal activation 
at the same time as the observed reductions in mean HR as a result of L-
TNS and H-TNS. 
The participants in the present study were slightly younger than those in 
Chapter 3 (29.69 ± 2.13 years and 33.09 ± 2.18 years respectively) and this 
age difference may have had an influence on baseline HRV.  The high 
baseline HRV of the subjects in this study may have impacted on the 
response to TNS, as high HRV suggests that cardiovascular autonomic 
function in these subjects was already well-regulated and as such may not be 
readily modulated by an external stimulus.  However, profound autonomic 
dysfunction affecting both the parasympathetic and sympathetic nervous 
systems has been associated with different types of epilepsy during seizures 
(known as the ictal period), in the period immediately following a seizure 
(postictal period) and also in the latent period between seizure attacks 
(interictal period) (Devinsky, 2004).  A common observation during seizures 
is an increase in sympathetic nervous system activity which manifests in 
symptoms such as sinus tachycardia (Leutmezer et al., 2003).  Given this 
sympathetic activation associated with seizures, future clinical trials of TNS 
for intractable epilepsy should include methods of assessing sympathetic 
nervous system activity such as microneurography to determine if there is 
any change in MSNA.  Measures of HRV and BRS could also be included to 
provide non-invasive although less specific measurements of the effects of 
TNS on cardiovascular autonomic function over time.   
In the majority of clinical studies of TNS, stimulation was delivered for a 
relatively long duration e.g. ≥ 8 hours per night for ≥ 3 months, meaning that 
it is difficult for the outcomes of the present study with healthy participants to 
be generalised to a clinical context.  Shorter durations of TNS have been 





= 60 minutes) and migraine (20 minutes) (Pop et al., 2011, Cook et al., 2013, 
DeGiorgio et al., 2013).  However with the exception of Pop et al., where a 
small decrease in heart rate was observed on an acute basis, these trials 
have generally failed to detect significant changes in heart rate or blood 
pressure as a result of stimulation.  In a randomised crossover study with 
healthy volunteers (n = 16), Waki et al. found that 5 minutes of 
electroacupuncture applied to the supraorbital region at 100Hz in resting 
volunteers did not alter the LF/HF ratio compared to controls, although an 
increase in HF power was observed during stimulation (Waki et al., 2017).  
This study however did not specify the proportion of male and female 
participants included in the sample.   
In the present study, a reduction in total power, LF power and HF power was 
observed as a result of H-TNS in female participants, suggesting that H-TNS 
may be able to evoke an acute reduction in vagal activation which is sex-
specific in character.  However this should be interpreted with caution as no 
significant changes in normalised LF power or normalised HF power were 
detected at the same time-points for H-TNS.  This may be due to the small 
sample size and normalised measures of LF and HF power are known to 
minimise the effect of changes in total power on LF and HF power (Malik, 
1996).  Pre-menopausal women are known to have a predominance of 
parasympathetic nervous system activity over sympathetic activity and this 
relatively increased vagal tone, reflected in higher HRV, may protect them 
from the onset of cardiovascular disease and sudden cardiac death (Kuo et 
al., 1999, Behbahani et al., 2016).  There is limited information on the 
influence of sex on HRV in patients with epilepsy, although Behbahani et al. 
found that middle-aged female patients with epilepsy had lower values for HF 
power compared to men (Behbahani et al., 2016).  This would suggest that 
female epilepsy patients may have reduced vagal tone compared to men and 
this may be an important consideration for future trials of TNS using the H-
TNS parameters 







In conclusion, the results of the present study suggest that short-term 
application of non-invasive TNS delivered at either a lower frequency (30Hz) 
or a higher frequency (120Hz) has a limited effect on cardiovascular 
autonomic function in young healthy volunteers.  Future clinical trials of TNS 
for disorders such as treatment-resistant epilepsy should include 
assessments of autonomic function such as HRV, BRS and 
microneurography to further elucidate the impact of TNS in conditions where 


















































7.1 Summary of findings 
7.1.1 TENS applied to different sites on the external ear can elicit 
variable cardiovascular autonomic responses in healthy adults 
 
This thesis found that transcutaneous electrical nerve stimulation (TENS) 
applied to the tragus could induce a reduction in LF/HF ratio and an increase 
in BRS in a subgroup of participants (n = 12; 54.5%) who were termed tragus 
responders.  This reduction in LF/HF ratio also occurred during TENS applied 
to the spine of the helix, which is known to be innervated by the 
auriculotemporal nerve, but no change in BRS was observed as a result of 
stimulation at this site.  In addition, no significant changes in cardiovascular 
autonomic function were observed during stimulation of the earlobe 
(innervated by cervical spinal afferents) or the cymba concha (innervated by 
ABVN).  This would suggest that stimulation of the auriculotemporal nerve 
may have an influence on autonomic activity, as this nerve can also be found 
at the tragus, but in vivo investigation is needed to investigate the exact 
mechanisms of tragus stimulation before this can be verified. 
   
7.1.2 tVNS applied to the tragus of the external ear can alter 
cardiovascular autonomic function towards parasympathetic 
predominance in healthy aged adults and heart failure patients 
This thesis provides physiological evidence that tVNS applied to the tragus 
can induce acute changes in cardiovascular autonomic function in healthy 
adults aged 60 years and older with no prior medical history of cardiovascular 
disease.  A significant decrease in LF/HF ratio occurred alongside an 
increase in spontaneous BRS during active tVNS but not sham tVNS.  
Microneurographic recording of MSNA in a subset of participants showed a 
decrease in vasoconstrictor sympathetic nerve activity, suggesting that the 
change in cardiovascular autonomic function was a shift towards 
parasympathetic predominance. In addition, tVNS applied to the tragus 





function in a small sample of patients with chronic heart failure who were 
already receiving optimal medical therapy, with a reduction in LF/HF ratio and 
an increase in BRS during stimulation.  However, it was not possible to 
perform microneurography in these patients to confirm changes in 
sympathetic nervous system activity.  No adverse effects were identified in 
these patients during stimulation and tVNS was well-tolerated. 
 
7.1.3 Supraorbital TNS has a minimal effect on cardiovascular 
autonomic function in healthy humans 
This thesis demonstrates that non-invasive trigeminal nerve stimulation 
delivered to the supraorbital region of the forehead has a minimal acute 
effect on cardiovascular autonomic function in healthy human volunteers.  
This is regardless of whether stimulation was delivered at a lower frequency 
(L-TNS; 30Hz) or a higher frequency (H-TNS, 120Hz).  Both induced small 
reductions in mean heart rate but no significant changes were observed in 
measures of HRV or BRS.  However, future studies in both healthy and 
clinical populations should include microneurography to assess changes in 
sympathetic outflow, as well as assessment of measures of HRV and BRS 
over longer durations of stimulation. 
 
7.2 Potential mechanisms behind the cardiovascular autonomic effects 
of tVNS applied to the tragus  
While the exact mechanisms behind the autonomic effects of tVNS are 
unclear, there is evidence that the activation of vagal afferents projecting to 
the NTS may be responsible.  The NTS is a key relay point for the processing 
of cardiovascular reflexes and the control of autonomic outflow, with a 
number of animal studies reporting that the ABVN also has projections to the 
NTS.  ABVN afferents have been found to project to the NTS in rats (He et 
al., 2013), while application of HRP to the ABVN in cats showed significant 
neuronal labelling not only in the NTS but also in the spinal trigeminal 





and Mizuno, 1984). In humans, BOLD fMRI have detected brainstem 
activation as a result of tVNS applied to the tragus (Kraus et al., 2007, Kraus 
et al., 2013).  A further human fMRI study showed that electrical stimulation 
of the left cymba concha could activate the ipsilateral NTS and could also 
induce significant bilateral activation of the spinal trigeminal nuclei, locus 
coeruleus and dorsal raphe nuclei (Frangos et al., 2015).  In a rat model of 
transient focal ischaemia, Ay et al. showed that electroacupuncture applied to 
the ABVN dermatome caused a 28% reduction in infarct volume (Ay et al., 
2015a). This study also identified bilateral c-fos staining in the NTS, 
confirming activation of the NTS as a result of tVNS. In this way, the ABVN 
projections to the NTS may be significant with regards to the potential for 
tVNS to influence cardiovascular activity.   
However, the tragus responder subgroup of participants in Chapter 3 (n = 12) 
observed a decrease in LF/HF ratio as a result of stimulation to both the 
tragus and the helix using the same stimulation parameters.  Consequently, 
this may implicate afferent fibres in the auriculotemporal nerve rather than 
the ABVN as being responsible for the change in cardiovascular autonomic 
function seen with tragus stimulation.  A potential explanation for this may be 
auriculotemporal afferent fibre projections to the NTS, as a previous 
neuroanatomical tracing study by Jacquin et al. showed some evidence of 
auriculotemporal nerve projections to the NTS in rats, although a later study 
by Takemura et al. did not report any projections to this site (Jacquin et al., 
1983, Takemura et al., 1987).  In addition, Chien et al. reported some HRP-
labelled nerve terminals in the canine NTS from the rostral internal auricular 
nerve, the canine equivalent of the auriculotemporal nerve (Chien et al., 
1996).  The study also observed HRP-labelling from the middle and caudal 
internal auricular nerves in the NTS and the majority of neurons were found 
to have their cell bodies in the jugular ganglion of the vagus nerve, consistent 
with the ABVN (Chien et al., 1996).  Evidence of NTS activation has also 
been found in an fMRI study where electrical stimulation was applied to the 
inner surface of the tragus in human volunteers (Kraus et al., 2013).  In this 
way, activation of the NTS by afferent fibres from one or both of the ABVN or 





tragus stimulation.  Activation of the NTS could then also activate the nucleus 
ambiguus and dorsal motor nucleus of the vagus to elicit an increase in 
parasympathetic outflow via the vagus nerve (Izzo et al., 1993).  This is 
consistent with the observation that the tragus responder subgroup of 
participants exhibited a significant increase in normalised HF power during 
both tragus and helix stimulation, with an additional increase in BRS 
observed during tragus stimulation.  However, as it is not possible to perform 
direct recordings of vagus nerve activity in humans, further preclinical in vivo 
experiments are necessary to clarify the effects of tragus stimulation on 
parasympathetic activity.  Nonetheless, this thesis provides evidence that 
tVNS can increase BRS and HRV in both aged healthy volunteers and heart 
failure patients, suggesting an increase in vagal tone.  
Of particular relevance to this thesis is the finding that tVNS significantly 
reduced the concentration of plasma norepinephrine in conscious dogs with 
healed myocardial infarction following bilateral stimulation of the tragus, 
adding further evidence to the ability of tVNS to modulate sympathetic nerve 
activity (Wang et al., 2015a).  A more recent study in anaesthetised dogs by 
the same research group showed that the acceleration in heart rate produced 
in response to stimulation of the right stellate ganglion was attenuated 
following tVNS applied to the tragus (Zhou et al., 2016).  This was further 
accompanied by a reduction in LF/HF ratio (Zhou et al., 2016).  tVNS was 
also found to reduce c-fos expression in the right stellate ganglion, 
suggesting a reduction in cardiac sympathetic activation. The precise 
mechanisms underlying this sympathoinhibitory pathway are uncertain, but 
excitation of ABVN (or auriculotemporal) afferent projections to the NTS may 
inhibit activity in the rostral ventrolateral medulla (RVLM) via activation of the 
caudal ventrolateral medulla.  The RVLM regulates the basal level of central 
sympathetic outflow and tVNS may therefore be able to reduce sympathetic 
nerve activity through RVLM inhibition (Figure 7.1; Guyenet, 2006).  In this 
way, tVNS applied to the tragus may be a potential therapeutic adjunct for 
conditions associated with chronic sympathetic activation such as in heart 






 Figure 7.1: Outline of potential neural pathways through which 
stimulation of the auricular branch of the vagus nerve (ABVN) could 
influence cardiac activity.  Electrical stimulation applied to skin innervated 
by ABVN afferents increases input to the nucleus tractus solitarius (NTS) in 
the dorsal medulla.  This in turn leads to increased activation of NTS 
neurones projecting to the dorsal vagal nucleus (DVN) and nucleus ambiguus 
(NA), which contain vagal preganglionic efferent neurones. These vagal 
efferent neurones increase activation at the sinoatrial (SA) node, inducing a 
bradycardiac response.  Stimulation of ABVN afferents may also excite 
neurones in the NTS with excitatory projections to the caudal ventrolateral 
medulla (CVLM). The CVLM has inhibitory projections to the 
rostroventrolateral medulla (RVLM), the principal source of excitatory drive to 
sympathetic preganglionic neurones in the intermediolateral cell column (IML) 
of the spinal cord. This inhibition would lead to a reduction in sympathetic 






7.3 Potential clinical applications of tVNS applied to the tragus 
 
7.3.1 tVNS for treatment-resistant hypertension  
Hypertension is the foremost risk factor for premature mortality and heart 
disease, with the global prevalence predicted to increase to 1.56 billion 
people by 2025 (Kearney et al., 2005). The prevalence of hypertension in 
England has been determined to be around 30% of the population (Joffres et 
al., 2013).  Up to half of hypertensive patients are treatment-resistant, 
defined as persistently high blood pressure that remains elevated despite the 
use of at least three antihypertensive pharmacological agents including a 
diuretic (Calhoun et al., 2008, Esler et al., 2010).  As such, there has been 
substantial interest in the use of neuromodulatory therapies in treatment-
resistant hypertensive patients. 
One such technique is renal nerve denervation, where afferent and efferent 
nerve fibres surrounding the renal artery are ablated using radiofrequency or 
ultrasound energy in an attempt to reduce sympathetic activation (Esler et al., 
2010). This is achieved using specialised catheter-based electrodes inserted 
percutaneously into the femoral artery and fed superiorly into the renal artery 
to allow for large-scale ablation of nerve fibres in the arterial adventitia (Patel 
et al., 2015).  The SYMPLICITY-HTN1 trial of renal nerve denervation in 
treatment-resistant hypertension patients (n = 45) showed therapeutic 
promise at 12 months after denervation, with ambulatory BP recordings 
detecting a mean reduction in systolic blood pressure of 27 mmHg and 
diastolic blood pressure of 17 mmHg from a mean baseline BP of 177/110 
mmHg (Krum et al., 2009).  By three years, 93% of patients had experienced 
a reduction in systolic blood pressure of at least 10 mmHg (Krum et al., 
2014).  The SYMPLICITY-HTN2 trial, where patients (n = 106) were 
randomised to renal nerve denervation or optimum medical therapy, showed 
a reduction in office BP measured in clinic of -32/12 mmHg and a reduction in 
ambulatory BP of -11/7mmHg, no significant changes in the control group 





controlled trial (n = 500) failed to detect a significant reduction in systolic BP 
at 6 months between patients who received renal nerve denervation and 
patients who received a sham procedure (Bhatt et al., 2014). 
Another invasive neuromodulatory technique which has been trialled for 
treatment-resistant hypertension has been baroreflex activation therapy 
(BAT).  Given that an increase in BP will trigger activation of carotid sinus 
baroreceptors to initiate a subsequent reduction in BP via the arterial 
baroreflex, electrical stimulation applied to the carotid sinus could be used to 
improve BP control in treatment-resistant hypertension.  In this way, a 
baroreflex-mediated decrease in sympathetic nervous system activity and 
blood pressure could also be achieved in these patients.  Baroreflex 
activation therapy was initially tested using the Rheos™ carotid sinus 
stimulation system, which involved the surgical implantation of bilateral 
bipolar electrodes around the carotid sinus (Tordoir et al., 2007, Scheffers et 
al., 2010).  A significant decrease in BP was observed following 12 months of 
BAT in 45 patients with treatment-resistant hypertension (Scheffers et al., 
2010).  Reductions in MSNA have also been reported in hypertensive 
patients as a result of BAT (Heusser et al., 2010).  A subsequent randomised 
sham-controlled trial in 265 treatment-resistant hypertension patients 
involved patients receiving either active BAT one month after implantation 
(treatment group) or six months after implantation (sham group) (Bisognano 
et al., 2011).  While the trial did not observe a significant difference between 
groups in its primary efficacy endpoint (decrease of ≥ 10mmHg systolic BP 
after 6 months), 42% of participants in the active BAT group achieved a 
decrease in systolic BP to < 140mmHg (Bisognano et al., 2011).  In addition, 
the reductions in systolic BP were observed at long-term follow-up in this 
cohort of patients (Bakris et al., 2012).  A second-generation system has 
since been developed called Barostim neo™, which uses a smaller electrode 
to perform unilateral carotid sinus stimulation as opposed to bilateral 
stimulation (Hoppe et al., 2012, Gassler and Bisognano, 2014).  Preliminary 
testing in 30 patients with resistant hypertension showed a mean systolic BP 
reduction of 26 mmHg at 6 months, comparable to the effects observed with 





denervation, both of these methods of BAT requires an invasive surgical 
procedure, which ultimately limits their clinical potential. 
The results of this thesis have shown that tVNS can reduce MSNA and 
increase BRS in humans with no medical history of cardiovascular disease, 
so there is potential for tVNS to have a similar effect in patients with 
hypertension.  To date there has not been much investigation into the 
antihypertensive effects of VNS or tVNS in humans, but as tVNS is a non-
invasive technique it may offer the greater therapeutic potential.   
 
7.3.3 Obstructive sleep apnoea 
Obstructive sleep apnoea (OSA) is a common sleep disorder which may 
affect up to around 100 million individuals worldwide (Senaratna et al., 2017).  
OSA is characterised by recurrent episodes of apnoea (obstruction of the 
pharyngeal section of the airway) leading to reduced airflow and 
consequently hypoxia which can then disrupt normal sleep (Gaspar et al., 
2017).  Moreover, ageing is known to significantly increase the risk of 
developing OSA, with around 24 – 62% (Young et al., 2002).  Patients with 
OSA have been found to have increased sympathetic activation while awake, 
as assessed by measures such as plasma norepinephrine and MSNA 
(Somers et al., 1995, Narkiewicz et al., 1998b).  Reduced heart rate 
variability has also been demonstrated in OSA patients compared to controls 
(Narkiewicz et al., 1998a).  Patients with severe OSA have also been found 
to have evidence of impaired BRS, but crucially this impairment in 
baroreceptor reflex function was restricted to severe cases of OSA and no 
baroreflex dysfunction was observable in patients with mild OSA (Blomster et 
al., 2015, Sforza et al., 2016).  A common treatment strategy for OSA is 
continuous positive airway pressure (CPAP) and this has been found to 
reduce MSNA (Narkiewicz et al., 1999, Henderson et al., 2016).  However, a 
major limitation of CPAP is the need to wear a mask for the device while 
sleeping, which in itself can lead to sleep disturbances as well as poor 





tVNS, which might be better tolerated but could also reduce sympathetic 
activation.  Moreover, tVNS might also increase BRS in patients with severe 
OSA. 
 
7.3.3 Rheumatoid Arthritis 
Rheumatoid arthritis (RA), a chronic inflammatory disorder which affects 
around 1% of the Western world (Firestein, 2003). It typically manifests in 
mid-life as musculoskeletal joint problems such as swelling and pain 
accompanied by persistent fatigue (Stack et al., 2013).  However the 
symptom remission rate for RA patients is low despite the existence of a 
number of pharmacological therapies which target the inflammatory 
mechanisms of RA (Smolen et al., 2017).  In addition, RA patients have an 
increased risk of cardiovascular morbidity and mortality (Solomon et al., 
2003, Kapetanovic et al., 2011), which could be in part due to chronic 
cardiovascular autonomic dysfunction.  RA patients have been found to have 
impaired BRS (Aydemir et al., 2010, Adlan et al., 2017) as well as increased 
sympathetic activation measured through plasma norepinephrine (Vlcek et 
al., 2008) and microneurographic recordings of multi-unit MSNA (Adlan et al., 
2016).  Heart rate variability has also been shown to be reduced in RA 
patients.  Evrengul et al. described a sample of RA patients (n = 48) who had 
a greater LF/HF ratio and a reduced HF power compared to a group of 
healthy controls (n = 50), suggesting reduced vagal tone (Evrengul et al., 
2004).  
Implanted VNS has been trialled in a 17 RA patients who had > 6 months of 
symptoms and increased CRP levels (≥ 7mg/L) at baseline (Koopman et al., 
2014, Koopman et al., 2016).  VNS initiated two weeks after implantation for 
60 seconds per day showed improvements in RA severity at day 42 as 
determined by reduced values for the Disease Activity Score-28 for 
Rheumatoid Arthritis with CRP (DAS28-CRP) composite scoring tool 
(Koopman et al., 2016).  VNS was then stopped for 14 days and DAS28-CRP 





(Koopman et al., 2016).  However this trial did not assess any changes in 
autonomic function and a number of adverse events were reported during the 
trial including dysphonia, dyspnoea and paraesthesia of the skin of the neck 
(Koopman et al., 2014; Koopman et al., 2016).  Although VNS appears to be 
effective in reducing RA severity, the invasiveness of the implantation 
procedure and the side-effects associated with VNS limit its therapeutic 
potential.  Thus, tVNS applied to the tragus to stimulate the ABVN could be a 
potential non-invasive alternative to VNS which may have a similar efficacy in 
RA patients.  The effects of tVNS on cardiovascular autonomic function 
described in this thesis for healthy volunteers and heart failure patients may 
also be observed in patients with RA.  
 
7.4 Limitations 
A significant limitation of this thesis is the small sample size of CHF patients 
recruited to the study in Chapter 5. There was a high incidence of cardiac 
arrhythmias in CHF outpatients who were screened at the outpatient clinic, 
which had a detrimental effect on recruitment.  Moreover, many patients who 
were recruited had no prior diagnosis of arrhythmia but were found to have 
frequent ectopic beats during the experimental recordings.  This meant that it 
was not possible to analyse HRV in these patients due to the data loss 
caused by the ectopic beats.  In addition, the early phase of the study 
involved recruitment and testing of patients during the outpatient clinic hours, 
which severely restricted the time available for each experiment.  This meant 
that it was not possible to obtain post-stimulation recovery recordings for all 
patients to clarify the short-term residual effects of tVNS in CHF.  Later 
experiments conducted in the Cardiovascular Clinical Research Facility at 
Leeds General Infirmary were able to offer patients the opportunity to return 
at a convenient day and time for their experiment, although due to frequent 
ectopic beats only two patients from this phase were eligible for inclusion to 
the study.  In addition, patient recruitment for the CHF study was stopped 
prematurely due to a shortage of clinical care staff available to screen the 





obtaining funding for a part-time research assistant or research nurse who 
would be required to screen patients.   
All of the studies included in this thesis relied analyses of HRV and BRS, two 
non-invasive estimates of cardiovascular autonomic function as opposed to 
direct measurements.  However, the lack of significant change in sham tVNS 
and sham TNS in Chapters 4 and 6, where no stimulus was applied to either 
the tragus or the supraorbital region, suggested that the effects observed 
with these non-invasive measures during active stimulation were valid.  
Sham tVNS was not performed in the heart failure patients in Chapter 5, or in 
the study with healthy participants in Chapter 3.  However, Chapter 3 
included earlobe stimulation, which has been previously used in some tVNS 
studies as a control stimulation site (Frangos et al., 2015; Yakunina et al., 
2016).  No significant differences in measures such as BRS or the LF/HF 
ratio were identified for earlobe stimulation, suggesting that stimulation of 
great auricular nerve afferents may not significantly influence autonomic 
activity in humans.  However, due to experimental time constraints it was not 
possible to perform microneurography for the study in Chapter 3 to directly 
assess changes in sympathetic nervous system activity.  
Microneurography was however performed in healthy participants in Chapter 
4, which showed a reduction in MSNA as a result of active tVNS. 
Nevertheless, a limitation of this technique is that changes in MSNA 
represent changes in sympathetic outflow at a systemic rather than regional 
level and it was not possible to measure regional changes in sympathetic 
nervous system activity as part of this study.  In future, this could be 
investigated in healthy volunteers or heart failure patients using cardiac 
norepinephrine spill-over measurements obtained using a catheter inserted 







7.5 Future directions 
 
7.5.1 Effects of chronic tVNS in healthy aged volunteers 
The elderly are at an increased risk of developing chronic cardiovascular 
disease (North and Sinclair, 2012).  The preliminary data presented in 
Chapter 4 indicates that tVNS applied to the tragus of the external ear can 
alter cardiovascular autonomic function in healthy older adults with no 
previous history of cardiovascular disease in a potentially beneficial way.  
Specifically, this alteration was a reduction in sympathetic nervous system 
activity assessed through microneurographic recording of MSNA and an 
increase in parasympathetic predominance observed through a decrease in 
LF/HF ratio and an increase in spontaneous BRS.  In this way, tVNS may 
represent a method of preventing or attenuating the onset of cardiovascular 
disease in aged individuals.  However, the long-term autonomic effects of 
tVNS in older people are at present unknown.  The changes in HRV and BRS 
observed in Chapter 4 were short-lived, with values for LF/HF ratio and BRS 
returning to near-baseline levels within 15 minutes of the end of stimulation 
(recovery period).  Daily application of tVNS for 15 minutes or more over a 
number of weeks or months could, however, have a residual cumulative 
effect on cardiovascular autonomic control. 
To investigate the autonomic effects of chronic tVNS, an initial pilot study 
design would be to recruit a cohort of elderly volunteers who would receive 
15 minutes of tVNS twice daily (morning and evening) over the course of one 
month.  An initial baseline visit would assess the short-term response to 15 
minutes tVNS using non-invasive measures of autonomic function such as 
HRV and BRS, as well as microneurography to record MSNA in participants 
who consent to this more invasive technique.  At the end of this baseline visit, 
participants would receive their own auricular electrode clips and a TENS 
machine so that they could self-apply tVNS in their own home.  The TENS 
machine would have a built-in compliance meter to monitor use and 





self-reported effects of tVNS.  Participants would be asked to return for two 
additional visits at day 14 and day 28 to assess if the residual effects of 
chronic tVNS.  Following completion of 28 days of tVNS, a follow-up period of 
28 days could be undertaken where the TENS machines are taken away 
from the participants, who are then asked to return for additional visits at 
days 42 and 56 to assess if there have been any persistent post-tVNS 
changes in HRV, BRS and MSNA.  If positive results are detected at the end 
of this period e.g. reductions in MSNA, increased BRS and HRV, then the 
TENS machines could be returned to the participants for daily use and an 
extended protocol of six months to one year of chronic tVNS performed with 
assessment visits every three months.  In addition, quality of life 
questionnaires could be used to assess any changes in mood as a result of 
chronic tVNS. 
  
7.5.2. Effects of long-term application of tVNS in chronic heart failure 
Following on from the work in Chapter 4 with the healthy aged volunteers, a 
group of chronic heart failure (CHF) patients were recruited in an effort to 
investigate the short-term autonomic effects of tVNS in individuals with a pre-
existing cardiac condition.  As with the older volunteers in Chapter 4, the 
CHF patients saw a decrease in LF/HF ratio and an increase in BRS during 
tVNS.  This change was not reflected in a sample of age-matched and sex-
matched healthy controls (n = 8) who were compared to the patients, but this 
lack of an effect may have been due to the small sample size.  It was not 
possible to obtain post-stimulation (recovery period) recordings for the 
majority of patients due to time constraints in the experiments.  Moreover, the 
time constraints in the clinical setting meant it was not possible to perform 
microneurography.  
However, the promising results observed for HRV and BRS during 15 
minutes of tVNS supports further investigation of the long-term effects of 
tVNS in patients with CHF.  A similar study design could be used as with the 





patients could self-apply tVNS twice daily for one month in the first instance.  
In addition to measures of autonomic function such as HRV and BRS, clinical 
measurements could be incorporated into the assessment visits including 
quality of life questionnaires to identify improvements in mood, 6-minute walk 
tests to assess the effects of tVNS on exercise tolerance and 
echocardiography to detect any changes in measures of cardiac function 
such as LVEF.  Depending on the outcome of an initial one month pilot study, 
further investigation could be carried out to identify the autonomic and clinical 
effects of tVNS over the course of six months to one year.  In this way, the 
clinical efficacy of long-term exposure to daily tVNS in patients with CHF 
could be compared and contrasted with the outcomes of the VNS for CHF 
trials (DeFerrari et al., 2011, Premchand et al., 2014, Zannad et al., 2015, 
Gold et al., 2016).   
 
7.5.3 Distribution of the ABVN 
Chapter 3 attempted to compare the autonomic effects of stimulation at 
different sites on the ear, with the sites selected based on the auricular 
innervation patterns described in 7 human cadavers (Peuker and Filler, 
2002).  However, the physiological effects observed in Chapter 3, in 
particular the lack of any significant change in HRV or BRS as a result of 
cymba concha stimulation, suggests that the reported distribution of nerves 
such as the ABVN may not be completely accurate. The cymba concha was 
reported by Peuker and Filler to be innervated exclusively by the ABVN, yet 
the response observed during cymba concha stimulation was similar to that 
observed for the earlobe, which is innervated by the great auricular nerve 
(GAN) (Peuker and Filler, 2002).  A larger-scale cadaveric dissection study is 
needed to determine the extent of inter-individual anatomical variation in the 
ABVN dermatome, as this information could be used to optimise the 






7.5.4 Determining the central mechanisms of tVNS  
A potential method of investigating the central mechanisms of tVNS is 
through the working heart brainstem preparation (WHBP), an arterially 
perfused in situ decerebrate rodent preparation which does not require the 
use of anaesthetic agents (Paton, 1996).  The WHBP allows for intracellular 
recordings of the neurons associated with medullary autonomic neuronal 
circuits, as these can be preserved using WHBP.  The baroreceptor reflex 
can be activated in the WBHP through maximally increasing the arterial 
perfusion pressure, thereby eliciting a reduction in heart rate (Lall et al., 
2012).  Modified versions of the electrode clips used in this thesis could be 
used to investigate the autonomic effects of stimulation at different sites on 
the rodent ear in a similar way to the study design of Chapter 3.  Another 
approach would be to use a carbocyanine lipophilic neuronal tracer such as 
DiI in fixed human cadaveric tissue, as DiI can travel through fixed neuronal 
tissue in both an anterograde and retrograde direction (Lanciego and 
Wouterlood, 2011).  DiI applied to the cut central end of nerves such as the 
ABVN or auriculotemporal nerve could be used to visualise the central 




This thesis has demonstrated that it is possible to use transcutaneous 
electrical nerve stimulation applied to the tragus (tVNS) to elicit a modulatory 
effect on autonomic function in older healthy humans and also in heart failure 
patients.  This thesis also shows that supraorbital TNS appears to have a 
minimal influence on autonomic function in healthy humans.  Further clinical 
studies are needed to determine if tVNS applied to the tragus could be an 
effective adjunctive therapy for disorders where autonomic dysregulation is 
present.  In addition, the precise mechanisms behind the autonomic effects 
of tVNS should be further investigated in animal studies in order to optimise 
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